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Abstract 
Peptides are crucial in biological processes: depending on their structure and location in the 
body they play different important roles. In vivo, peptides can be cleaved by proteases that 
degrade and reduce their activity. Studies have shown that peptide bonds can be mimicked 
in order to prevent cleavage in vivo while retaining bioactivity and increasing the solubility 
as well as the ability to control the folding of the peptide. Furthermore, synthetic targets that 
mimic conformational features of biologically active protein’ domains have raised an intense 
interest for organic and medicinal chemists. The target in peptidomimetics nowadays is to 
get a better biological activity than natural occurring peptides by mimicking their structure.  
This project focuses on the synthesis of peptidomimetics containing a cyclopropane as an 
amide bond isostere. Incorporation of a cyclopropane allows the molecule to be constrained 
conformationally, bringing hydrogen bond donor and acceptor groups together and 
facilitating reverse turn formation. To demonstrate this concept, the racemic and 
enantioenriched {GlyΔGly} dipeptide replacement units were synthesised and then 
incorporated at the centre of different short peptide chains. Optimisation and development 
of a new strategy is described in this thesis along with spectroscopic analyses to identify the 
secondary structure adopted by the peptides.  
IR, concentration-dependant NMR, 2D NOESY NMR and circular dichroism (CD) analyses 
were conducted to prove the formation of this secondary structure. The studies were 
performed on peptides with different lengths, in order to demonstrate the propensity of b-
turn formation depending on number of residues (from two to five) but also depending on 
the solvent. Intramolecular hydrogen bond formation was determined by NMR and IR 
spectroscopy, which allowed identification of the conformation. 2D NMR and CD 
spectroscopy allowed to isolate precisely the conformation adopted by the mimics.  
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Promising results from these model systems were obtained and applied to the synthesis of 
novel cyclopropane-based Leu-enkephalin and TrpZip peptide analogues. Those peptides 
are known to form b-turn and b-hairpin respectively, so controlling hydrogen bonding and 
the folding properties is particularly important.  
 
Herein is described the synthesis of the longer analogues using the Gly-Gly surrogate 
designed and their full conformational analysis. CD and 2D NMR conformational analysis 
were conducted in order to identify the folding pattern of the analogues designed. 
This project was achieved with the kind help of Dr. Drew Thomson and his PhD student 
Selma Crecente Garcia who provided MD calculation and helped with the acquisition of the 
different NMR experiments followed by the assignments of protons of the TrpZip peptides; 
Dr. Brian Smith who kindly provided the 600 MHz NMR spectrometer and his expertise in 
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protein conformational analysis; and Dr. Sharon Kelly for the CD measurements and 
interpretation.  
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Chapter 1  
Introduction 
1.1. Proteins and peptides: structure and function 
Proteins and peptides are of fundamental importance in most biological processes. They 
perform a variety of important roles both within and outside of the cells of all organisms. 
The role can be a structural (collagen or elastin),1 a dynamic function such as transport 
(myoglobin)2, a metabolic control (hormones, receptors),3 muscle contraction agent 
(myosin),4 or catalysis of a chemical reaction (enzymes, Figure 1).5  
 
Figure 1: 3D structure of collagen (PDB 4CLG), myoglobin (PDB 3GRK), myosin (PDB 2V26) 
and enzyme-substrate complex 
Proteins and peptides are polymers of amino acids linked together by a peptide bond. The 
large number of natural amino acids means that a vast range of proteins with unique 
properties is possible. Variation of the sequence of the amino acids, the length of the chain 
and/or the intramolecular interactions within the protein and therefore the conformation of 
the protein leads to huge number of peptide and protein structures.6 Around 500 different 
amino acids can be found in nature but 22 are encoded by human codons (Figure 2).7 Nine 
of these amino acids (Phe, Trp, Val, Thr, Met, Leu, Ile, Lys, His) are called essential amino 
acids, which means that they must be supplied in the diet to have a sufficient production of 
them. A further six (Arg, Cys, Gln, Pro, Gly, Tyr)  are considered “conditionally essential 
amino acids” meaning that the synthesis can be disturbed by some pathologic conditions.8 
The rest (Ala, Asp, Asn, Glu, Ser) are non-essential amino acids because they can be 
+
Enzyme Substrate [enzyme-substrate] complex
  2 
synthesised in the body in sufficient quantities. The last two (Sec and Pyl) are present in 
proteins by a specific mechanism.9,10 Peptides differ from proteins on the basis of size and 
are defined as having a chain of 50 or fewer amino acids.11 The structure that comes from 
the assembly of the amino acids will determine the function and the location of the protein 
in the body. 
 
Figure 2: 22 natural α-amino acids and side chains’ pKa value. 
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An amino acid is a small molecule or monomer, with a carboxylic acid (C-terminus) and a 
primary amine (N-terminus) functional groups (except for Pro), connected by carbon that 
bears a side chain of variable length depending on the nature of the specific amino acid. 
Natural amino acids (those encoded by the genome) have the side chain located on the α-
position relative to the carboxylic acid as the S-enantiomer (except Gly), and so they are 
therefore referred as α-amino acids.12 The amino acids are classified depending on the 
properties of their side chains as shown below and each is designated by a three-letter or 
single-letter code.  
Since the discovery of amino acids, peptides and proteins in the 19th century,13 various 
methods have been developed to synthesise natural or non-natural proteins/peptides and in 
recent years the use peptide synthesizers or genetically modified organisms has come to the 
fore. The advantage of using proteins as potential therapeutic agents, is that they can be more 
selective for their targets than conventional drugs with fewer side effects. Unfortunately, in 
most cases, proteins fail to meet the criteria of Lipinski’s rule of five because they usually 
have a molecular weight above 500 Da, and possess too many hydrogen-bond 
donors/acceptors.14 The Lipinski’s rule of five describes the five key physiochemical 
parameters and the molecular properties that confer favourable pharmacokinetic properties 
(absorption, distribution, metabolism and excretion) on a drug and make it likely to be orally 
active. The components are: the molecule must have five or fewer hydrogen bond donor 
groups (HBD), 10 or fewer hydrogen bond acceptor groups (HBA), a molecular weight of 
less than 500 Da, and a logP (a measure of the lipophily, thus the membrane permeability of 
molecules) of 5 or less.  By using this method of “Lipinski rule of five” it was possible to 
categorised compounds as drug-like or lead-like molecules and filter libraries to remove 
poor candidates.15,16 Moreover, proteins usually bear a charge at physiological pH ~ 7.4 
[pKa(C-ter) ~ 1.7–2.3, pKa(N-ter) ~ 7–9,17 the pKa of the side chains substituent can vary 
between 3 and 12], thus their ability to cross the membrane is reduced. That is why research 
is conducted into small peptides and peptidomimetics in order to satisfy the Lipinski’s rule 
of five by synthesising smaller and more cell permeable molecules. In addition, small 
peptides and peptidomimetics can represent a biologically active section of a protein of 
interest and be used without the need to synthesise and purify an entire protein (which can 
be expensive and time consuming).18  
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1.2. The peptide bond: generality and isosteres 
Proteins and peptides are polymers of amino acids joined through amide linkages. The 
resonance energy of the peptide bond is around 16 kcal/mol (in comparison benzene has a 
resonance energy of 46 kcal/mol) and possesses extra stability as a consequence of its partial 
double bond character (Figure 3). This is due to the delocalisation of the nitrogen lone pair 
into the antibonding orbital π∗ of the carbonyl group. The energy required for rotation about 
a single C–C bond is approximately 3 kcal/mol and about 60 kcal/mol for a C=C double 
bond. Rotation around an amide C–N bond with its partial double-bond character requires 
greater energy, which limits rotation about this bond.6,19 Due to this partial double bond 
character, the entire amide group is planar and so there are two possibilities: trans- or cis- 
conformation.  
         
Figure 3: peptide bond resonance structures and dihedrals angles 
The trans-conformation is the conformer that usually occurs in all open peptide chains,20 
implying that the side chains of adjacent amino acids lie on opposite sides of the main 
chain.21 The cis-conformation is less stable as a consequence of the steric hindrance between 
the side chains; nevertheless, it can be found in peptide bonds between any amino acids and 
Pro (Xaa-Pro). A peptide bond is defined by three dihedral angles: ϕ, ψ and ω. The ϕ angle 
of the i residue is defined by the torsion Ci–1-Ni-Cαi-Ci, ψ by the torsion Ni-Cαi-Ci-Ni+1, and 
ω by the torsion Cαi-Ci-Ni+1-Cαi+1. These angles are an important feature for protein folding 
analysis.22 By definition, the trans-conformation is that in which the dihedral angle ω (Cα-
C-N-Cα angle) is 180 ° and the cis-conformation is the one where ω is 0 °.23  
The peptide bond presents a paradox in terms of its stability when one considers how it 
behaves chemically: vigorous conditions are required (concentrated acid or base at elevated 
temperature) to promote hydrolysis but on the other hand protease-mediated in vivo by 
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hydrolytic cleavage occurs under mild conditions (physiological pH and temperature). 
Proteases comprise four different mechanistic classes: serine proteases, cysteine proteases, 
aspartyl proteases and metalloproteases (Figure 4).24 
                          a)    b)  
                c)                d)  
Figure 4: proteases and their mechanism. a) Serine protease, b) cysteine protease, c) aspartyl 
protease, d) metalloprotease 
In serine proteases (Figure 4a) there is a catalytic triad formed by Asp, His and Ser amino 
acids in the active site. His deprotonates the Ser-OH, with the help of the proton-withdrawing 
Asp, and allows nucleophilic attack of the nucleophilic Ser onto the carbonyl group of the 
peptide bond. The cysteine proteases (Figure 4b) work in a similar way to the serine 
proteases, but in this case a strongly nucleophile sulphur atom on the Cys residue is 
deprotonated by His in the active site. Aspartyl proteases (Figure 4c) function via acid-base 
mechanism in which a water molecule serves as a nucleophile. In this case, water coordinates 
with the Asp carboxylate and is then activated by the abstraction of a proton and the polarised 
water can now attack the carbonyl of the peptide bond. Metalloproteases (Figure 4d) use a 
coordinated metal, usually Zn, in the catalytic mechanism. The metal coordinates to the 
imidazole groups of two His residues and an acidic side chain, or with the imidazole groups 
of three His residues and a water molecule hydrogen bonded to a Glu residue, the activated 
water can then attack the carbonyl group.  
In addition to its stability, the peptide bond possesses two hydrogen-bond acceptors and one 
hydrogen-bond donor. Hydrogen bonds play a critical role in stabilizing secondary structure,  
facilitating inter- and intramolecular interactions and protein-protein recognition processes 
(enzyme-substrate for example).25 In principle, the folding and shape, and thus consequently 
intramolecular interactions, of a protein can be controlled in order to increase its specificity 
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and/or the mode of action, by replacement of the peptide bond with a suitable isostere. An 
isosteres is a functional group with similar chemical or physical properties to the group that 
it replaces; a molecule containing an isostere should produce the same biological response 
as the natural substrate. In medicinal chemistry, isosteres are used frequently in drug design 
to improve the pharmacodynamic and pharmacokinetic properties of a drug.26 In order to 
avoid degradation by peptidase, some studies have been focused on replacing the peptide 
bond by different isosteres.  
For example, the peptide bond can be replaced by another functional group such as a urea, 
without modification of the synthesis strategy commonly employed for peptide synthesis.27 
Liskamp et al. have demonstrated that a peptidomimetic can be synthesised using the Fmoc 
protection strategy in a peptide synthesiser. Every peptide bond was replaced by a urea 
moiety and every residue was replaced by its β-equivalent without significant losses in the 
overall yield or purity (Figure 5).  
 
Figure 5: urea peptidomimetic 
Other researchers have reported that replacement of a peptide bond by a triazole unit does 
not alter the biological activity of the compound.28 V. D. Bock et al. have synthesised mimics 
of the natural product cyclo-[Pro-Tyr-Pro-Val] (Figure 6).  
 
Figure 6: cyclo-[Pro-Tyr-Pro-Val] peptide and one of the analogues 
In this study, three peptidomimetics were synthesised. In two of them, a triazole was used to 
replace one peptide bond on each side (red in Figure 6), and in the third one both peptide 
bonds were replaced with triazoles. The inhibitory effect of these analogues was then 
evaluated on mushroom tyrosinase and compared to the activity of the natural product. The 
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inhibitory activity was not only retained but increased for two of the analogues. Nonetheless, 
in most cases replacement of a peptide bond resulted in a loss of a hydrogen bond, which 
could be crucial for inter- and/or intramolecular interaction, making the mimics a good tool 
for the understanding of such interactions.29  
1.3. Structure of proteins and peptides 
Proteins and peptides can be described in terms of their level of organisation by use of the 
term primary, secondary, tertiary and quaternary to describe structure. The general folding 
of a protein is stabilised by multiple weak interactions and so it is essential to describe them 
before discussing the different levels of organisation. These weak interactions are non-
covalent and reversible.  
1.3.1. Interactions stabilising the folding of a protein/peptide 
1.3.1.1. Hydrophobic interactions 
Hydrophobic interactions occur between non-polar groups. In peptides and proteins, this 
corresponds to the interactions between the hydrophobic side chains of non-polar residues 
(such as Ala, Val, Phe etc.). Water can repel these hydrophobic residues causing them to be 
buried in the native state of the protein (i.e. the folded protein). An example of a hydrophobic 
interaction in a peptide is aromatic-aromatic side chain interaction stabilising β-hairpin 
formation.30  
1.3.1.2. Ionic interactions 
Ionic interactions are electrostatic interactions between two charged or partially charged 
groups of opposite polarity. These interactions occur between two groups having significant 
electronegativity differences. In peptide stabilisation, ionic interactions correspond to the 
interactions between paired anionic and cationic amino acid side chains (e.g. between Lys 
and Asp).   
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1.3.1.3. Van der Waals interactions 
Van der Waals and hydrogen bonding interactions are crucial for the stability and function 
of molecules.31 They are weak electrostatic interactions between two permanent or induced 
dipoles. They have three major contributions and are distance dependant:  
Permanent dipole-dipole interaction, or Keesom force: this interaction can be attractive or 
repulsive; the dipole of opposite signs will be attracted and dipoles of opposite signs will be 
repelled.  This is represented in the figure 7 by the dipole moment of a molecule (a carbonyl 
group for example). 
 
Figure 7: Keesom force 
Dipole-induced dipole interactions, or Debye forces: these attractions result when a polar 
molecule induces a dipole in a nonpolar molecule/atom by disturbing the arrangement of 
electrons around it (induction or polarisation). They are always attractive and depend on the 
polarizability of a molecule.32 For instance, a carbonyl group with a dipole moment can 
induce a dipole in an adjacent aromatic ring (Figure 8) because π-electrons are more 
polarizable than σ-electrons.  
 
Figure 8: Debye force 
Dispersive interactions, or London forces: they correspond to attractive interactions between 
any pair of molecules or atoms caused by the instantaneous multipole interactions. As in the 
case of Debye forces, they depend on the polarizability of molecules. In a folded protein, 
there are numerous dispersive interactions (mainly involving aromatic residues) that make 
important contributions to its overall stability.32 
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1.3.1.4. Hydrogen bonds 
A hydrogen bond is an electrostatic attractive interaction between a hydrogen atom that is 
covalently bonded to an electronegative atom (N, O, S, F) and the lone pair of an 
electronegative atom (N, O, S, F). These groups are called, respectively, the hydrogen bond 
donor (HBD) and the hydrogen bond acceptor (HBA). A hydrogen-bonding interaction is 
weaker than a covalent bond or an ionic interaction but is stronger than hydrophobic or van 
der Waals interaction. The electronegative bonding partner pulls the electrons away from 
the hydrogen in the HBD and the hydrogen nucleus is exposed on the back side, which 
becomes electron deficient (δ$). This allows an electrostatic interaction to be established 
with a Lewis basic electron pair of an electronegative atom which is partially negatively 
charged (Figure 9).  
 
Figure 9: Hydrogen bond and cooperativity of hydrogen bonds 
In biology, the hydrogen bonds are responsible for base pairing in DNA and RNA, the 
formation of elements of secondary structure in proteins/peptides and intermolecular 
protein-protein interactions. In biological systems, hydrogen bonds can have a cooperative 
character, which means that the strength of a hydrogen bond will be increased by an adjacent 
hydrogen bond (Figure 9). The hydrogen bond increases the acidity of the proton and the 
basicity of the oxygen (or any electronegative atom). This greatly stabilises base pairing and 
protein folding.  
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1.3.2. Primary and secondary structure 
The primary structure corresponds to all the amino acids linked together by peptide amide 
bonds. It is the denatured state where the peptide/protein is unfolded and inactive. With 20 
different natural amino acids, an infinite combination of these is possible, allowing huge 
diversity in primary structure. For example, a dipeptide involves two residues, thus 202 = 
400 different combinations are possible. However, a sequence of amino acids will not 
usually adopt a linear, extended conformation, but instead will fold into a complex three-
dimensional structure of lower energy, stabilised by hydrogen bonds and other 
intramolecular interactions (electrostatic, π-stacking, hydrophobic etc.). The structure based 
on this hydrogen bonded arrangement is the secondary structure. It includes turns, α-helices 
and β-sheets.  
1.3.2.1. α-helix 
Linus Pauling was the first to report the a-helix conformation in 1951.33 It is described as 
right-handed helical conformation with 3.6 residues per turn and a distance of 5.4 Å. In this 
structure, the peptide C=O bond of the ith residue points towards the peptide N–H group of 
the i-4th residue to generate a 13-membered pseudocyclic structure (Figure 10). a-Helices 
represent the most prevalent type of the secondary structure in proteins (about 30% in 
globular proteins),34 and could play an important role in the early stage of protein folding. 
Pace et al. observed that certain amino acid residues are more frequently found in a-helices 
such as Ala, Leu and Glu because of their favourable enthalpic contribution of between 0–
0.4 kcal/mol (0–1.67 kJ/mol) compared to Gly which contributes around ~1 kcal/mol (4.18 
kJ/mol) as a consequence of its greater flexibility, which reduces its propensity to stabilise 
a-helices. Proline does not stabilise an a-helix because it does not have a free N–H to form 
a peptide bond with another residue.  
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Figure 10: structure of an α-helix and of myoglobin protein 
a-Helices perform a variety of functional roles, such as recognition (protein-protein or 
protein-nucleic acid),35,36 membrane spanning and other mechanical properties,37 which 
means that the a-helix is a good target for medicinal chemistry research.  
 
1.3.2.2. β-sheet 
Another prominent secondary structure unit is the β-sheet, it is formed by successive β-
strands joined by a turn. A strand is an almost fully extended chain of amino acids (3 to 10 
residues). The dihedral angles ϕ and ψ of the strands’ residues are near 135° and –135° 
respectively, whereas these angles are at 180° and –180° in an extended conformation, which 
gives a characteristic twist in the sheet conformation.38 The two β-strands, comprising the β-
sheet, are stabilised by cross-strand hydrogen bonds between peptide bonds. They can align 
themselves to be parallel or antiparallel (Figure 11a and b). Hydrogen bonds are planar 
(HBA and HBD in front of each other, the hydrogen bond is perpendicular to the strands) in 
an anti-parallel β-sheet, and non-planar (HBA and HBD slightly deviated), therefore slightly 
less stable, in a parallel β-sheet. The strands don’t necessarily follow each other in the 
sequence and may be located at different regions of the protein/peptide. β-hairpin 
corresponds to the simpliest motif of the β-sheet consisting of two β-strands joined by a loop 
(Figure 11c).  
5.4 Å 
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a)                           b)  
c)  
Figure 11: a) parallel β-sheet from pectate lyase, b) anti-parallel β-sheet from human PCNA, c) 
zoom on anti-parallel β-hairpin.  
In both parallel and anti-parallel, the side chains along the strands alternate above and below 
the plane (Figure 11c), while the side chains of the opposite residues on neighbouring strands 
lie in the same plane and in close proximity, facilitating interactions across the strands.  
  
C-ter 
N-ter 
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1.3.3. Tertiary and quaternary structure 
The tertiary structure is the overall folded form of the protein where the energy is usually 
minimised and includes the three-dimensional arrangement of the protein including 
orientation of the side chains. It is an assembly of secondary structures and disordered 
conformations in a protein/peptide. The formation of tertiary structure depends on the 
interactions between amino acids in close proximity to each other to form secondary 
structure, and also between side chains of distant amino acid residues in the primary 
sequence by ionic, hydrophobic, disulfide or other interactions.  
Many proteins are composed of a single chain protein but some feature more than one 
subunit forming a stable folded structure. The subunits can be strictly identical in their amino 
acid sequence (Tobacco mosaic virus, Figure 12a), relatively similar (a and β subunits of 
the haemoglobin, shown in blue and red in Figure 12b) or completely different (aspartate 
transcarbamylase, Figure 12c). Once completely folded, the protein is in its so-called “native 
state”, this is the quaternary structure of proteins.  
       a)                          b)  
c)  
Figure 12: quaternary structure of a) tobacco mosaic virus, b) haemoglobin, c) aspartate 
carbamylase 
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Many large proteins do not fold spontaneously and instead are assisted by proteins called 
chaperones. These chaperones help the newly formed proteins to fold and avoid misfolding 
or aggregation, which can result in the formation of proteins that are potentially toxic. 
Molecular chaperones are described as “any protein that interacts with, stabilises or helps 
another protein to acquire its functionally active conformation, without being present in its 
final structure”.39 Some of these proteins are known as heat-shock protein (HSP), as they are 
upregulated under conditions of stress, in which more aggregated intermediates are formed. 
Chaperones are then classified accordingly to their molecular weight given in kilodaltons 
(e.g. HSP40, HSP70 etc.).  
Combinations of amino acids (the primary sequence) and their interactions will produce the 
three-dimensional shape of the protein on folding and are therefore responsible for the 
functionally active conformation.40 This will determine the role and location of the protein 
in the body. Elements of secondary structure, such as the β-turn, have piqued a keen interest 
of medicinal chemists in recent decades as possible target sites for drug development 
because they often play a critical role in protein folding, stability and molecular recognition.  
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1.4. β-turn, generality and medicinal chemistry 
target 
1.4.1. Definition and interest  
Segments with regular secondary structures such as a-helices or b-sheets are usually joined 
by stretches of polypeptide (typically 4 residues) that promote abrupt changes of direction, 
which are referred to as U-turns or reverse turns. Depending on the number of residues 
involved in the turn, a variety of distinct types of turn can form: γ-turns involve three 
residues, β-turns involve four residues and α-turns involve five residues. Consequently, NH-
-OC hydrogen bonded pseudo-rings of various sizes can be formed: 7-, 10- or 13-membered 
rings correspond to γ-, β- and α-turns respectively (Figure 13).41  
 
Figure 13: different types of reverse turn 
Another characteristic of turns is that the distance between Cαi and Cαi+4 has to be less than 
7 Å. The most common and stable turn found in peptides and proteins is the β-turn. The 
work presented in this thesis will focus only on a mimic of the β-turn. 
β-Turns are classified according to the value of the dihedral angles of the i + 1 and i + 2 
residues (central residues of the turn, Table 1). Nine established β-turn conformations have 
been reported by Thornton et al..42 All turns have specific, well-defined torsion angles (or 
dihedral angles) with the exception the type IV β-turn, in which the dihedral angles are not 
well-defined but a stable turn structure is formed nevertheless.  
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Table 1: β-Turn types and their corresponding dihedral angles and general representation of a 
β-turn stabilised by a hydrogen bond 
 
 
 
            
  
       
 
 
All types of β-turn are stabilised by a hydrogen bond between the oxygen atom of ith residue 
and NH of the i + 3th residue. In most cases b-turns are composed of hydrophobic residues 
such as Gly (also gives more flexibility), Pro or Asn.43 A β-turn with strands on N-terminus 
and C-terminus sides is known as β-hairpin (basic component of a β-sheet), it is stabilised 
by cross-strand hydrogen bonds between opposite residues. It is important to note that β-
hairpins do not necessarily involve a β-type turn, it could be any type of turn.44,45  
b-Turns are often composed of hydrophobic amino acids and they occur between regions of 
regular secondary structure (such as helices and sheets), consequently they tend to be located 
at the surface of the protein, and play a role in ligand-receptor or substrate-enzyme 
interaction recognition, making it a potentially interesting motif and target for novel 
medicinal agents.41,46 b-Turns are also thought to play an important role in the process of 
protein folding where formation of stable secondary structures is initiated by turns, which 
position strands in close proximity so that they interact with one another.47 In contrast, it is 
possible that β-turns form passively during the process of protein/peptide folding and arise 
as a consequence of folding rather than functioning as folding promoters. Hydrophobic side 
chains can interact with each other across strands and this will allow a turn to be formed, 
this is known as hydrophobic collapse.  
β-Turns are an important feature in protein secondary structure as well as in the native state 
of proteins (in GPCR ligands for example),41 which makes it a challenging and important 
target in peptidomimetic research. Within the last few decades many studies concerning b-
turn mimicry have been conducted, especially in relation to the use of carbon-carbon single 
or double bonds as peptide bond replacements.  
β-Turn type Dihedral angles (°) 
 ϕi+1 ψi+1 ϕi+2 ψi+2 
I –60 –30 –90 0 
I’ 60 30 90 0 
II –60 120 80 0 
II’ 60 –120 –80 0 
VIa1 –60 120 –90 0 
VIa2 –120 120 –60 0 
VIb –135 135 –135 160 
VIII –60 –30 –120 120 
IV All other values 
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1.4.2. Conformational analysis tools for β-turn identification 
1.4.2.1. Infrared spectroscopy 
Vibrational spectroscopy is a particularly useful method for the detection of hydrogen 
bonded structures in peptides, thanks to the strong infrared (IR) bands of the amide group 
present.48 In the early 50s, Elliot and Ambrose demonstrated that IR spectroscopy could 
provide useful data about the secondary structure of proteins and peptides.49 The method has 
evolved in the decades since then, with the arise of the Fourier-transform infrared 
spectroscopy (FT-IR). The advantage of using FT-IR, is that high quality spectra can be 
obtained with relatively small amounts (1 mM is usually enough) of the protein/peptide under 
investigation in a variety of environments (aqueous, miscellaneous or organic). Furthermore, 
IR spectroscopy relies on vibrational bond energy, so no external probes are required for the 
conformational study (unlike NMR or CD). The bands arising in IR spectra as a consequence 
of the vibration of the peptide groups provide information about the secondary structure of 
peptides and proteins, an additional chromophores are not required.50 The IR spectrum of a 
protein is characterised by nine different absorption regions known as amide modes, which 
means a planar CONH group would give nine amide bands, commonly called amide mode 
A, B, I to VII (table 2).51  
Table 2: Amides mode and their approximate frequencies 
Amide Approximate Frequency (cm−1) 
A 3300 
B 3100 
I 1650 
II 1550 
III 1300 
IV 725 
V 625 
VI 600 
VII 200 
Amide mode A arises from NH stretching, amide mode I from C=O stretching vibrations, 
amide mode II from NH bending with a contribution from CN stretching. Amide mode III 
is usually weak and rarely seen in conventional IR spectra but arises from NH bending and 
CN stretching. The other modes, are usually not used to interpret IR spectra and most 
conformational studies based on IR spectroscopy have been performed with reference to 
amide I and A bands exclusively.52,53  
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The wavenumber corresponding to each amide vibrational mode can be influenced by the 
environment of the peptide/protein. Hence, the wavenumber can be influenced by the 
intermolecular interactions between various molecules or interactions with the solvent, and 
by intramolecular interactions. The major type of bond that can be analysed with IR 
spectroscopy is the hydrogen bond, because bonding of this type changes the vibrational 
characteristics and dipole moment of a bond. Typically, in the case of hydrogen bond 
formation, the amide modes A and I will shift to lower wavenumbers, while amide mode II 
will shift to a higher wavenumber.  
With this technique, it is possible to analyse whether or not the NHs of a small peptide are 
involved in intramolecular hydrogen bonds in various solvents; in the event of a β-turn study, 
it is possible to analyse the formation of the 10-membered hydrogen bonded system by use 
of an appropriate model, as described in a following section.54 
1.4.2.2. Circular dichroism 
Circular dichroism (CD) is an essential tool for probing the structure of peptides. The 
technique was developed in the 1970s for the structural analysis of the secondary structure 
of peptides/proteins.48 CD results as a consequence of the interactions of polarised light with 
chiral molecules. Proteins, which are composed by chiral amino acids, are chiral by 
definition and display a unique spectrum depending on their 3D conformation. Indeed, it is 
important to note that the CD spectrum of a protein is not simply the sum of the CD spectra 
of its residues but is the result of a chiral macromolecule greatly influenced by its the 3D 
structure, and therefore the secondary structure. CD allows secondary structures (α-helix, β-
sheet, β-turn) to be analysed in solution with great accuracy because each secondary 
structure unit results in the generation of a specific CD spectrum (Figure 14).55 
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Figure 14:CD spectra in the far-UV of “pure” secondary structures56 
The far-UV (180–260 nm) corresponds to the region of the spectrum where there is a great 
sensitivity to the backbone conformation of peptides/proteins.57 Near-UV (250–320 nm) 
acquisition can provide information about the contribution of aromatic side chains to the 
folding process.  
α-helix has a high positive peak around 190 nm followed by two negatives at 210 and 225nm. 
β-sheet and β-turn present a positive at respectively 195 and 205 nm followed by a negative 
curve. In early studies, β-turns were overlooked in terms of their contribution to the folding 
of a protein,58 thus CD spectra were not recorded. Within the past few decades CD spectra 
of type I and II β-turns have been obtained and it is now known that they are the most found 
in proteins.59,60,61 
1.4.2.3. Nuclear Magnetic Resonance 
All chemists are aware of the power of the NMR spectroscopy for the determination of 
molecular structure and conformation but also for the elucidation of the selectivity and 
stereocontrol of some reactions. NMR is also a major tool for the determination of the 3D 
structure of macromolecules such as proteins or peptides.  
The folding pattern of a peptide/protein can be analysed through by the use of various NMR 
techniques. In the case of relatively small peptides (less than 10-12 residues), it is possible 
to study the formation of intramolecular hydrogen bonds between amides within the peptide 
directly. Concentration-dependent NMR studies provide good evidence to indicate the 
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presence and strength of both intra- and inter-molecular hydrogen bond formation. In this 
study the chemical shift of a selected NH of the peptide is targeted. If the chemical shift 
changes with the log of the concentration, it indicates that this NH is involved in an 
intermolecular hydrogen bond.62 Indeed, the higher the concentration the more the molecules 
will interact with one another. If the chemical shift does not change significantly with the 
concentration, this provides evidence that the NH is intramolecularly hydrogen bonded 
because the degree of hydrogen bonding is not dependent on concentration in this case.63 
The same observation can be made with data from temperature dependant NMR studies. In 
this case, the chemical shift-temperature dependence ratio &'&(  is measured and the lower it 
is, the stronger the intramolecular hydrogen bond.64 Another NMR experiment that is used 
to detect hydrogen bond formation consists of calculating the exchange rate between a 
hydrogen and deuterium present in a protic NMR solvent. The hydrogen concerned is usually 
the NH of an amide bond, but it can also be from an acidic side chain (attached to N, O or S 
atom as C-H exchange very slowly with the solvent).65 The rate is calculated over time and 
is a good indicator of the formation of a hydrogen bond and how stable it is. Indeed, if an 
NH does not appear in a deuterated solvent (D2O, MeOD, d-TFE etc.) it means that it is 
exchanging rapidly with the solvent so is solvent-exposed and not protected by an 
intramolecular hydrogen bond. The techniques described above are useful for the detection 
of hydrogen bonds, but NMR spectroscopy can provide much more information about the 
overall 3D structure of a peptide or protein thanks to 2D NMR. 
Homonuclear 2D NOESY (Nuclear Overhauser Effect) NMR is important for the 
determination of the structure of organic and biological molecules. Indeed, cross-peaks in 
the 2D spectrum correspond to the interaction between protons that are close in space. This 
is a powerful tool for the identification of the stereochemistry of complex molecules, but 
also the general configuration of a peptide. By identifying the cross-peaks between protons 
at the α-position of the residues composing the peptide, it is possible to tell, for instance, in 
a four-residue peptide, if Hα of residue i is interacting with Hα of residue i+3. If it is, this 
suggests that the peptide is adopting a turn conformation.  
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1.5. β-Turn peptidomimetics 
1.5.1. Introduction to peptidomimetics and examples  
Natural peptides and proteins should be, by their structure and function, attractive drug-
candidates because they are essential to every biochemical process. Even though large 
peptides have great stability and are more specific than small-molecule drugs with respect 
to their targets and fewer side effects, they do have several disadvantages: they have poor 
bioavailability (short half-life), are rapidly degraded by proteases in the blood stream, suffer 
rapid clearance and have poor oral absorption characteristics.66 These parameters are the 
pharmacokinetic properties of ADME (Absorption, Distribution, Metabolism, Excretion). 
Low ADME means that a molecule is not a good drug-candidate. For instance, some natural 
peptide-derived inhibitors such as pepstatin, a pepsin inhibitor (pepsin is a protease found in 
the stomach that degrades proteins into smaller peptides), have shown promising 
hypertensive activities in biological tests, but their low bioavailability and lack of target 
selectivity have precluded their further development.67 Wiley and co-workers defined a 
peptidomimetic as “a small nonpeptide structure that can mimic the activity of a native 
peptide or protein”. Nowadays, the challenge is to find a low-molecular-weight molecule 
with desired pharmacokinetic properties (superior to those of native peptides) that would 
bind specifically to a target receptor. Expansion of our knowledge of proteins and their 
domains has allowed the peptidomimetic field to develop. Indeed, determining the 3D 
structure of a key point of contact between the protein and the receptor is important as this 
develops understanding of exactly which structural features and functional groups are 
important for activity to take place.68 The structure-based design of molecules that can mimic 
the binding site to a specific target (structurally and functionally) or so-called structure-
activity relationship (SAR) has developed rapidly over the past few decades and is essential 
for designing new peptidomimetic drug candidates.69,70 Once the targeted conformation for 
biological activity is known, a small molecule can be designed to form and stabilise the 
required conformation with the same functional group in place for interactions. A library of 
similar compounds can then be synthesised following a generic synthetic route and screened 
for biological activity. Features that improve or decline the activity can then be identified 
and the structure refined for a better biological activity. Peptidomimetics that possess peptide 
bond surrogates or transition state analogues have been developed in which the main 
polyamide chain is absent or interrupted by a non-peptidic group, which makes the molecule 
less susceptible to proteolytic degradation.71 
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Hanessian and Auzzas have reported the synthesis of conformationally constrained azacyclic 
peptidomimetics that contain proline and pipecolic acid building blocks (with a 5- and 6-
membered ring respectively, Figure 15).72   
 
Figure 15: Proline and pipecolic acid building block and PPACK peptidomimetics. 
In spite of the synthetic challenges presented by these constrained amino acids, the 
researchers pursued the synthesis of the polycyclic proline analogues 1a,b and 2, which are 
peptidomimetics of PPACK (Phe-Pro-Arg chloromethyl ketone) peptides. PPACK is a 
potent inhibitor of thrombin, a serine protease that is involved in the coagulation process, 
with an IC50 of 110 nM. The synthesis of 1a and b proved to be challenging but the 
compound was obtained with good stereocontrol. The three analogues were tested against 
thrombin and the hydroxyl analogue 1a was found to be five-fold less active than the amine 
analogue 1b (IC50 = 4 nM in vitro). Co-crystallisation of 1a with thrombin followed X-ray 
analysis revealed that the peptidomimetic was interacting with the protease at the same 
amino acid residue as the native peptide and therefore has the same binding mode.  
G-protein-coupled receptors (GPCRs) are a large family of proteins with seven 
transmembrane helices as a common structural motif. They are located at the surface of cells 
and are implicated in the transduction of extracellular signals into intracellular responses. 
The natural ligands of the GPCRs are extremely diverse, ranging from hormones to 
nucleosides or lipids and Ca2+ ions. Such a variety of ligands indicates a great diversity of 
actions, and GPCRs are potential targets for various disorders, such as allergies, 
hypertension, cancer and asthma, etc. (Figure 16).70 Around 50% of the drugs that have been 
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launched on the market recently target GPCRs. These receptors are attractive targets for 
medicinal chemists and amenable to the development of peptidomimetics.73  
 
 
Figure 16: rhodopsin GPCR and some examples of drugs targeting GPCRs 
It has been demonstrated than GPCR ligands often interact with the receptor via a turn 
structure,41 implying that the turn is generally located at the surface of the protein. Therefore, 
they are interesting targets to study in order to gain an understanding about the molecular 
interactions between receptors and ligands as well as other interactions involved in 
biological process.  
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1.5.2. β-Turn peptidomimetics, synthesis and analysis  
1.5.2.1. Robinson’s work on synthetic vaccines 
The application of peptidomimetics is not only drug design and development but is also in 
the field of synthetic vaccines. Natural peptides have several weaknesses in this area. They 
are usually too flexible and unable to preserve a specific conformation that is required for 
recognition with the antibody. An epitope is the part of the antigen that binds with the 
antibody and b-hairpin are a known structure found in epitopes. Furthermore, it has been 
described that the interaction is possible or not depending on the loop sequence. So, 
constraining the loop to stabilise the hairpin is an important progress in synthetic vaccines. 
Immunoglobin contains six domains where the antigens will bind, they are called the 
complementary-determining regions (CDRs).74 Some of them adopt a b-hairpin 
conformation. Robinson has designed CDRs mimic containing a D-Pro-L-Pro loop to fix the 
b-turn position in the peptide (Figure 17).75 
 
Figure 17: Hairpin mimetic based on CDR loop 
3D average conformations extracted from solution NMR study of both cyclic peptides 3 and 
4 overlay perfectly respectively with the 3D structure of CDR loops of antibody HC19 
(influenza) and antibody TE33 (anticholera). Accurate structural mimetics are possible by 
replacing a flexible loop by a more rigid moiety such as Pro and could be valuable tool for 
small molecule antibody mimetics. 
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1.5.2.2. Gellman et al., alkene as a peptide bond isostere and β-turn 
initiator 
Within the last few decades many studies have been conducted in the field of b-turn mimicry, 
especially in relation to the use of carbon-carbon single or double bonds as peptide bond 
replacements. Gellman et al. have worked on the use of trans-alkenes as peptide bond 
surrogates and have obtained promising results.63 In order to retain the backbone flexibility 
of an authentic dipeptide a mimic of  the Gly-Gly sequence was chosen because the absence 
of any stereogenic centres simplified its synthesis. Initially, simple di- and tetra-substituted 
alkene dipeptide mimics were synthesised and analysed (Schemes 1 and 2):  
 
 
Scheme 1: Gellman dipeptide mimic synthesis and acetal replacement mechanism 
The synthesis of the mimetics 7 and 8 was achieved in 9 steps starting from 1,4-dibromo-
2,3-dimethyl-3-(E)-butene. The synthesis started with the installation of thioacetal 
protecting group, followed by nucleophilic substitution using sodium azide. The resulting 
azide 5 was subjected to a Staudinger reaction to obtain the corresponding amine, which was 
acylated with isobutyryl chloride to yield the corresponding amide 6. The dithiane was then 
replaced by a dimethyl acetal under acidic conditions, which was then cleaved to yield the 
corresponding aldehyde. Pinnick oxidation afforded the corresponding carboxylic acid, 
amenable to peptide coupling using DCC and HOSu affording 7 and 8 depending on the 
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amine used for the final coupling. The disubstituted alkene equivalent was also synthesised 
in just six steps (Scheme 2).76  
 
Scheme 2: disubstituted alkene dipeptide mimetic designed by Gellman et al. 
(E)-Hex-3-enedioic acid was submitted to a mono-esterification under acidic conditions and 
subsequent conversion of the remaining carboxylic acid into a Boc protected amine using 
DPPA afforded 9. Saponification and coupling followed by N-deprotection and acylation of 
the primary amine afforded the desired disubstituted alkene mimics 10 and 11.  
The conformational studies on the mimics started with an analysis of solvent effects in order 
to identify the most suitable solvent for NMR studies.54 The solvent needed to exhibit no 
hydrogen bond donor or acceptor behaviour in order to avoid hydrogen bonding between the 
compound and the solvent. In addition, the compound had to be soluble in the chosen 
solvent. Acetonitrile (MeCN) and dichloromethane (CH2Cl2) were chosen, but unfortunately 
interactions between the mimic and solvent were apparent when MeCN was used. Therefore, 
concentration dependent NMR studies of compound 7 (Figure 18) were undertaken in 
dichloromethane. The variation in NH chemical shift highlighted at different concentrations, 
from 0.05 mM to 20 mM, is presented in the figure below.  
 
Figure 18: concentration dependent NMR study of 777 
Both NHs shifted significantly when the concentration was increased above 1mM, meaning 
that they started forming intermolecular hydrogen bond above this concentration. The 
concentration of 1mM is the highest at which intramolecular hydrogen bond formation is 
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predominant and so this was chosen by Gellman and co-workers as the reference 
concentration for subsequent IR studies. Two different intramolecular hydrogen bonds can 
be formed in this case, either between the external CO-NH hydrogen bond (red) to form a 
10-membered ring, or between the internal CO-NH hydrogen bond (blue) to form an 8-
membered ring. In order to understand which hydrogen bond is formed and which stabilises 
the system best, Gellman and co-workers undertook an IR study on the four mimics 
synthesised (Figure 19). 
 
Figure 19: : IR study of tetra and disubstituted alkenes77 
Compounds 7 and 10 allow understanding of which hydrogen bond is formed, if not both. 
The mimetics 8 and 11 has the terminal amide capped with two methyl groups, which 
prevents hydrogen bond from the nitrogen (NH is absent). Consequently, only one hydrogen 
bond can be formed and that is the one that does so through an 8-membered ring system. 
Figure 19 shows NH-stretch region in the IR spectrum for these compounds. Four bands 
were shown for compound 7 – the band at 3329 cm–1 occurs in the region expected for an 
intramolecularly hydrogen bonded NH and the other bands at higher wavenumber 
correspond to solvated NHs or intermolecularly hydrogen bonded NHs. Intramolecular 
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hydrogen bonds were observed in both 7 and 10, but there is less hydrogen bonding in the 
disubstituted mimic (smaller area for the band corresponding to the intramolecularly 
hydrogen bonded NH). When the external hydrogen bond was blocked (compound 8 and 
11), only one band at 3440 cm–1 was observed, which suggests that there is only interaction 
with the solvent or intermolecular hydrogen bond so the 8-membered ring system is not 
formed. The system 7 displays extensive 10-membered ring hydrogen bonding but no 8-
membered ring hydrogen bonding. The presence of an intramolecular hydrogen bond in 
compound 11, as shown by the presence of a band at 3307 cm–1, indicates that the avoidance 
of allylic strain results in good conformational control.   
Encouraged by promising results, Gellman and co-workers extended their study to include 
the tri- and tetra-peptide mimics of Ac-Val-Gly-Gly-NMe2 and Ac-Val-Gly-Gly-Leu-NMe2 
that contained the tetrasubstituted alkene These compounds were synthesised in the same 
manner as the dipeptides and the same NMR and IR analyses were conducted. The 
concentration-dependent NMR study showed that both externals NHs (NHi and NHi+3) were 
concentration independent and so were involved in intramolecular hydrogen bond. The peak 
corresponding to the internal NH started to shift at 5 mM, meaning the 8-membered ring is 
the less stable hydrogen bonded ring formed.  
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Figure 20: NH-stretch IR of tri- and tetra-peptides and NOE cross peaks observed77 
The IR spectrum of compound 12 indicates formation of intramolecular hydrogen bond to a 
greater extent (bigger area in region corresponding to intramolecular hydrogen bond NHs 
than in the solvent-exposed region, Figure 20) and suggests that probably all NHs are 
involved in intramolecular hydrogen bond. The mimic 13 was analysed in order to 
understand which intramolecular hydrogen bond was the driving force of the β-turn 
formation. In this case, two hydrogen bonds can be formed within the molecule: an 11-
membered or an 8-membered hydrogen bonded system. As was the case with the previous 
results, the 8-membered ring is not favourable and not formed, but neither is the 11-
membered ring because the IR spectrum contains only one band at 3429 cm–1, which 
indicates that the NHs are solvated. Consequently, no intramolecular hydrogen bonds are 
formed and so a β-turn is not observed for this analogue showing that the 10-membered ring 
hydrogen bonded system is the driving force of the folding. Additionally, NOESY 
experiments were undertaken on 12 and long-range NOE cross peaks between the acetamide 
and the dimethyl groups and between the internal NHs were observed, which demonstrates 
that the tetrapeptide is adopting a folded conformation in CH2Cl2. The Gly-Gly surrogate 
placed at the centre of a peptide is useful for the development of an understanding of β-turn 
formation.  
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1.5.2.3. Leu-enkephalin analogues by Dory et al. 
Enkephalins are endogenous pentapeptides that bind to opioid receptors. Three classes of 
opioid peptides have been described: enkephalins, endorphins and dynorphins (Figure 21). 
They are naturally produced in the central nervous system by the action of peptidases and 
by post-translational modification.78  
 
Figure 21: endogenous opioids peptides and structure of morphine 
Opioid receptors belong to the superfamily of GPCR described earlier.79 They can be 
activated by endogenous or exogenous agents (such as morphine or heroin). Opioid receptors 
can be divided into three categories: μ-opioid receptors (MOR), activated by compounds 
such as morphine an opiate analgesic; δ-opioid receptors (DOR) and κ-opioid receptor 
(KOR)s.  These last two receptor types have also been targeted for the development of 
analgesic agents, which have fewer side effects than compounds binding to MOR. Indeed, 
MOR is also responsible for tolerance to and dependence on narcotics and opioid drugs.80  
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Enkephalins were discovered in the 1970s as endogenous agonists with high affinity for 
DOR and MOR, with a preference for the DOR.81 Two pentapeptides differing in their last 
residue were isolated from pig brain and were named Leu-enkephalin and Met-enkephalin. 
The ratio between them in the body seems to depend on the species. Once the structure of 
Leu-enkephalin had been elucidated, it was shown by X-ray crystallography that it can adopt 
two kinds of β-turn in its unbound form (4→1 or 5→2), stabilised by antiparallel hydrogen 
bonding between Tyr-Phe or Gly-Leu residues (Figure 22).82,83 Aside from the X-ray 
crystallography data, there is no evidence that this conformation is the one adopted by Leu-
enkephalin when interacting with its receptor. Furthermore, there is no spectroscopic data 
(IR, CD, NMR) to indicate β-turn formation of this peptide in solution.  
 
Figure 22: enkephalins and -turn conformation stabilised by hydrogen bond 
Recently, Dory and Gendron investigated the replacement of the peptide bonds in Leu-
enkephalin by either a trans-alkene or a triazole, and studied the affinity and activity of the 
resulting conformationally constrained analogues towards DOR. 84,85 Initially, each peptide 
bond was replaced with an (E)-disubstituted alkene to analyse the roles that the various 
amide bonds play in binding affinity to DOR or MOR (Figure 23).  
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Figure 23: Leu-enkephalin and the alkene analogues 
Binding affinity tests showed that the replacement of the Gly-Gly or Gly-Phe and Phe-Leu 
amide bonds (15, 16 and 17) resulted in a significant decrease in affinity for the DOR (Ki 
values were 761 ± 32 nM, 587 ± 19 nM and 196 ± 29 nM respectively compared to 6.3 ± 
0.9 nM for the native peptide), this indicates that these amide bonds are essential for efficient 
binding to the receptor. The replacement of the first amide bond (14) does not change the 
affinity for the receptor significantly. The hybrid peptides 14, 16 and 17, are still active to 
DOR, albeit to a lesser extent, while compound 15 is completely inactive, proving once more 
that this amide bond is essential for the binding and activity of the agonist. The sequential 
replacement of amide bonds by an E-alkene is an efficient way to understand the role and 
nature of interactions involving peptide bonds. The loss of affinity and activity for all 
analogues might be due to the loss of a crucial hydrogen bond to the binding pocket of the 
DOR. In order to address this issue, Dory et al. replaced selected peptide bonds with a 
triazole in order to retain rigidity in the system and provide two hydrogen bond donors; 
consequently, the hydrogen bonds could still be formed with the binding site of the receptor 
(Figure 24). 
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Figure 24: Leu-enkephalin and its triazole analogues 
The affinities and potencies of the analogues towards DOR were tested. In all cases, it was 
found that the affinity is greatly diminished even more than the analogues with an alkene 
isoster. Only the analogue 21 in which the final amide bond was replaced with a triazole 
showed a modest affinity and activity (Ki = 89 ± 12 nM, EC50 = 830 ± 66 nm), but even this 
compound was almost 13-fold less active than the native peptide. This study showed that a 
triazole is not a good peptide bond isostere because all analogues demonstrate lower activity 
and affinity for the DOR than the native peptide.  
These examples suggest that the replacement of peptide bonds by more rigid moieties may 
be useful for pharmaceutical and molecular design application. However, it is clear that 
careful design of the mimic is required and replacement of an amide bond can result in the 
loss of important hydrogen bonds or produce unfavourable steric interactions. 
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1.5.2.4. Enkephalin and endorphin mimetics by Kahn et al.  
Opioids analogues are a widely described target for peptidomimetics and β-turn mimics. The 
examples exposed by Dory and Gendron exhibited a decrease of the affinity and activity 
when a peptide bond is replaced by an alkene or a triazole. Other studies were investigated 
towards the replacement of the turn sequence by a more constraint peptide in which a 
bicyclic core is used (Scheme 3). This peptide developed by Kahn and co-workers has the 
advantage to have four different sites readily accessible by solid phase synthesis.86 The aim 
of this study was to find a potent and selective ligand towards one of the opioid receptors 
(MOR, DOR or KOR).  
 
Scheme 3: β-Turn and its bicyclic analogue general synthetic route 
The synthesis started from the commercially available bromoacetal resin which underwent 
nucleophilic substitution with various primary amine to afford the corresponding secondary 
amine 22. This is then submitted to peptide coupling with the Fmoc-protected amino acid to 
yield peptoid 23. Fmoc is then removed using 25% piperidine following by coupling with 
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β-alanine and HOBt leading to 24. After deprotection the amine was treated with the 
corresponding aryl p-nitrophenyl carbonates in the presence of DIEA to afford 25. Treatment 
with formic acid allowed cleavage of the acetal resin followed by cyclisation via aldehyde-
amide condensation to give the bicyclic peptide 26.87 With this general synthesis a library of 
compound could be accessed easily with various substituents (Figure 25). Binding affinity 
study was then undertaken by looking at competitive selective binding on radioligand 
[3H]naloxone for relatively nonselective opioid receptors in rat cerebral cortex. 
 
 
Figure 25: Diversity of component for bicyclic mimetic 26 
 From this study four compounds have been selected because they are representative of an 
enkephalin 5→2 and endomorphin 4→1 β-turn models base on the functional groups located 
at the i and i + 3 positions (Figure 26). Their IC50 has been measured to validate the SAR 
results and understand the effect of the substituent on the activity. 
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Figure 26: Four selected analogues and their IC50 
 The replacement of an alkyl chain in i + 3 position by an aromatic improved the inhibitory 
activity almost two-time fold (26b). When the i + 2 position is modified from benzyl to 
phenethyl (one more carbon in the alkyl chain, 26c), the activity greatly improved from 149 
to 27 nM, and can be further enhanced three-time fold by changing the i + 3 position with a 
benzyl group (26d, IC50 = 9 nM). The two last compounds were further studied in order to 
examine the receptor selectivity and both compounds exhibited an excellent selectivity 
towards MOR. Conformational analyses allowed to identify that 26d was adopting a type III 
β-turn. This study undertaken by Kahn and co-workers allowed the optimisation of a general 
synthesis for a large library of compounds and identify by SAR four potent analogues. 
Among these four peptides, two were further tested and showed high affinity towards MOR 
at nanomolar concentration and their binding conformation has been determined as a type 
III β-turn.  
1.5.2.5. Ellman’s cyclic b-turn mimetic library 
Following the same scheme developed by Kahn et al. with the general synthesis of 
enkephalin and endomorphin analogues, Ellman and co-workers have designed a library of 
b-turn mimetics by solid phase synthesis with various side chains functionality (Scheme 4).88 
A variety of analogues was synthesised via this method. 
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Scheme 4: Ellman's analogues and their general synthesis 
Compound 27 was obtained by treatment of rink amide resin with standard conditions for 
SPPS. Bromo acetic acid was coupled to it using DICI, which then underwent nucleophilic 
substitution with disulphide amine to obtain peptide 29. Further coupling on secondary 
amine using HATU and corresponding amino acid yielded 30. Upon Fmoc deprotection 
coupling with symmetric anhydride, the mixed disulfide was cleaved using 
tributylphosphine in a mixture of polar solvents to give 31. Rapid cyclisation using 
tetramethylguanidine followed by resin cleavage using H2O/TMS/TFA cocktail afforded 32. 
11 compounds were synthesised following this route (Table 3). 
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Table 3: analogues synthesised by Ellman and co-workers 
32 Ri+1 Ri+2 n 
a CH3 CH2-Ph 2 
b CH3 CH2-Ph 2 
c CH(CH3)2 CH2-Ph 2 
d CH2CO2H CH2-Ph 2 
e CH3 (CH2)4NH2 2 
f CH3 CH2CO2H 2 
g H CH2-Ph 2 
h H CH2OH 2 
i CH3 CH2C6H4-4-OH 2 
j CH3 CH2-Ph 1 
k CH2C6H4-4-OH CH3 1 
With this method they accessed to a rapid construction of turn mimic with a low level of 
epimerisation occurring. A 9-membered b-turn mimetic without the p-nitrophenyl alanine 
chromophore and Me chains at i + 1 and i + 2 positions was chosen as a model compound 
for conformational analysis. The 3JNH-Hα of the central amide with Hα of i + 2 residue was 
9.5 Hz, which corresponds to a dihedral angle Φi+2 of –120 ° ± 20 ° (using Karplus equation). 
On the basis of comparison with different types of turn and computational analysis, the 
lowest energy conformer adopted a type II’ b-turn conformation.89  
1.5.2.6. Katzenellenbogen’s type I b-turn mimic 
Constraint cyclic b-turn mimic were largely studied in the past decades. A highly constrained 
ten-membered lactam 33 was developed by Katzenellenbogen et al. that proved to be a good 
mimic of a type I  b-turn mimic by molecular mechanic conformational searching.90 Two 
different routes were investigated to obtain mimic 33, via curtius rearrangement and 
macrolactamisation or by ring closing metathesis (RCM). The Second route proved to be 
more efficient and represented the first example of a ten-membered lactam cyclised using 
RCM (Scheme 5).  
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Scheme 5: Spiro-bicyclic b-turn mimic synthesis 
The synthetic approach started by the alkylation of Schöllkopf’s auxiliary 34 with 1-
bromobutene affording alkene 35 in good yield and de. Diastereoisomers were then 
separated by column chromatography and hydrolysis of the auxiliary under acidic conditions 
afforded the corresponding amine which was then protected yielding protected amino acid 
36. Boc group was removed under acidic conditions affording 37 and 36 was saponified to 
afford corresponding carboxylic acid 38. 37 and 38 were coupled using standard coupling 
conditions (PyBOP and DIEA) to RCM precursor 39. Optimisation of the RCM afforded the 
desired macrolactam in 65% yield. The other diastereoisomer could be obtained following 
the same scheme. With the core turn mimic in hand, tetrapeptide derivatives were prepared 
for conformational analysis (Table 4). 
 
Table 4: tetrapeptides analogues obtained 
33a R R1 
1 Boc-Phe- -Met-NH2 
2 Boc-Phe- -Phe-OMe 
3 Boc-Ala-Phe- -Phe-OMe 
The conformational analysis consisted in temperature dependent, concentration and solvent 
dependent NMR studies and MD calculations. 33a2 was analysed and an intramolecular 
hydrogen bonds were identified between the carbonyl of the Boc group and the ring amide 
proton and between the Boc carbonyl and the NH of the N-ter Phe indicating the formation 
of a b-turn in solution. Vicinal 3J coupling constant were then measured and dihedral angles 
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extracted with the Karplus equation and used the value for torsional constraint for molecular 
modelling, the torsion angles measured were within 30° of the ideal angles for a type I b-
turn. 1D NOE experiment was also undertaken and expected b-turn cross-peaks were 
observed. The spectroscopic data proved that peptide 33a2 was experiencing a type I b-turn 
conformation in solution. Coupling constant was then compared between 33a1, 33a2 and 
33a3 and no significant difference was observed meaning that all derivatives have a similar 
conformation under various conditions. The bicyclic core was a good choice of mimetic to 
stabilise a turn conformation.  
1.5.2.7. Examples of b-turn peptidomimetics including cyclopropane 
moiety 
A small number of research groups have considered using a cyclopropane as a b-turn or b-
strand inducer. Shuto et al. reported the synthesis of conformationally restricted 
peptidomimetics based on the structural features of cyclopropane.91 Depending on whether 
the substituents on the cyclopropane are in a trans- or a cis-configuration, the system could 
mimic either a b-turn or a b-strand (Figure 27).  
 
Figure 27: b-turn or b-strand mimicking regarding cyclopropane configuration 
The natural melanocortin receptor (MCR) ligand possess the key sequence Ac-His-Phe-Arg-
Trp-NH2, which plays an important role in its receptor binding affinity. Considering this, a 
synthesis of analogues of this sequence was developed including cis- or trans-cyclopropane 
by Shuto and co-workers (Figure 28).  
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Figure 28: Designed analogues of MCR ligand 
Biological assays showed that trans-cyclopropane 40 exhibited a higher affinity for the MCR 
than the corresponding cis-cyclopropane 41. Trans-isomer 40 also showed better activity 
and specificity for one of the MCR receptors – hMC4R (Ki = 0.37-0.88 μM) – and also 
possesses a longer half-life than the original tetrapeptide (t1/2 > 24 h and about 1.7 h 
respectively in human serum). Thus, utility of cyclopropane-containing peptidomimetics to 
identify non-peptidic analogues of bioactive peptides as novel lead compounds was 
demonstrated.  
Martin et al. have also explored the use of cyclopropane unit as a rigid peptide bond 
replacement because of its potential ability to preorganised the resulting hybrid peptide into 
a conformation that is similar to the bound conformation of the original more flexible 
peptide92. A part of the peptide bond was substituted, either the NH of the ith amide 
(modification a) or the C=O of the (i + 1)th amide (modification b, Figure 29): 
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Figure 29: peptidomimetics with cyclopropane 
Various peptidomimetics were synthesised and tested on several biological targets (Renin, 
Matrix Metalloprotease, HIV-protease inhibitor and enkephalin assays).91 The results 
showed that the cyclopropyl group enforced an extended or turned conformation in each 
case whilst projecting the amino acid side chains into well-defined positions. In some cases, 
cyclopropyl peptidomimetics were highly active and more potent than the flexible 
analogues, but in other cases it was detrimental to change the peptide amide bond because 
crucial hydrogen bonding was lost. This hydrogen bonding is needed because it allows the 
peptide to bond with the target and thereby inhibit or activate it, as seen with Leu-enkephalin 
analogues. In all cases, a trans-cyclopropane unit appears to be more compatible with locally 
extended structures than a cis-cyclopropane. 
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1.5.3. Cyclopropanes: generality and synthesis 
All carbons of a cyclopropane lie on the same plane and all the C–C bonds have the same 
length which means the three carbons are at the corner of an equilateral triangle. This 
structure is considerably strained due to the bond angle (60 °) deviating greatly from the 
optimum tetrahedral angle of 109.5 °. Any rotation around a simple C–C bond in a 
cyclopropane is impossible, so all of the C–H bonds are forced to be eclipsed (Figure 30). 
The C–C bonds of cyclopropane are bent and can be considered to be intermediate in 
character between s- and p-bonds. In fact, it has been shown that a cyclopropane attached 
to a carbonyl group has roughly the same spectroscopic properties as an α,β-unsaturated 
carbonyl.93 These properties make the cyclopropane much more reactive than other 
cycloalkanes such as cyclohexane and cyclopentane as an amide bond surrogate.  
 
Figure 30: View along C–C bond and orbitals arrangment in cyclopropane 
Cyclopropanes are present in many natural compounds. Indeed, everyone is familiar with 
the ‘salty’ smell of the sea which is actually the dictyopterene (Figure 31), a family of 
volatile cyclopropanes used by female algae to attract male gametes.94 A cyclopropane is 
also present in hypoglycin,95 a blood sugar level lowering agent from the ackee tree. More 
than a hundred pharmaceutical agents contain a cyclopropyl group, such as the antidiabetic 
drug Sexagliptin and U-106305, 96,97 which is a potential therapeutic agent for coronary heart 
disease.  
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Figure 31: natural and synthetic compound containing cyclopropyl group 
The synthesis of cyclopropane was first reported by August Freund in 1881 who treated 1,3-
dibromopropane with sodium leading to the cyclopropane by a Wurtz reaction.98 Most 
chemical syntheses of cyclopropanes involve the addition of a carbene or a carbenoid to an 
alkene. This is well demonstrated by the Simmons-Smith reaction in which an alkene 42 
reacts with a zinc carbenoid species that has been formed in situ from diethylzinc and 
diiodomethane (Scheme 6a).99 In 1998, Charette et al. developed an asymmetric 
cyclopropanation reaction in which one equivalent of the boronate ligand 44 was used as 
chiral auxiliary and used this method to complete the total synthesis of U-106305.100,101 A 
yields of more than 80% were obtained and good enantiomeric excesses (>90%) were 
achieved for a wide range of allylic alcohols 43 (Scheme 6b) by use of this method. Allylic 
alcohols undergo cyclopropanation much faster than the corresponding unfunctionalised 
alkenes because of the coordination between the zinc and the Lewis-basic oxygen of the 
hydroxyl group in the transition state; coordination also explains the high levels of 
stereoselectivity. In 2003, Shi et al. reported the use of modified zinc carbenoids employing 
trifluoroacetate.102 This method increases the rate of conversion considerably via a [2+1] 
pathway at room temperature when a conjugated or symmetric alkene 45 in reacted (Scheme 
6c).  
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Scheme 6: Simmons-Smith reaction and its variations 
An alternative cyclopropane synthesis has been developed recently that involves a different 
transition metal mediated reaction to generate the carbenoid. Fokin et al. developed a 
reaction that involves in situ generation of a rhodium carbenoid from a triazole or 
sulfonyltriazole (Scheme 7).103 When a chiral complex such as Rh2{(S)-NTTL}4 was used, 
cyclopropanes were obtained with yields of up to 99% and with high enantioselectivity (ee 
> 96%) and diastereoselectivity (dr 1:20). However, this method could be only used to 
produce trisubstituted cyclopropanes enantioselectively.  
 
Scheme 7: Fokin's enantioselective cyclopropanation 
Ruthenium was also reported as an excellent transition metal for the generation of carbenoids 
from diazoesters. Indeed, Iwasa and co-workers found that Ru(II)-Pheox could be used to 
catalyse the reaction of ethyl diazoacetate with an enamine to form a cyclopropylamine 
within 5 h in 99% yield and good selectivity (ratio trans/cis 7:3) (Scheme 8).104 In contrast, 
the use of rhodium acetate as the catalyst resulted in poor stereoselectivity. However, it is 
possible to epimerise from the cis-isomer to the trans-isomer in a further step which will be 
described in a future section.  
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Scheme 8: cyclopropanation using diazoester and Ru catalyst 
Despite its explosiveness and toxicity diazomethane has been found to be a good reagent for 
cyclopropanation. Diazomethane is usually generated in situ or immediately prior to use by 
the reaction of Diazald® and a solution of KOH in water (Scheme 9).105 
 
Scheme 9: cyclopropanation using diazomethane generation in situ 
Table 5 summarise some of the conditions that have been described for the formation of 
cyclopropanes from diazomethane. In most of the procedures, alkene possesses an electron-
withdrawing substituent.  
 
Table 5: Cyclopropanation using diazomethane reported in literature 
Entry Alkene Cat. Ligand Results 
1 R1 = Ph, R2 = R3 = H, R4 = CO2Me CuOTf·0.5PhCH3 
 
40-80% yield 
48-77% ee 
2 R1 = H or Me, R2 = Aryl, R3 = R4 = H 
 
- 
64-89% yield 
Open to air 
 
3 R1 = H, R2 = Aryl, R3 = H or CONMeOMe, R4 = H or CO2Me Pd(OAc)2 - 
64-99% for 
trans-alkene 
15-73% for 
cis-alkene 
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Charette et al. have described the use of a bis-(oxazoline) ligand and copper triflate to 
generate a cyclopropanation catalyst (Table 5, entry 1).106 They noticed that CuOTf or 
Cu(OTf)2 were equally effective for catalyst formation. They reported decent yields with 
acceptable levels of stereocontrol for the trans-cyclopropane formed. Carreira and co-
workers improved the use and formation of diazomethane in situ by using an iron catalyst 
(Table 5, entry 2).107 Indeed, the use of this catalyst combined with very slow addition of 
Diazald® in the pre-mixture allowed the reaction to be performed in open air. This method 
gave relatively good yields and selectivities for formation of trans-cyclopropanes, but an 
asymmetric variant of the reaction was not reported. Cyclopropanation of alkenes with 
diazomethane has also been used for the synthesis of therapeutic targets (Table 5, entry 3).108 
In this case, the synthesis of trans- and cis-cyclopropane in a relatively good yield was 
reported.  
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1.6. Introduction to the design and synthesis of b-
turn mimics in the Clark group 
1.6.1. Previous work in the group 
1.6.1.1. Ynamides and alkynes Leu-enkephalin peptidomimetics 
The first approach of the Clark group towards a b-turn mimetic was to synthesise 
macrocyclic ynamides or alkynes that would mimic the turn conformation of the 
pentapeptide Leu-enkephalin (Figure 32).109  
 
Figure 32: Ynamides and alkyne peptidomimetics 
As shown in Figure 32, it was intended that an ynamide or alkyne would replace the 
hydrogen bond by a covalent bond, restraining the system and forcing it to adopt the turn 
conformation. Those units were chosen for several reasons. Firstly, almost all the functional 
groups remain and the only group to be replaced is the hydrogen bonded carbonyl; secondly, 
the bond distance between atoms 1 and 2 in the figure is similar (Table 6).  
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Table 6: bond lengths of mimetics 
Structure Distance (Å) 
 
4.2183 
 
4.14a 
 
4.21a 
a using known average bond lengths summed up 
The bond length is relatively similar to that in the hydrogen bonded structure, which makes 
the surrogates good choices for use in b-turn mimicry.   
Various models were used in order to explore reactions required to prepare the ynamide and 
alkyne and effect the macrocyclization reaction. The initial strategy involved formation of 
the ring by intramolecular ynamide synthesis from precursor 50, which was obtained by 
coupling between 48 and 49. TFA salt 48 was obtained in two steps from Phe methyl ester 
hydrochloride by amide coupling with Boc-Gly and subsequent deprotection. Alkyne 49 was 
obtained by tosylation of propargyl amine followed by N-alkylation using t-butyl 
bromoacetate affording the desired acetylenic fragment. Bromination of the alkyne with 
NBS and AgNO3 followed by ester cleavage afforded 49 in 65% over 4 steps (Scheme 10).  
 
Scheme 10: precursor 50 synthesis 
The synthesis of compound 50 meant that the intramolecular cyclisation reaction could be 
explored. The initial attempt to construct the ring was performed using Hsung’s second 
generation amidation condition (Table 7, entry 1).110 This revised amidation reaction 
involves the use of copper sulphate pentahydrate as catalyst, phenanthroline as ligand and 
K3PO4 as base. When the loading and temperature described by Hsung was followed, there 
was no reaction. When, loadings of the catalyst and ligand were increased and the reaction 
temperature was raised, decomposition of the substrate was observed.   
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Table 7: macrocyclisation attempts for ynamide formation 
Entry Conditions Results, comments 
1 
10-20 mol% CuSO4·5H2O 
20-40 mol% 1,10-phenanthroline, K3PO4 
Toluene, 70 °C 
Slow or no conversion 
Decomposition with high loading and 
temperature 
2 
FeCl3·6H2O 
DMEDA, K2CO3 
Toluene 90 °C 
No conversion 
SM recovered 
3 
CuI 
KHMDS, Pyridine 
THF, rt 
No conversion 
SM recovered 
4 
CuCN 
K3PO4, Pyridine 
Toluene, 90 °C 
No conversion 
SM recovered 
5 
10 mol% CuSO4·%H2O 
20 mol% 1,10-phenanthroline, K3PO4, 
Ni(acac)2 
Toluene, 70 °C 
Little conversion 
Decomposition with time 
6 
, 
, 
Toluene, 85 °C 
Dimerisation of SM 
The reaction was then performed using conditions described by Zhang et al. using Iron(III) 
chloride hydrated (Table 7, entry 2).111 These workers had used the reaction to couple 
oxazoidinones, sulfonamides and lactam substrates, but had not explored intramolecular 
amidation. Intramolecular cyclisation did not occur under these conditions and starting 
material was recovered. Danheiser and co-workers had reported amidation promoted by a 
stoichiometric amount of CuI.112 Unfortunately, under Danheiser’s conditions, no reaction 
occurred and almost all of the starting material was recovered (Table 7 entry 3). Following 
these disappointing results, Hsung’s first generation conditions were employed in which 
CuCN was used as the copper sources instead of CuSO4 (Table 7 entry 4). This reaction 
resulted in no conversion of the starting material and so attempts were made to optimise the 
reaction conditions, by changing the ligand, the metal, the alkyne, the solvent and the 
reaction temperature. The use of Ni as additive showed promising results for intermolecular 
coupling reaction between (bromoethynyl)benzene and protected Gly (73% yield) and so the 
reaction was tested on substrate 50 (Table 7 entry 5). Unfortunately, this reaction resulted in 
decomposition of the starting material over time and the required product was not obtained.  
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The reaction was then investigated further using various ligand and catalyst combinations 
(Table 7 entry 6), via an allenamide intermediate. In this case, the catalyst was copper 
thiophenecarboxylate (CuTC) and 1,2-dimethylaminocyclohexane was employed as the 
ligand. This procedure produced interesting results for the synthesis of ynamide using 
alkynyl bromide.113 Unfortunately, reactions performed in toluene delivered an undesired 
compound, which appeared to be a dimer of 50. Attempts were made to conformationally 
constrain the system by installing a Pro residue in the peptide chain (Scheme 11) in the 
expectation that this would orientate the alkynyl bromide and the amide for cyclisation and 
reduce the entropic penalty in the transition state.  
 
Scheme 11: Proline analogue and its precursor 
Compound 53 was synthesised in four steps with yield of 34% by a series of deprotection 
and amide coupling reactions. This substrate was then submitted to macrocyclisation under 
the conditions of Hsung’s second general protocol and also reaction with CuTC catalyst. The 
former reaction resulted in no reaction with recovery of the starting material and the latter 
reaction produced an undesired compound that appeared to be the dimer by NMR analysis. 
As a consequence of these negative results and the failed attempts to achieve prepare target 
53 by an amidative cross-coupling reaction, the target was revised and the precursor 55 was 
synthesised (Scheme 12).  
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Scheme 12: synthesis of precursor 57 
The synthesis of 57 started from commercially available glycidol. Epoxide opening was 
accomplished using optimised Yamaguchi-Hirao alkylation conditions with n-BuLi and 
BF3·THF complex.114 This reaction afforded the alkyne 54 in 66% yield. N-Alkylation gave 
55 followed by azide displacement of the tosylate and a Staudinger reaction afforded amine 
56. Subsequent ester cleavage using TFA, produced the cyclisation precursor 57 in 22% 
yield over 6 steps. Efforts were then focused on the cyclisation by amide coupling by use of 
conditions that are summarised in Table 8. 
 
Table 8: amide coupling screening 
Entry Conditions Results 
1 BOP, HOBt, DIPEA CH2Cl2/DMF No conversion 
2 EDCI, DMAP CH2Cl2/DMF No conversion 
3 FDPP, DIPEA DMF Decomposition 
4 DMTMM, DIPEA DMF Decomposition 
5 PyBOP, DIPEA DMF Decomposition 
6 Co2(CO)8, CH2Cl2 Then amide coupling reagents No to poor conversion 
Common coupling reagents were used (table 8, entries 1, 2 and 5, Figure 33) in attempts to 
affect the cyclisation reaction. Unfortunately, the required lactam was not obtained, even 
after extended reaction times of several days and addition of further amounts of the coupling 
reagent(s).  
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Figure 33: coupling reagents used for the screening 
It had been reported that pentafluorophenyl diphenylphosphinate (FDPP) and 4-(4,6-
dimethoxy-1,3,5-triazin-2-yl)-5-methylmorpholinium (DMTMM) were efficient coupling 
agents for peptides containing macrolactams.115 Precursor 57 was then submitted to amide 
coupling using FDPP or DMTMM (Table 8, entries 3 and 4) but only decomposition of the 
starting material was observed by NMR of the reaction mixture. A hypothesis that could 
account for the failure of these reaction conditions was that the precursor might be too 
constrained by the triple bond, which prevented cyclisation. In order to address this issue, it 
was decided to form a cobalt-alkyne complex with the expectation that triple bond would 
show more double bond type character and a less strained ring-system would be produced.116 
The cobalt complex of 57 was prepared and isolated, but the subsequent amide coupling 
reaction did not deliver the required target 58 (Table 8, entry 6). The various coupling 
reagents listed in table 5 were used as well, but none gave promising results.  
Optimisation of both ynamide synthesis and alkyne cyclisation reactions to give the desired 
peptide mimic were unsuccessful. The replacement of the non-covalent hydrogen bond by a 
covalent triple bond was considered to be a good strategy considering the atom distance 
mentioned earlier, but another target was required in order to avoid the macrocyclisation 
step, which seemed to be impossible to achieve.  
1.6.1.2. Trans-cyclopropane peptide bond isostere 
The Clark group strategy moved towards the synthesis of a completely different class of 
analogues. It was decided that replacement of a peptide bond by a rigid group such a 
cyclopropane would be better than replacement of the hydrogen bond by a covalent linker. 
This would constrain the system more than in a regular peptide bond and increase the 
stability of the mimic under physiological conditions by preventing proteolytic cleavage at 
this position.  
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Initial studies towards the synthesis of the protected cis- or trans-cyclopropane-containing 
Gly-Gly surrogate (Figure 34) were undertaken.  
 
Figure 34: trans- and cis- cyclopropane targets 
Several route towards these compounds were investigated. The synthesis of the trans-59 was 
accomplished in 9 steps with an overall yield of 36% starting from the commercially 
available propan-1,3-diol (scheme 13).117  
 
Scheme 13: trans-59 synthesis via HWE olefination and Shi cyclopropanation 
The synthesis started with mono-protection of propan-1,3-diol with a TBDPS group. 
Subsequent Swern oxidation delivered the corresponding aldehyde necessary for the Horner-
Wadsworth-Emmons (HWE) olefination.118 This reaction involved the phosphonate 62 and 
resulted in the stereoselective formation of the (E)-alkene 63. Ester reduction with DIBAL-
H afforded the allylic alcohol 64 and a Simmons-Smith reaction was undertaken using Shi’s 
conditions to give the trans-cyclopropane 65.119 From the alcohol 65, a Mitsunobu reaction 
was performed using phthalimide to introduce the desired protected amine functionality and 
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deliver the imide 66. The silyl ether was cleaved and the resulting alcohol 67 was oxidised 
to the corresponding carboxylic acid trans-59 via stepwise Swern and Pinnick oxidation 
reactions. The synthesis of the racemic protected amino acid trans-59 was completed in 9 
steps.  
An analogous route was used to synthesise cis-60.120 Previously, cyclopropanation of the 
(E)-alkene 64 had resulted in formation of the trans-cyclopropane, but in this case a Still-
Gennari olefination reaction was used instead of the HWE reaction to access to (Z)-alkene 
69.121 cis-Cyclopropane 71 was installed in the next step using the conditions described in 
scheme 14. The synthesis was completed by the same sequence of reactions as above to give 
the racemic target compound cis-60 in 9 steps and in a 10% overall yield.  
 
Scheme 14: cis-60 synthesis via Still Gennari olefination 
The Still-Gennari modification employs two electron-withdrawing trifluoroalkoxy 
substituents on the phosphonate 68 rather than the ethoxy group on the phosphonate 62 
which produced the (Z)-alkene 69 with Z/E a ratio of 20:1. The subsequent steps followed 
the same procedure as described for the synthesis of trans-59.  
This work was promising in that it produced dipeptide mimics that are similar to those 
described by Gellman et al. but in which an alkene is used to replace the amide bond instead 
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of a cyclopropane.76 Both dipeptides were synthesised as racemic mixtures and no analyses 
concerning intramolecular hydrogen bond formation were undertaken. Analysis of hybrid 
peptide that contain cyclopropane-containing peptide mimics to establish whether 
intramolecular hydrogen bonding is present was to be one of the main challenges of the work 
presented in this thesis. 
1.6.2. Aim of this work 
Using the concept of cyclopropane peptidomimetics, the Clark research group was interested 
in synthesising cyclopropane derivatives where a cyclopropane is used to replace a peptide 
bond (Figure 35) in order to induce b-turn formation. The first objective was to synthesise 
both racemic and enantioenriched dipeptide surrogates containing a cyclopropane moiety. 
Following their successful synthesis, the next step was to be the incorporation of these 
isosteres into various peptides. Various NMR and IR spectroscopy techniques would then 
be used to perform conformational analysis to verify formation of intramolecular hydrogen 
bond and identify general conformations adopted by the peptides.  
 
Figure 35: b-turn in a peptide, hypothetic b-turn mimicry, structure of the desired dipeptide 
surrogate 
The length of the peptide was to be varied from 2 to 12 residues in order to understand the 
stability of the peptides and their propensity to adopt the desired conformations. The peptides 
were to be analysed by IR, NMR and CD methods in order to prove b-turn formation. 
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Chapter 2  
Results and discussion 
2.1. Compounds Naming and Abbreviations  
Abbreviations have been used throughout this thesis to simplify the naming of the 
compounds that have been synthesised. Peptides and proteins are named from the N-
terminus to the C-terminus so the nomenclature is consistent. The dipeptide mimic 74 will 
be named PGN-{GlyΔGly}-OH, where PG is the protecting group installed (Figure 36) and 
Δ refers to the cyclopropane that replaces the peptide bond. 
 
Figure 36: PGN-{GlyΔGly}-OH 
The stereocenters are named from N-terminus to the C-terminus, carbon 1 represents the CH 
of the cyclopropane located on the N-terminal side, carbon 2 the CH located on the C-
terminal side. For example, (R,S)-NPG-{GlyΔGly}-OH corresponds to carbon 1 with R-
configuration and carbon 2 with S-configuration. In the case of racemic mixtures, the peptide 
will be named (±)-NPG-{GlyΔGly}-OH. In the event of longer peptides, the residue will be 
incorporated in the name as in the official nomenclature; e.g. (R,S)-PGN-X1-{GlyΔGly}-X2-
OH. The stereochemical assignments given in brackets correspond only to the configuration 
of the cyclopropane, the configuration of the natural amino acids X1 and X2 will not be 
included. 
2.2. Strategy 
b-Turn mimetics have proven to be promising tools in medicinal chemistry as well as 
synthetically challenging targets in organic and peptidomimetic chemistry. Over the past 
few decades, they have allowed chemists and biologists to develop a better understanding of 
protein-protein interactions in biological processes.84,91 From natural peptides to constrained 
peptidomimetics, research in the area of b-turn mimetics has grown rapidly in recent decades 
and promising results have been obtained in the field of drug discovery.122,123,124  
PGN 1*
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The objective of this project was to demonstrate that b-turn-like structures could be 
generated in small peptides by the synthesis non-natural hybrid peptide analogues that 
contain an amide bond replacement group. Constrained peptides have been shown to be 
capable of b-turn mimicry and at the outset of the project, Gellman et al. had demonstrated 
that it was possible to detect intramolecular hydrogen bonds in non-natural hybrid peptide 
analogues using FTIR and NMR spectroscopy (cf. section 1.6.1.2). In Gellman’s case, a 
combination of FTIR and NMR spectroscopy was used to identify formation of the b-turn 
in hybrids in which a peptide bond between two Gly residues had been replaced by a (E)-
alkene (Figure 37).125,126 Hydrogen bonds between the amide groups present in the 
compounds were identified. Tetrasubstituted alkenes were found to be effective amide bond 
surrogates and enhanced the formation of a b-turn in small peptides. The challenge was to 
identify differences when the peptide bond is replaced by a non-planar moiety such as a 
trans-cyclopropane instead of an alkene. Analogues of the model peptides designed by 
Gellman and co-workers were synthesised and analysed using the same conditions by IR 
and NMR in order to provide a benchmark for our own analogues (Figure 37).  
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Figure 37: Gellman peptidomimetics and our analogues 
The strategy was to prepare the trans-cyclopropane at the start of the synthesis by an efficient 
route that would permit access to significant quantities of both enantiomers. After 
enantioenriched compounds had been obtained, the Gly-Gly surrogates PGN-{GlyΔGly}-
OH were to be synthesised. Before revisiting the first-generation route previously developed 
in the group, the readily available racemic dipeptide mimic (±)-NPhth-{GlyΔGly}-OH 59 
was subjected to peptide coupling to produce the first analogue (±)-75 (Scheme 15). 
 
Scheme 15: Towards the dipeptide mimicry for IR study 
Peptide coupling using EDCI and DMAP was performed to give the amide (±)-81 in 65% 
yield. Cleavage of phthalimide protecting group was attempted using hydrazine but this 
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reaction did not succeed. Consequently, the Boc group was chosen for N-protection in the 
revised route because the removal of this group does not require harsh conditions. 
2.3. Boc-{GlyΔGly}-OH Synthesis 
2.3.1. Retrosynthetic Analysis 
An optimised route towards the trans-PGN-{GlyΔGly}-OH was designed and the 
functionalised cyclopropane was constructed first so that cyclopropanation of a more 
complex alkene substrate was avoided. Diastereoselective cyclopropanation of butadiene 
has been well described and various methods are available to accomplish this reaction, so 
this was an attractive starting point for synthetic work.127,128,129,130  
 
Scheme 16: Retrosynthesis 
Preliminary retrosynthetic analysis suggested that PGN-{GlyΔGly}-OH 74 could be 
obtained from the boronate ester 83 by successive oxidation reactions (scheme 16).131 The 
boronate ester 83 could be installed by performing a cross metathesis reaction on the terminal 
alkene 84,132 which possesses a protected amine functionality. The amine could be 
introduced by reduction of the carboxylic acid 85 to the corresponding alcohol, followed by 
a Mitsunobu substitution reaction with a suitable N-nucleophile. The carboxylic acid 85 
could be obtained by cyclopropanation of butadiene using diazoester to yield a mixture of 
cis- and trans-cyclopropanes. It was anticipated that a reaction epimerisation would be used 
in order to obtain mainly the trans-isomer and subsequent resolution of the racemic 
carboxylic acid using a chiral amine would deliver two separable diastereoisomers, which 
would then be hydrolysed to give sufficient quantities of the enantioenriched compounds.  
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2.3.2. Towards the Synthesis of 2-Ethenyl-cyclopropanemethanol 
Precursor    for N-terminus Installation  
The first challenge was the synthesis of trans-cyclopropane motif with high 
distereoselectivity (scheme 17). It is known that it is difficult to achieve high levels of 
diastereocontrol when metal carbenes bearing chiral non-racemic ligands are used to 
promote the reaction of diazo compounds with disubstituted alkenes.133 Consequently, the 
decision was made to use Rh2(OAc)4 as catalyst for the cyclopropanation reaction and then 
epimerise the resulting mixture of cyclopropanes to give the more stable trans-isomer as 
describe in literature.134  
 
Scheme 17: Synthesis of 2-ethenylcyclopropane-1-carboxylic acid 85 
The synthesis of cyclopropane 86 was performed by reaction of ethyldiazoacetate with 
butadiene under Rh2(OAc)4 catalysis. When ethyldiazoacetate was added too quickly, 
diethyl fumarate and maleate were obtained as side-products due to dimerization of the 
diazoester. Indeed, the reaction of dimerization of the diazoester is faster than the 
cyclopropane formation. Therefore, optimisation of the reaction conditions was undertaken 
to avoid the formation of these by-products (Table 9). 
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Table 9: Optimisation of the cyclopropanation reaction of butadiene 
Entry 
Butadiene 
in CH2Cl2 
(M) 
Ethyldiazoacetate  
in CH2Cl2 (M) 
Addition 
rate 
(mL.h–1) 
Reaction 
time 86:87–88 ratio
a trans:cis ratioa 
1 11.4 neat 14  4 h 0:1 - 
2 10.5 neat 7  4 h 1:1 1:1 
3 10.5 1.75 10 2 h 2.5:1 1:1 
4 10.5 1.75 8 1 h 1:0 1:1 
aDetermined by 1H NMR 
In the first experiment, neat ethyldiazoacetate was added at a rate of 14 mL/h (Table 9, entry 
1), but in this case only diethyl fumarate 87 and maleate 88 were isolated. When the reaction 
mixture was diluted slightly and the rate of addition was reduced to 7 mL/h (Table 9, entry 
2), a ratio 1:1 of side-products to products was obtained. The isomers were differentiated by 
NMR by measuring the coupling constant on the CH of the cyclopropane. Separation of the 
isomers by column chromatography was attempted but both compounds and side-products 
eluted together so was attempts were made to further optimise the reaction. 
Ethyldiazoacetate addition rate and concentration seemed to be the main issue so it was 
added as solution in CH2Cl2 (Table 9, entries 3 and 4). The best result was obtained with the 
slowest flow rate (Table 9, entry 4) and in this case only the cyclopropanes were obtained in 
good yield (69%, 1:1 dr). The next objective was to perform based-mediated epimerisation 
of the diastereomeric mixture to obtain a trans-cyclopropane (Table 10).  
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Table 10: Epimerisation Optimisation 
Entry Base Time (days) Product trans:cisa 
1 NaOEt in situ 
(from NaH and EtOH) 
1 R = OEt, 86 3:7 
2 DBU 6 R = OEt, 86 3:2 
3 NaOEt in situ 
(from NaH and EtOH) 
4 R = OH, 85 3:2 
4 NaOEt 2 м 
(from Sigma Aldrich) 
7 R = OEt, 86 3:2 
5 NaOEt in situ 
(From Na solid and EtOH) 
1 R = OH, 85, 95% 9:1 
a Determined by NMR 
DBU is commonly used as a base for epimerisation,135 but the observed ratio of 3:2 did not 
improve after 6 days (Table 10, entry 2). Sodium ethoxide (NaOEt) is also a common based 
used for epimerisation and EtOH has a similar pKa to that of t-BuOH. NaOEt can be 
generated in situ or used as a commercially available solution. When it was generated in situ 
from NaH and ethanol (Table 10, entries 1 and 3), slow epimerisation occurred after a day 
and a ratio 3:7 of isomers was obtained which favoured the cis isomer. After a longer time 
of reaction (4 days) the trans:cis ratio was improved to 3:2 and an acidic work up gave the 
corresponding carboxylic acid instead of the ester, which obviated subsequent ester 
hydrolysis. This was contrasted with the case in which commercially available solution of 
NaOEt was used (Table 10, entry 4).134 However, the ratio observed after seven days was no 
better than that which had been obtained previously. When NaOEt was formed in situ using 
sodium metal dissolved in EtOH (Table 10, entry 5), epimerisation and hydrolysis occurred 
with an acidic work-up to give the carboxylic acid with a 9:1 dr and in 95% yield after only 
one day. Freshly prepared NaOEt was essential for the epimerisation to occur rapidly and 
the source of sodium was essential for in situ generation to produce good quality reagent. At 
this stage of the synthesis is was impossible to establish the configuration on the 
cyclopropane, the compound being an oil and the cyclopropyl hydrogens overlapping on the 
NMR spectrum, no data could be collected towards the obtention of the trans compound. 
However, crystal structure could be obtained from racemic peptide 75 synthesised later 
(Scheme 18). It was clear that this peptide synthesised from the cyclopropanation using 
carbene chemistry described earlier was trans. As no epimerisation could occur along the 
route designed, it was possible to state that trans-cyclopropane was obtained and isolated. 
EtO2C EtO2C
trans-86 cis-86
+
RO2C RO2C
trans cis
+
conditions
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Scheme 18: Resolution of carboxylic acid (±)-85 and hydrolysis of the resulting amide and X-ray 
crystal structure of peptide 75.  
The diastereoenriched carboxylic acid (±)-85 was now available in reasonable quantities and 
so separation of the enantiomers by formation of diastereoisomeric amides with (R)-
phenylglycinol could be investigated (scheme 18).136 The carboxylic acid was deprotonated 
with N-methylmorpholine and converted to its mixed anhydride using i-BuOCOCl. 
Nucleophilic attack of (R)-phenylglycinol on the activated electrophile gave the resulting 
amides 89. The diastereoisomers were obtained in a 1:1 ratio and were easily separable by 
careful column chromatography. Once separated, the synthesis of the dipeptide mimic was 
pursued using both enantioenriched compounds in parallel. Hydrolysis of the amide using 
10% KOH in MeOH afforded (R,S)-85 and (S,R)-85 in yields of 95% and 82% respectively. 
Acidic hydrolysis reactions using various concentrations of sulfuric acid were also attempted 
but only decomposition of the substrate was observed. Reduction of the carboxylic acid was 
performed using LiAlH4 to give the primary alcohols (R,S)-90 and (S,R)-90 in good yield 
but the reaction solvent had to be removed carefully by distillation owing to the volatility of 
the products. Overall, enantioenriched alcohols (R,S)-90 and (S,R)-90 were synthesised in 5 
steps in yields of 9% and 14% respectively.  
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Scheme 19: Amide reduction attempts 
Attempts were made to reduce the amide 89a-b directly to the corresponding primary amine 
in order to avoid the hydrolysis steps (Scheme 19). Various metal hydrides (LiAlH4, LiBH4, 
Red-Al) were tested in small scale reactions but they were unsuccessful. N-Alkylation of the 
amide was undertaken, in order discover if tertiary amides would be more prone to 
reduction.137 Unfortunately, attempts to alkylate the amide were ineffective and only the 
alcohol was alkylated. At this stage, this route was abandoned and alternative approaches 
were considered.  
The difficulties in reproducing some of the steps in good yield combined with the low overall 
yield prompted the design of an alternative synthesis. The new route was designed to avoid 
low-yielding and unnecessary steps such as the epimerisation and resolution reactions. An 
attractive approach to the synthesis of the cyclopropane was evident from the work of Brandi 
and co-workers who has described a 3-exo-cyclisation of an allylic anion generated using 
the superbasic reagent LIDAKOR, (scheme 20).138 The LIDAKOR base is generated from 
n-BuLi, diisopropylamine and potassium tert-butoxide and is similar to the Schlosser’s base 
(BuLi/t-BuOK) except that diisopropylamine is added to the equimolar mixture. The 
presence of a dialkylamine makes the base less nucleophilic and in this case prevents 
elimination of the epoxide directly. This allows LIDAKOR to deprotonate the substrate at 
the α-position of the alkene. The resulting allylic anion undergoes a 3-exo-cyclisation with 
opening of the epoxide to give the thermodynamically stable trans-cyclopropane exclusively 
at low temperature.  
74
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Scheme 20: LIDAKOR Cyclopropanation and mechanism 
In this case, use of the previously reported reaction conditions gave the cyclopropane 90 in 
quantitative yield (Scheme 20). It was found that the reaction was amenable to scale-up (20 
g) by use of very concentrated 11 M n-BuLi commercially available. Comparison with the 
NMR of enantioenriched alcohol 90 obtained via carbene chemistry allowed to identify that 
only the trans isomer was obtained.  
2.3.3. N-Terminus Functionalisation 
The aim was to convert alcohol 90 into the corresponding primary amine bearing an 
appropriate protecting group. The first approach was installation of the amine by use of a 
Staudinger reaction and subsequent Boc-protection (Scheme 21).  
 
Scheme 21: Towards Staudinger reaction for amine installation 
Elaboration of the alcohol 90 commenced with the activation of the alcohol to generate a 
good leaving group. Generation of a tosylate was attempted but the reaction led to 
decomposition of the starting material.139 It was possible to prepare the mesylate 91 but it 
was unstable and had to be used immediately. Azide substitution using sodium azide was 
successful and the reaction delivered compound 92 in 79% yield over 2 steps.140 
Unfortunately, Staudinger conditions did not deliver the corresponding protected amine 93. 
This method was not only unsuccessful but also considered to contain too many steps for 
efficient installation of the amine.  
An alternative approach, in which the protected amine would be installed by a Mitsunobu 
reaction in a single step, was very attractive (Scheme 22). Reaction with phthalimide was 
explored first and previously described Mitsunobu conditions were employed, the required 
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compound 94 was obtained in quantitative yield (Scheme 22a).141 Conditions for phthalimide 
removal are known to be harsh and it proved very difficult to remove this group. It was 
impossible to remove the protecting group in good yield even when the imide 94 was heated 
at reflux in neat hydrazine; only starting material was recovered. The phthalimide cleavage 
reaction was attempted at later stages of the synthesis but was never successful.  
Le Corre et al. has reported N-Boc ethyl oxamate to be compatible with Mitsunobu 
conditions because of its low NH pKa (pKa = 8.3 in H2O, Scheme 22b).142,143,144 It seemed 
likely that this compound could serve as an N-nucleophile during a Mitsunobu reaction with 
the alcohol 90. The synthesis of N-Boc ethyl oxamate 97 started from the commercially 
available ethyl oxamate, which was treated with oxalyl chloride to produce the isocyanate 
96 in variable yields. Subsequent treatment of the product with 1.1 equivalents of tert-
butanol led to 97. However, the reaction to form the isocyanate was very difficult to 
reproduce and the main product in each case was the bis-oxalate 98 because of the highly 
reactive isocyanate reacting quickly with another isocyanate. Altering of several of the 
reaction parameters (scale, solvent, order and time of addition, temperature of reaction, 
concentration) did not improve matters. Even when reactions were performed under identical 
conditions and in parallel, varying amounts of products were observed by 13C NMR analysis. 
In spite of the poor reproducibility of the reaction, sufficient quantities of the isocyanate 96 
were obtained over the course of this study (Scheme 22b). The Mitsunobu reaction with 
alcohol 90 afforded 99 in very good yield and the oxamate was cleaved by treatment with 
LiOH in H2O/THF to afford the Boc protected compound 93 in a respectable yield.  
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Scheme 22: Mitsunobu reaction 
The synthesis of the oxamate nucleophile required for the Mitsunobu reaction was 
impractical so NH(Boc)2 was investigated as an alternative nucleophile (Scheme 22c). 
NH(Boc)2 is less acidic than the phthalimide or N-Boc ethyl oxamate but is still sufficiently 
acidic to participate in the Mitsunobu reaction.145 The substitution reaction proceeded to give 
the bis protected amine 100 but in slightly lower yield than before owing to the higher pKa. 
As described previously,146 mono-Boc removal was performed by treatment of the bis-
carbamate 100 with 1.5 eq. of TFA to afford the mono-deprotected amine 93 in 83% yield 
after purification by column chromatography. Although, one Boc group could be cleaved 
efficiently, both Boc groups were retained at this stage because of efficiencies later in the 
synthesis.  
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2.3.4. C-Terminus Installation  
Cross metathesis between terminal alkene and vinylboronate and subsequent oxidation is 
known to be an efficient method for the generation of aldehydes from terminal alkenes. Frey 
et al. have also demonstrated that it is possible to perform cross metathesis reactions on 
cyclopropane-containing substrates.147 The cross metathesis reaction was applied to the 
alkene 93 (Scheme 23).  
 
Scheme 23: Cross metathesis using vinyl boronic pinacolic ester 
The substrate was treated with the pinacol vinylboronate as the cross metathesis partner in 
presence of 5 mol% of Grubbs II catalyst. However, little conversion was observed over the 
course of two days and the product 101 degraded rapidly on column chromatography.  Only 
traces of the desired aldehyde 102 were obtained when oxidation was performed on the crude 
reaction mixture using sodium perborate.148 A potential alternative way to obtain the required 
aldehyde 102 from alkene 93 with anti-Markovnikov selective Wacker oxidation (Scheme 
24).149 
 
Scheme 24: Selective Wacker oxidation 
The alkene 93 was subjected to Wacker oxidation under a flow of oxygen overnight. 
However, only traces of aldehyde were detected by NMR analysis of the crude reaction 
mixture and so another approach had to be adopted. The third option was to introduce the 
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carboxylic acid by hydroboration of the alkene and then oxidation of the resulting alcohol 
(Table 11).150  
 
Table 11: Hydroboration optimisation 
Entry SM NPG Borane source Oxidising agent Product, Yield 
1 (±)-93 NHBoc 9-BBN (2 equiv.) NaOH/H2O2 103, SM recovereda 
2 (R,S)- 93 NHBoc 9-BBN (3 equiv.) NaBO3.4H2O 103, 35% SM recovereda 
3 (R,S)- 93 NHBoc BH3.THF NaBO3.4H2O pH7 buffer 103, 63% 
4 (±)-93 NHBoc BH3.THF NaBO3.4H2O pH7 buffer 103, Quant. 
5 (S,R)- 93 NHBoc BH3.THF NaBO3.4H2O pH7 buffer 103, 61% 
6 (±)-94 Phth BH3.THF NaBO3.4H2O pH7 buffer 104, 80% 
7 (±)-100 N(Boc)2 BH3.THF NaBO3.4H2O pH7 buffer 105, 97% 
8 (R,S)- 100 N(Boc)2 BH3.THF NaBO3.4H2O pH7 buffer 105, 91% 
9 (S,R)- 100 N(Boc)2 BH3.THF NaBO3.4H2O pH7 buffer 105, 91% 
aDetermined by NMR 
When hydroboration was performed by treatment of the alkene with two equivalents of 9-
BBN and oxidation of the resulting borane with hydrogen peroxide (Table 11, entry 1),151 
poor conversion of the starting material was observed. The reaction was repeated with a 
larger excess of 9-BBN and sodium perborate as oxidant, but once again the required alcohol 
was not produced and some decomposition had occurred (Table 11, entry 2).152 The borane 
source was then replaced by 1 M borane tetrahydrofuran complex solution and oxidation was 
performed with sodium perborate at pH 7 (phosphate buffer).153 This method proved to be 
very efficient and a good yield of the alcohol was obtained which was of sufficient purity 
that it could be used in the next step without any purification. These conditions were then 
applied on the various protected amines used in the course of the project (Table 11, entries 
4 to 9) to give primary alcohols 103-105. 
The next step was oxidation of the primary alcohol 103 to give the C-terminal carboxylic 
acid 106 (Scheme 25). In a two-step process, DMP oxidation gave a poor yield and 
purification of the aldehyde by column chromatography resulted in degradation of the 
product (Scheme 25a). Pinnick oxidation afforded the Boc-protected amino acid 106 in 77% 
yield (31% over two steps). Oxidation of the alcohol 103 under Parikh-Doering conditions 
GPN
1) hydroboration
2) oxidation
OH
GPN
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gave only a trace amount of aldehyde after purification. 154 When aldehyde 102 was not 
isolated but instead submitted directly to the subsequent Pinnick oxidation reaction, the 
carboxylic acid 106 was obtained in 22% yield over two steps (Scheme 25b).155  
 
Scheme 25: Two-step oxidation of the alcohol 103 to access to the carboxylic acid 106 
TPAP oxidation is commonly used to oxidise primary alcohols to give aldehydes and, in this 
case, dry NMO is usually used as the stoichiometric oxidant. In this case, hydrated NMO 
was used as the oxidant to stabilise the resultant aldehyde by forming a 6-membered ring 
(Scheme 26), which activates the aldehyde to further oxidation to the carboxylic acid. NMO 
plays a dual role in this reaction: as a Lewis-base to stabilise the aldehyde hydrate and as a 
co-oxidant to recycle the catalyst.156 This single-step oxidation of the alcohol 106 to give the 
carboxylic acid 107 was performed to avoid dealing with sensitive intermediate aldehyde 
102.157 
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Scheme 26: TPAP Oxidation and its mechanism 
Slow and controlled addition of TPAP was necessary because of the exothermic character 
of the reaction, especially when working on big scale. After optimisation, an addition rate of 
20 mg/20 min resulted in the the best conversion. Carboxylic acid 107 was unstable and 
decomposed during chromatographic purification, so the product was used immediately for 
the next step without purification.  
In summary, the Gly-Gly surrogate was synthesised in good yield and on multigram scale 
by a route that involved sequential super-base-mediated rearrangement of 1,2-epoxy-5-
hexene, Mitsunobu, hydroboration and oxidation (Scheme 27). The key cyclopropane 
peptide mimic (±)-Boc2-{GlyΔGly}-OH 106 was now available for incorporation into 
various peptides to give hybrid compounds  
 
Scheme 27: Synthesis of the racemic mixture of (±)-Boc2-GlyΔGly-OH 107 
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2.4. Synthesis of Single Enantiomer Mimics by 
Resolution of Racemic Intermediates 
2.4.1. Early Stage Resolution 
Now that an efficient route to racemic Boc2-{GlyΔGly}-OH 107 had been developed, the 
next challenge was to find the optimal method to resolve the enantiomers. The resolution of 
epoxides to provide enantioenriched building blocks is a well-established strategy in organic 
chemistry,158,159 and so it seemed likely that the terminal epoxide starting material could be 
resolved and each enantiomer could be taken through the whole synthesis separately with 
the main challenge being chirality transfer during the LIDAKOR-mediated rearrangement 
reaction. The kinetic resolution procedure developed by Jacobsen was selected because it 
has been used on similar substrates to generate an enantiopure epoxide and an enantiopure 
diol (Scheme 28). 
 
Scheme 28: Jacobsen resolution 
The epoxide was subjected to resolution with both (S,S)- and (R,R)-Co-salen catalyst in 
parallel. After a reaction time of 8 h, the NMR analysis showed that a mixture of epoxide 
108 and diol 109 had been generated in a 2:1 ratio when either enantiomer of the catalyst 
was used. Unfortunately, the epoxide was difficult to handle due to its volatility and 
separation of the epoxide from the diol could only be achieved by column chromatography 
(100% EtOAc) because distillation was unsuccessful on both a small and large scale. The 
epoxide could not be obtained without traces of water, which was an issue for the LIDAKOR 
reaction, and so this approach was abandoned.  
O
(±)
(R,R)-109
AcOH
THF/H2O
0 °C to rt
(R) O
OH
OH
Co
N
O O
N
t-Bu
t-Bu t-Bu
t-Bu
H H
108b
109b
+
(S,S)-109
AcOH
THF/H2O
0 °C to rt
(S) O
OH
OH
108a
109a
+
Co-Salen Salt
  74 
2.4.2. Alcohol Resolution by Steglich Esterification 
Another method to resolve racemic intermediates was investigated. The Steglich 
esterification reaction is often used to resolve alcohols into diastereoisomeric esters with 
chiral acids and coupling agents.160,161 Alcohol 90 was subjected to Steglich esterification 
using enantiomerically pure (R)-mandelic acid to produce diastereomeric esters (Scheme 
29).  
 
Scheme 29: Steglich esterification on alcohol 90 
The esterification reaction was performed at room temperature overnight but several 
products were obtained following purification of the crude product by column 
chromatography. The small amount of the required ester that was obtained suggested that 
separation of the diastereomers would be difficult and so various chiral acids were explored 
as resolving agents (Scheme 30).  
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Scheme 30: Resolution optimisation on alcohol 88 by Steglich esterification and TLC of the 
scope 
 
Six chiral carboxylic acids (111 to 116) were used for the resolution reaction. Unfortunately, 
as shown by TLC, the starting material (alcohol 90) was still present in all reactions after 
heating overnight at reflux and there was little conversion. Furthermore, only one other spot 
was visible in all of the reactions. HPLC analysis of one of the reactions (that performed 
with acid 114) showed both diastereoisomeric esters had been formed but they were 
inseparable by chromatography. Altering TLC eluent (PET/EtOAc 1:1, 6:1, 6:2, 8:2, 1:2) 
did not make any difference to the separation.  
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2.4.3. Amide Coupling Resolution on Protected Amine 
Resolution of the racemate by ester formation was unsuccessful and so attention was turned 
to the formation of diastereoisomeric amides because these had been successful earlier 
(Table 12).  
 
Table 12: resolution of 93 by amide coupling 
Entry Chiral acid Conditions Results 
1 
(R)-mandelic acid 
 
N-methylmorpholine 
i-BuOCOCl decomposition 
2 
 
(S)-(+)-a-methoxyphenyl acetic acid 
 
N-methylmorpholine 
i-BuOCOCl decomposition 
3 
(R)-mandelic acid 
 
HOBt, EDCI, DIPEA no conversion 
4 
(S)-(+)-a-methoxyphenyl acetic acid 
 
HOBt, EDCI, DIPEA no conversion 
The mixed anhydride method used for the resolution of carboxylic acid 85 was performed 
on 93 using N-methylmorpholine and i-BuOCOCl.136 This method led to  decomposition of 
the product (Table 12, entries 1 and 2). Amide formation mediated by HOBt and EDCI was 
attempted because these reagents are known to give efficient formation of tertiary amides.162 
Attempts to form an amide with either (R)-mandelic acid or (S)-(+)-a-methoxyphenyl acetic 
acid (Table 12, entries 3 and 4) did not result any conversion of the starting material into the 
required products. At this stage, resolution of the initial epoxide, the alcohol 90, and the 
protected amine 93 had failed and so attention was turned to resolution of (±)-BocH-
{GlyΔGly}-OH.   
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2.4.4. Resolution of Carboxylic Acid Intermediates 
Instead of using the amine to form an amide suitable for resolution, the carboxylic acid on 
C-terminus of final dipeptide mimetic was considered as a site for diastereomer formation. 
Under the same procedure as before, mono protected (±)-Boc-{GlyΔGly}-OH 106 or bis 
protected (±)-Boc2-{GlyΔGly}-OH 107 were treated with N-methylmorpholine, i-
BuOCOCl and (R)-phenylglycinol. After a reaction time of several hours, there was no 
evidence that amide coupling had occurred (scheme 31).  
 
Scheme 31: Resolution on final dipeptide mimic 
Next, resolution was attempted by coupling of a carboxylic acid intermediate with a chiral 
amino acid by use of common amide coupling procedures (EDCI, DMAP, Scheme 31). As 
previously discussed, the amide obtained after purification was subjected to HPLC analysis 
and was found to be a mixture of diastereoisomers. Finally, attention was reverted to the 
previously successful method (cf. Scheme 18). To explore this method, it was necessary to 
oxidise the alcohol 90 to produce the carboxylic acid 85 (Scheme 32).  
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Scheme 32: Resolution of enantioenriched alcohol 90 at an early stage in the synthesis  
The alcohol (±)-90 was submitted to a TPAP oxidation in the presence of water in order to 
obtain the corresponding carboxylic acid (±)-85 directly. Addition of 20 mg/20 min of TPAP 
was required to control the exothermic character of the reaction and so the procedure was 
time consuming on large scale. It was found that Swern oxidation followed by a Pinnick 
oxidation was more practical on larger scale (≥ 20 mmol of alcohol).163 The carboxylic acid 
(±)-85 was obtained by use of these two methods in yields of 30% and 69%, respectively. 
The racemate reacted with (R)-phenylglycinol as chiral agent to produce two 
diastereoisomers (R,R,S)-89a  and (R,S,R)-89b that were separable by column 
chromatography. Absolute configuration was determined as in the initial route by their [𝛼],. 
Each diastereomer was then hydrolysed to yield the enantioenriched carboxylic acids (R,S)-
85 and (S,R)-85. The enantioenriched carboxylic acids were then reduced using LiAlH4 to 
provide the alcohols (R,S)-90 and (S,R)-90 in 14% yield over 4 steps. 
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2.4.5. Summary 
The initial route designed started with a cyclopropanation using carbene, a mixture of 
diastereoisomer was obtained (cis/trans ratio 1:1) and required epimerisation followed by 
resolution to get only the trans enantioenriched cyclopropane which was considered to be 
too many steps. The challenge of the cyclopropanation reaction was overcome by using a 
superbase-mediated rearrangement reaction to produce the racemic trans-cyclopropane 90 
in a very good yield. Resolution of the racemic mixture at various stages of the synthesis 
was attempted and the best method was found to be the amide coupling of the acid 85, 
obtained by two-stage oxidation of the alcohol 90, to (R)-phenylglycinol as described in the 
initial route. The diastereoisomeric amide were easily separable by column chromatography 
and were obtained in reasonable yields (scheme 33).  
 
Scheme 33: Summary of the synthesis of the enantioenriched dipeptide 
Synthesis of the enantioenriched carboxylic acids allowed the dipeptide mimics 107 to be 
achieved in 5 steps by sequential Mitsunobu reaction to install the bis-protected N-terminus, 
optimised hydroboration and subsequent oxidations at the C-terminus. This new route was 
designed and optimised to reduce the number of steps and improve the overall yield from 
1% to 8%. The enantioenriched mimic Boc2-{GlyΔGly}-OH 107 was obtained in 8 steps (9 
in the inital route).  
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2.5. Synthesis of Model Peptides Containing the 
Dipeptide Mimic 
2.5.1. Capped Dipeptide Synthesis 
In order to investigate the formation and extent of intramolecular hydrogen bonds within 
cyclopropane-containing peptide hybrids, two molecules were designed (Figure 38). The 
targets selected were analogues of the peptides used by Gellman et al. to demonstrate the 
formation of intramolecular hydrogen bonds in systems where the peptide bond has been 
replaced by an alkene (cf. section 1.6.1.2, Scheme 1).  
 
Figure 38: Dipeptide mimics 
β-Turns are stabilised by a 10-membered hydrogen bonded ring (cf Figure 13); and so the 
systems were designed to explore formation of this type of hydrogen bond.  The peptide 75 
contains two amide bonds that are able to form hydrogen bonds (Gly-NH and NH-i-Pr). In 
contrast, the peptide 76 is capped with a dimethylamino group at the C-terminus to removal 
hydrogen bond donor capability at this position and allow only one hydrogen bond to be 
formed. 
Unfortunately, the polar Boc2-{GlyΔGly}-OH dipeptides decomposed during purification 
due to the presence of a free carboxylic acid and the corresponding methyl ester 117 was 
prepared to enable purification (Scheme 34).164  
 
Scheme 34: Methyl ester formation and attempted amide synthesis 
The ester 117 was prepared by treatment of the carboxylic acid (±)-107 with sodium 
bicarbonate and iodomethane in solution at reflux. The reaction was performed overnight 
and methyl ester was obtained after column chromatography in 47% yield over two steps. 
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Attempts to perform amide formation directly by treatment of the ester 117 with 
isopropylamine were unsuccessful.165 Consequently, the carboxylic acid 106 was used in 
subsequent coupling without purification to avoid problems encountered during 
chromatography. 
The peptide coupling reaction of crude Boc2-{GlyΔGly}-OH 107 with isopropylamine and 
dimethylamine was investigated under a variety of conditions (Table 13).  
 
Table 13: First amide coupling optimisation 
Entry Amine Coupling agent Base Product Yield 
1 HNMe2(a) DCC HOSu (±)-119 -(b) 
2 iPrNH2 DCC HOSu (±)-118 -(b) 
3 iPrNH2 EDCI DMAP (±)-118 31% 
4 HNMe2(a) T3P Et3N (±)-119 33% 
5 HNMe2(a)  T3P Et3N (±)-119 37% 
6 iPrNH2 T3P Et3N (±)-118 46% 
(a) 2 M in THF 
(b) hard purification, impure after column chromatography 
Initially, DCC coupling agent was used in presence of hydroxysuccinimide (HOSu) as an 
additive in order to avoid side reactions.166,167 However, reaction of the carboxylic acid 107  
with dimethylamine or isopropylamine in THF (Table 13, entries 1 and 2) afforded coupled 
product that was contaminated with undetermined impurities and HOSu. When EDCI was 
used in combination with DMAP (Table 13, entry 3), the formation of water-soluble by-
products facilitated purification of the product. Unfortunately, a low yield of the coupled 
product 118 was obtained and so the use of T3P (propylphopshonic anhydride) instead of a 
carbodiimide was explored (Table 13 entries 4,5 and 6).168 The yield was improved when 
the coupling reaction was performed with dimethylamine over a longer reaction period. The 
amides 118 and 119 were produced in a satisfactory yield and sufficient pure material was 
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obtained for the next coupling reaction. These conditions were used for the synthesis of all 
N-terminus amide (Table 14, T3P coupling).  
 
Table 14: summary of dipeptide synthesis 
Entry Isomer R1, R2 T3P coupling yield Final product, yield 
1 (±) R1 = H, R2 = iPr (±)-118, 46% (±)-75, 69% 
2 (S,R) R1 = H, R2 = iPr (S,R)-118, 52% (S,R)-75, 17% 
3 (R,S) R1 = H, R2 = iPr (R,S)-118, 35% (R,S)-75, 31% 
4 (±) R1 = R2 = Me (±)-119, 37% (±)-76, 7% 
5 (S,R) R1 = R2 = Me (S,R)-119, 48% (S,R)-76, 65% 
6 (R,S) R1 = R2 = Me (R,S)-119, 74% (R,S)-76, 40% 
N-Deprotection was performed using 10 equivalents of TFA to afford the free amine which 
was then treated (iPrO)2O and trimethylamine to give the analogue of interest. The final 
capped dipeptide mimics were obtained in low to reasonable yield (from 7 to 69% over 2 
steps), but sufficient material was produced to undertake the intended spectroscopic 
analyses. Racemic and enantiomerically enriched (both antipodes) samples of both peptides 
were synthesised and then used to explore hydrogen bond formation in the hybrid model 
turn mimics (Figure 39).  
 
Figure 39: Dipeptide mimics 
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2.5.2. Synthesis of Tri- and Tetra-peptide Hybrids that Contain the 
Mimic 
Longer peptides were synthesised in order to mimic the loop section of a β-hairpin, with the 
{GlyΔGly} surrogate mimicking the i + 1 and i + 2 turn residues and the two external 
residues (i and i + 3) playing the role of the strands. The influence of the lengths of the 
peptide and the addition of extra amide bonds on the stability of the conformation adopted 
by the hybrid was analysed and the contribution of the side chains was also studied. 
To this end the hybrid peptides Ac-Val-{GlyΔGly}-Leu-NMe2 77 and 78 and Ac-Val-
{GlyΔGly}-NMe2 79 and 80 were synthesised.54 The principle was to study hydrogen bond 
formation and discover whether the analogues possessed the hydrogen bonding arrangement 
observed in the native dipeptide system. The more flexible analogue Ac-Gly-{GlyΔGly}-
Gly-NMe2 120 was also synthesised and studied in order to understand how the side chains 
contribute to the folding process. The synthetic strategy adopted was similar to that used to 
prepare the simple dipeptides and amino acids were modified beforehand if needed (scheme 
35).  
 
Scheme 35: Tri- and tetra-peptides 77-80 and modified amino acid 121 and 122 synthesis 
Boc-Gly-NMe2 121 was synthesised in 86% yield following the approach used to prepare 
the dipeptide mimics described previously and using T3P as the coupling reagent. Boc-Val-
NMe2 122 was synthesised in a 65% yield by use of a DCC coupling reaction.169  
Two coupling reactions were performed on the C-terminus of Boc2-{GlyΔGly}-OH 107 
(Table 15). T3P was used for the first coupling reaction in all cases (Table 15, 1st coupling, 
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entries 1–6) and the corresponding C-terminal amide was obtained with variable yields (48–
85%). The TFA mediated deprotection of the N-terminus proceeded without incident and 
the resulting crude amine was used directly in the second peptide coupling reaction, which 
was performed using the same coupling agent (Table 15, 2nd coupling, entry 1).  The product 
120 was found to be sensitive and further purification was performed by trituration using 
cold pentane twice after column chromatography. 
 
Table 15: Tri- and tetrapeptide synthesis 
Entry isomer 
1st coupling 2nd coupling 
Amine Yield Acid, coupling agent Product Yield(a) 
1 (±) Boc-Gly-NMe2 123 63%(a) Ac-Gly-OH, T3P 120 52% 
2 (S,R) R1 = R2 = Me 119 48% Ac-Val-OH, T3P 80(b) -(b) 
3 (S,R) Boc-Leu-NMe2 124 72%(a) Ac-Val-OH, T3P 78(b) -(b) 
4 (S,R) R1 = R2 = Me 119 48% Ac-Val-OH, HATU  80 12% 
5 (R,S) R1 = R2 = Me 119 74% Ac-Val-OH, HATU  79 14% 
6 (S,R) Boc-Leu-NMe2 124 72%(a) Ac-Val-OH, HATU  78 76% 
7 (R,S) Boc-Leu-NMe2 124 85%(a) Ac-Val-OH, HATU  77 17% 
aYield over two steps  
bepimerisation occured, ratio 3:2 of diastereoisomers observed 
Submission of substrates 123 and 124 to the second peptide coupling reaction under these 
conditions resulted in a doubling of peaks in the NMR spectra (Table 15, 2nd coupling, entries 
2–3). This observation could have resulted from restricted rotation around one of the amide 
bonds giving rise to rotamers or epimerisation at the acidic α position of Val after activation 
with T3P and oxazolone formation. Techniques such as variable-temperature NMR, solvent 
switching and selective NOE NMR have been used to determine whether conformers or 
diastereomers are present and so careful NMR analyses were performed on the mimics 78 
and 80.170,171 Samples were prepared in various solvents of differing polarity (CDCl3, CDCl2, 
CD3CN, MeOD) and their 1H NMR spectra were compared (Figure 40). The peaks 
highlighted correspond to the Hα of the Val residue. Doubling of peaks was observed in all 
spectra (except those obtained for samples in MeOD, where peaks overlapped) and the ratios 
of isomers / rotamers were compared. The polarity of solvent would be expected to influence 
the population of rotameric conformers, but in these experiments all solvents gave a 
consistent 3:2 ratio.  
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Figure 40: 1H NMR spectrum of 78 in different solvents 
Variable temperature NMR analyses were also undertaken. The barrier to rotation around 
the amide bond generally decreases with increasing temperature. However, the 1H NMR 
spectra were obtained at 20 °C and 50 °C and the ratios of the key peaks were the same at 
both temperatures. Consequently, it was concluded that epimerisation had occurred when 
T3P was used to facilitate the second peptide coupling reaction and a diastereoisomeric 
mixture of products had been formed.  
In an attempt to avoid this problem, the use of HATU as an alternative coupling agent was 
explored.172 The reaction sequence was repeated as before but the yields obtained for the 
tripeptides were lower than before and the reactions suffered from poor reproducibility 
(Table 15, 2nd coupling, entries 4–7). Importantly, there was no doubling of peaks in the 
NMR spectra of the final products, which indicated that epimerisation had been avoided by 
the use of HATU as a coupling reagent.  
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Figure 41: Peptidomimetics synthesised based on Gellman’s work 
Although the sequence was not fully optimised, sufficient material was obtained for the 
conformational analysis to be undertaken. Five peptides were synthesised, including 
enantioenriched (both antipodes) and racemic variants (Figure 41) 
2.6. Synthesis of Ester Analogous of the Turn 
Mimics 
An alternative way in which the hydrogen bonding network within a peptide can be probed 
is by selective replacement of amides with the corresponding esters. The ester and amide 
have similar conformations but have different hydrogen bonding properties: an amide bond 
can act as hydrogen bond donor whereas an ester cannot and an ester is a much weaker 
hydrogen bond acceptor than an amide. A series of esters was designed to probe the deletion 
of single hydrogen bonds. The N-terminus amide was the first to be replaced by an ester 
group (Scheme 36). 
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Scheme 36: Synthesis of iPrCOO-{GlyΔGly}-N-iPr 127  
The key ester bond was introduced when alcohol 90, obtained from the original LIDAKOR 
rearrangement reaction, was esterified using (iPrCO)2O to produce the ester 125 in 48% 
yield. Subsequent alkene hydroboration and oxidation, following the same conditions 
described for Boc2-{GlyΔGly}-OH synthesis, delivered the alcohol 126 in a very poor yield. 
The alcohol was then oxidised directly to the corresponding carboxylic acid using TPAP and 
hydrated NMO. The carboxylic acid was not purified but instead was submitted to the T3P-
medaited amide coupling reaction with isopropylamine to give the amide 127 in 51% yield 
over two steps. A second analogue, in which the ester and amide functionality are reversed, 
was synthesised from Boc2-{GlyΔGly}-OH (106) (Scheme 37). 
 
Scheme 37: iPrCO-{GlyΔGly}-OiPr Synthesis 129 
The protected amino acid was subjected to Steglich esterification with isopropanol to 
produce the ester 128 as a mixture 3:1 of N(Boc)2 and NHBoc compounds. Global 
deprotection of the mixture by treatment with 10 equivalents of TFA afforded the 
corresponding amine, which was submitted for amide formation by reaction with isobutyric 
anhydride. Analogue 129 was obtained in 40% yield over 7 steps. Only a racemic mixture 
was prepared because the spectroscopic properties of the individual enantiomers were 
expected to be the same. 
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2.7. Conformational Analysis of Peptide Hybrids 
that Contain Turn Mimics 
2.7.1. Preliminary Results, NH Chemical Shift Comparison 
In 1H NMR spectroscopy, the chemical shift of  the signal for a given proton is sensitive to 
its chemical environment.173 In particular, the 1H NMR signal of an N-H or O-H  can display 
an important variation in its chemical shift depending on its environment and interaction 
with polar groups . Therefore, by considering the various NMR spectra in a library of related 
peptides, it should be possible to explore the presence or absence of hydrogen bonds.  
In this study, performed at 1 mM in CD2Cl2, the reference values of N-H chemical shifts 
were compared between the β-turn mimics and compounds that could not form turns, either 
because there was no hydrogen bond donor on the C-terminus available to form a 10-
membered ring (esters 129, and dimethyl amides 76 and 78) or the main chain was too short 
for a turn too form (Ac-Val-NHMe 130 and Ac-Leu-NMe2 131). It was anticipated that a 
significant difference in NH chemical shift value would indicate the presence of a hydrogen 
bond. In particular, when a NH is involved in an intramolecular hydrogen bond the chemical 
shift tends to move downfield. The NH chemical shift of Ac-Val-NHMe, Ac-Leu-NMe2 and 
alkene analogues had been measured previously by Gellman and co-workers’.76  
The data in Table 16 indicates extensive folding of tetrapeptide 12 designed by Gellman (the 
different NH bonds are colour coded for clarity). Val-NH and Gly-NH of peptide 13 have 
chemical shift values that are similar to those of the reference substrate 130 meaning 
hydrogen bonds are not formed with the NCO peptide bond and the peptide is in a linear 
conformation. Therefore, 8- or 11-membered ring hydrogen bonding is not expected in the 
tetrapeptide 12. The Val-NH of 12 is shifted downfield by 1.2 ppm relative to 13 and 130, 
which suggests that this NH is involved in a strong intramolecular hydrogen bond that 
results in formation of a 14-membered ring.  
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Table 16: Chemical shift comparison 
Entry Peptide NH NH NH 
1 Ac-Val-NHMe 130 5.99 5.77 - 
2 Ac-Leu-NMe2 131 - - 6.17 
3 Ac-Val-{Gly//Gly}-Leu-NMe2 12 7.24 6.55 6.80 
4 Ac-Val-{Gly//Gly}-NMe2 13 6.03 5.73 - 
5 (±)-iPrOC-{GlyΔGly}-iPr 75 - 6.79 5.44 
6 (R,S)-iPrOC-{GlyΔGly}-iPr 75 - 6.77 5.45 
7 (±)-iPrOC-{GlyΔGly}-NMe2 76 - 7.58 - 
8 (R,S)-iPrOC-{GlyΔGly}-NMe2 76 - 7.66 - 
9 (±)-iPrOC-{GlyΔGly}-O-iPr 129 - 6.40 - 
10 (±)-iPrOCO-{GlyΔGly}-N-iPr 127 - - 5.61 
11 (R,S)-Ac-Val-{GlyΔGly}-NMe2 79 6.62 8.12 - 
12 (S,R)-Ac-Val-{GlyΔGly}-NMe2 80 6.44 8.11 - 
13 (±)-Ac-Gly-{GlyΔGly}-Gly-NMe2 120 6.43 7.51 6.65 
14 (R,S)-Ac-Val-{GlyΔGly}-Leu-NMe2 77 6.34 7.70 6.34 
15 (S,R)-Ac-Val-{GlyΔGly}-Leu-NMe2 78 6.38 7.70 6.58 
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As it was expected, racemic and enantioenriched peptides have similar NH chemical shifts, 
showing that they behaved the same way in terms of their intramolecular interactions. The 
Gly-NH of both variants of 75 is shifted by 1 ppm downfield when compared to the reference 
compound 130 and the NH-i-Pr is shifted upfield of more than 0.7 ppm. This indicates that 
in the iPrOC-{GlyΔGly}-i-Pr peptide the Gly-NH is involved in considerable 
intramolecular hydrogen bonding to form an 8-membered ring rather than the expected 10-
membered ring. Peptide 75 has only Gly-NH free to interact and the chemical shift for this 
proton was found to be almost 2 ppm downfield relative to the relevant amide protons in 
compounds 13 and 130. The data suggest that a strong intramolecular hydrogen bond is 
formed between Gly-NH and CO group at the C-terminus of the mimic. The NMR data for 
this dipeptide mimic suggests that the peptide adopts hydrogen bonding arrangement I 
predominantly (Figure 42).  
 
Figure 42: Possible hydrogen bonding arrangements for dipeptide 75 
The ester 129 lacks the hydrogen bond donor required to form the 10-membered ring system. 
The Gly-NH chemical shift lies 0.7 ppm downfield compared to reference compound 130, 
which suggests that the intramolecular hydrogen bond observed in peptide 76 is also formed 
in the ester analogue. In contrast, it is not possible to form an 8-membered hydrogen bonded 
ring in the ester 127, but the chemical shift of NH-i-Pr is similar to that of 75, which suggests 
that intramolecular hydrogen bonding with C-ter carbonyl group does not occur. 
Consequently, conformation III in figure 42 is unlikely to occur in the dipeptide mimic. This 
data for the dipeptide mimetic suggests that an 8-membered hydrogen bonded ring is formed 
and this feature would be expected in tetrapeptide 120 and tripeptide 77. 
Each of the two NH chemical shifts of peptides 79 and 80 were found to be shifted downfield 
by 0.6 and 2.3 ppm when compared to corresponding signals for the compounds 13 and 130. 
An incredibly strong intramolecular hydrogen bond that involves Gly-NH and C-ter 
carbonyl group is formed along with a 14-membered hydrogen bonded ring produced by an 
interaction between Val-NH and the same carbonyl group. So, 8- and 14-membered were 
expected in tetrapeptides 120, 77 and 78 and could adopt conformation IV (Figure 43). The 
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chemical shifts of all three NH of flexible peptide 120 are shifted more than 0.4 ppm 
downfield compared to the reference peptides which suggests that they were all involved in 
intramolecular hydrogen bonding., Gly-NH is the most strongly hydrogen bonded. Gly-NH 
and Gly-NH have a similar variation in chemical shift which suggests that they form weaker 
intramolecular hydrogen bonds. Tetrapeptides 77 and 78 could adopt any of the 
arrangements I, II, III or IV because Val-NH is involved in the strongest hydrogen bonding 
as shown by data obtained for tripeptide 79 and 80.  
 
Figure 43: Possible hydrogen bonding arrangements adopted by peptides 77 and 78 
Ac-Val-{GlyΔGly}-Leu-NMe2 77 and 78 have chemical shift values that are very similar to 
the more flexible compound Ac-Gly-{GlyΔGly}-Gly-NMe2 120. These peptides behave 
similarly and the side chains seem to have little effect and our located on the outside of the 
turn. This completely excluded conformation V and VI to be adopted. The data obtained for 
peptides 77 and 78 show that Gly-NH can form an 8- or 11-membered hydrogen bonded 
ring (conformation I to IV, Figure 43) and it is always involved in intramolecular hydrogen 
bonding as indicated by the large shift downfield when compared to data for reference 
peptides. These data differ from the observations made by Gellman et al. on compounds 12 
and 13. The cyclopropyl mimic was not stabilised by the same intramolecular hydrogen 
bonds, furthermore the 10-membered ring that is supposed to stabilise a β-turn was not the 
most favoured ring as demonstrated by data for the dipeptide 76 and tripeptides 79 and 80 
which suggest that there is a strong intramolecular hydrogen bond between Gly-NH and C-
ter carbonyl group. It appears that all of the peptides containing the cyclopropyl peptide 
mimic adopt a folded conformation that is greatly stabilised by the cyclopropyl group. 
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Moreover, cyclopropyl group constrains the system more than the tetrasubstituted alkene 
group used by Gellman and co-worker and brings the Gly-NH hydrogen bond donor and the 
Gly-CO hydrogen bond acceptor into close proximity.  
2.7.2. Hydrogen bond formation analysis 
2.7.2.1. Dipeptides 75 and 76 
The conformation adopted by a peptide can be determined by measuring the intramolecular 
hydrogen bonds formed. This analysis started with the analysis of the racemic dipeptide turn 
mimetics 75 and 76. The C-terminus NH can be involved in a hydrogen bond with the 
carbonyl at the N-terminus to form a 10-membered ring system and this is the basis for 
stabilisation of β-turns (Figure 44). The other hydrogen bond network that can be formed is 
between the N-terminus NH and C-terminus carbonyl group, which results in a less stable 
hydrogen bonded 8-membered ring system. 
 
Figure 44: Two intramolecular hydrogen bonds possible in dipeptide 75 
The chemical shifts of both NHs (shown in green and orange in Figure 44) were measured 
at six different concentrations: 20, 10, 5, 1, 0.5 and 0.1 mM in CD2Cl2. Measurements were 
performed in deuterated dichloromethane CD2Cl2 because it is less polar than MeOD or 
deuterated acetonitrile and because the peptide cannot form hydrogen bonds with the 
solvent. 
The chemical shifts of both the amide protons NH-i-Pr and Gly-NH in (±)-iPrOC-
{GlyΔGly}-iPr 75 varied with the logarithm of the concentration above 1 mM but remained 
constant at lower concentrations (Figure 45). This suggests that at low concentrations, there 
are consistent strong intramolecular hydrogen bonds and that intermolecular hydrogen 
bonding occur at higher concentrations. The fact that both NH behave in the same way 
suggests that hydrogen bonded systems that contain 8- and 10-membered rings are formed. 
It could be that a secondary hydrogen bonded 8-membered ring arises after the formation of 
the expected 10-membered ring. In the dimethyl equivalent – (±)-iPrOC-{GlyΔGly}-NMe2 
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76 – no variation of Gly-NH chemical shift was observed across all the concentrations 
studied. In this case, only one hydrogen bond is possible and this leads to formation of an 8-
membered ring. The invariance of chemical shift was surprising because it suggests that the 
usually less favourable 8-membered ring system was being formed and that the cyclopropane 
forces the molecule into what would normally be considered to be an unfavourable hydrogen 
bonding arrangement.  
 
Figure 45: Racemic dipeptides mimic NMR and IR study, and Gellman’s analogue IR77 
The region of the IR spectrum studied corresponds to amide mode A, which is the NH stretch 
region showing intermolecular or intramolecular hydrogen bonded NH or solvent-exposed 
NH. According to the data obtained from the concentration-dependent NMR studies, the 
intramolecular hydrogen bonds were occurring at concentrations below 1 mM for (±)-
iPrOC-{GlyΔGly}-N-iPr 75. This concentration was the optimum one at which to analyse 
hydrogen bond formation by solution IR spectroscopy. Unfortunately, measurements could 
not be carried out at 1 or 5 mM due to poor quality data produced by the spectrometer at 
these concentrations. Consequently, the solution IR spectra of the compounds were 
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obtained at a concentration of 10 mM in dry CH2Cl2. For consistency, this concentration was 
used for all IR measurements.  
(±)-iPrOC-{GlyΔGly}-N-iPr 75 displays a strong band at 3318 cm–1, which arises from an 
intramolecularly hydrogen bonded NH, and a band at 3433 cm–1 due to NH exposed to 
solvent. These data suggest that intramolecular hydrogen bonds are still formed in peptide 
at concentrations above 1 mM and imply that the peptide exists in an equilibrium between a 
folded conformation (I, II or III in Figure 42) and an open conformation at 10 mM. The IR 
NH-stretch data for (±)-iPrOC-{GlyΔGly}-NMe2 76 has only one band at 3306 cm–1, which 
arises from an NH involved in intramolecular hydrogen bonding. This data is supported by 
the observation made by NMR that this Gly-NH is involved in a strong intramolecular 
hydrogen bond exclusively and excludes the presence of arrangement III (Figure 42) in 
CH2Cl2. In comparison, the IR spectrum of the analogous alkene system 8 synthesised by 
Gellman and co-workers was reported to have a single band at 3340 cm–1 which corresponds 
to solvent exposed NH (Figure 45), a finding that implies an absence of intramolecular 
hydrogen bonding in the alkene system. This comparison suggests that the cyclopropane was 
more effective than an alkene at folding a small hybrid peptide system into a hydrogen 
bonding arrangement.  
Considering these results, it was interesting to determine which of the two possible hydrogen 
bonds was the strongest and thus responsible driving the folding process. To this end, the 
two ester analogues (±)-iPrOCO-{GlyΔGly}-N-iPr 127 and (±)-iPrOC-{GlyΔGly}-O-iPr 
129 were analysed by IR spectroscopy (Figure 46). In (±)-iPrOCO-{GlyΔGly}-N-iPr 127, 
the Gly-NH is replaced by an ester Gly-O and so only the NH-iPr can be involved in 
intramolecular hydrogen bonding to form a 10-membered inner ring. In the case of (±)-
iPrOC-{GlyΔGly}-O-iPr 129, the Leu-NH is replaced by an ester O and so only the Gly-
NH can be involved in an intramolecular hydrogen bond to form an 8-membered ring. 
However, it is important to note that changing the amide group to an ester group also 
weakens the hydrogen bond, because esters are generally less effective hydrogen bond 
acceptors than the corresponding amides.174  
  95 
 
Figure 46: NH-stretch IR of ester analogues 127 and 129 
Only one band at 3433 cm–1 was observed for ester (±)-iPrOCO-{GlyΔGly}-N-iPr 127. This 
sharp band indicates hydrogen bonding with the solvent, or intermolecular bonding with 
another amide was in operation for 127.  In contrast, two bands were observed for (±)-iPrOC-
{GlyΔGly}-O-iPr 129. The sharp band observed at 3441 cm–1 suggests intermolecular 
hydrogen bonding and the broad band at 3365 cm–1 is attributed to intramolecular hydrogen 
bonding. The presence of two bands suggests an equilibrium is established between folded 
and unfolded states in the case of this system. Again, the presence of an intramolecular 
hydrogen bond supports the role of the cyclopropane in helping to form a turn motif, 
especially given the reduced propensity that esters have for hydrogen bond formation. 
The spectra of the (R,S)-enantiopure variants of the above racemic mixtures were also 
recorded under the same conditions (Figure 47). The Gly-NH of (R,S)-iPrOC-{GlyΔGly}-
iPr 75 did not vary significantly with concentration although a small shift was observed at 
the highest concentrations studied. This suggests that a very strong 8-membered hydrogen 
bond is formed in this system. The NH-iPr chemical shift was also found to be constant at 
low concentrations but more variation at higher concentration (> 1 mM). However, this still 
suggests that a strong intramolecular hydrogen bond is formed, but the increased degrees of 
freedom in the larger 10-membered system make it more susceptible to alternative hydrogen 
bonding patterns at higher concentrations. 
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Figure 47: NMR and IR studies of (R,S)-dipeptide mimics 75 and 76 
This finding confirmed that conformations I and II were more plausible than conformation 
III (Figure 42). The IR spectrum acquired was similar to obtained for the racemic mixture 
showing solvent exposed NHs and intramolecularly hydrogen bonded NH with observation 
of the same bands at 3429 and 3318 cm–1 respectively.  
A concentration dependent study of (R,S)-iPrOC-{GlyΔGly}-NMe2 76 showed that the 
chemical shift varied at between 1 and 5 mM and reverted to the same chemical shift at higher 
concentration. This implied intermolecular hydrogen bonds are not formed but some can be 
formed with the water present in the NMR solvent. However, the NH can be considered to 
be intramolecularly hydrogen bonded at all concentrations because the chemical shift is the 
same at very low and high concentrations. Two bands were observed by IR in the NH-stretch 
region. The one at 3306 cm–1 is suggestive of intramolecular hydrogen bonding, and the 
small peak at 3441 cm–1 indicates that Gly-NH is slightly solvent exposed at 10 mM, a 
finding which supports the variation observed by NMR.  
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In summary, the {GlyΔGly} surrogate was proven to promote the formation of a turn by 
spectroscopic measurements. Furthermore, iPrOC-{GlyΔGly}-NMe2 variants 76 were 
shown to be exclusively intramolecularly hydrogen bonded, which implies that an 8-
membered cyclic hydrogen bonded system is formed. The size of this hydrogen bonded 
system is unusual and suggests that the cyclopropane has a propensity to stabilise this type 
of interaction. Therefore the “β” designation could no longer be used for the turn motif 
adopted by the mimics prepared in the course of this project because the system is stabilised 
by formation of an 8-membered rather than the usual 10-membered cyclic hydrogen bonded 
network defined for β-turns. 
2.7.2.2. Analysis of Tri- and Tetrapeptide Systems 
After completion of studies on the small peptides, attention turned to the analysis of longer 
peptide systems. This was achieved by extending the amide sequence at both ends with 
glycine to form a tetrapeptide mimic. Based on the data obtained from the NMR chemical 
shift studies, it was clear that Gly-NH is involved in the formation of a strong intramolecular 
hydrogen bond that results in the formation of an 8- or 11-membered ring. The two other 
amide protons – Gly-NH and Gly-NH – have more freedom to rotate and interact either with 
solvent or intermolecularly with another molecule of the hybrid peptide (Figure 48).  
 
Figure 48: Possible hydrogen bonding arrangements adopted by hybrid peptide 120 in solution 
To discover which hydrogen bonded network was formed, concentration-dependant NMR 
studies were undertaken and solution IR spectra was recorded. The samples were prepared 
at concentrations that varied between 0.1 and 20 mM and 1H NMR spectra were recorded in 
CD2Cl2. The solution IR spectrum was recorded at 10 mM in CH2Cl2 (Figure 49). 
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Figure 49: Ac-Gly-{GlyΔGly}-Gly-NMe2 120 Hydrogen bond formation analysis 
The Gly-NH slightly varied above 5 mM, which suggests that at high concentration this 
peptide starts to interact with the solvent or intermolecularly. The hydrogen bonded 
arrangement III is probably the most populated at high concentrations (Figure 48). In 
contrast, Gly-NH and Gly-NH did not vary with concentration, even at relatively high 
concentrations, which suggests that they are protected by intramolecular hydrogen bonds.  
Bands at 3431 and 3327 cm–1 were observed in the NH-stretching region of the IR spectrum. 
The peak at higher wavenumber arises from NH that is either solvent exposed or 
intermolecularly hydrogen bonded and the other peak arises from intramolecularly 
hydrogen bonded NHs. These data show that there is a population of solvent exposed or 
intermolecularly hydrogen bonded NH and excludes network I as major conformer while 
showing that an equilibrium between folded and open systems is established. It is important 
to note that network I (Figure 48) is not the preferred arrangement but is a possible one.  
Results suggested formation of a turn structure for the peptide that contains glycine residues 
at either end so attention was focused on systems bearing more functionalised amino acids. 
The increased functionality was expected to lead to a decrease in conformational flexibility 
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of the molecule, which could alter the hydrogen bonding network. (R,S)-Ac-Val-
{GlyΔGly}-Leu-NMe2 77 was analysed first (Figure 50). The concentration-dependent 
NMR study had the same profile to that observed for (±)-Ac-Gly-{GlyΔGly}-Gly-NMe2 
120, which lacks amino acid side chains. The chemical shifts for Leu-NH and Val-NH were 
found to vary at concentrations above 5 mM in CD2Cl2, indicating that they are disposed to 
form intermolecular hydrogen bonds at higher concentrations. In contrast, the chemical shift 
for Gly-NH was observed to be completely independent of the concentration, which suggests 
that it is protected by formation of an intramolecular hydrogen bond.  
 
Figure 50: Hydrogen bond analyses on peptide 77 
Unfortunately, IR spectra obtained over a range of concentrations were inconclusive. The 
best acquisition was at 10 mM in CH2Cl2. Bands at 3421 and 3310 cm–1 were evident in the 
spectrum and these arise from solvent exposed / intermolecularly hydrogen bonded NHs and 
intramolecularly hydrogen bond NHs. Fully hydrogen bonded network I in Figure 48 can be 
excluded as major contributor. Gly-NH was protected by an intramolecular hydrogen bond, 
consequently networks II, III or IV could be adopted in solution. However, when steric 
hindrance between the side chains and data obtained from flexible peptide 120 are 
considered, it is unlikely that the peptide adopts the hydrogen bonded network IV (Figure 
43).  
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Figure 51: Hydrogen bond formation analysis of peptide 78 
The IR spectrum obtained for this peptide was of higher quality than that obtained for 
compound 77 and these results are supported data obtained by NMR analysis. The bands at 
3418 and 3306 cm–1 shows that there is an intramolecular hydrogen bonding network in this 
peptide with some flexibility of both the external residues constituting the strands. In 
comparison, Gellman and co-workers prepared the analogous tetrasubstituted alkene and 
observed that Gly-NH was the most exposed to intermolecular hydrogen bonding (or 
interaction with the solvent) and Leu-NH the most strongly intramolecularly hydrogen 
bonded (cf. section 1.6.1.2 Figure 20).  
Overall, the data demonstrate that Gly-NH is strongly intramolecularly hydrogen bonded in 
the tetrapeptide. Within the peptide, it is possible for Gly-NH to form two different hydrogen 
bonds, either with NH-CO or NMe2-CO (with formation of an 8- or 11-membered ring, II 
and III Figure 48). Therefore, the tripeptides 79 and 80, in which one carbonyl group is 
removed and hydrogen bond donor sites are restricted, were considered as a system for 
exploration of the hydrogen bonded network. 
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Figure 52: Possible hydrogen bonded ring formed with Gly-NH and possible conformers of 
79/80 
The enantioenriched variants of the peptides were analysed and similar results were obtained 
and so only results for (R,S)-Ac-Val-{GlyΔGly}-NMe2 79 are shown (Figure 53).  Analysis 
of the NMR spectra showed that the chemical shift for Val-NH showed a slight variation 
with concentration and Gly-NH chemical shift showed no variation. This suggested that 
these NH were both involved in intramolecular hydrogen bonding. Therefore, the two 
conformations presented in Figure 52 were likely to be in equilibrium in CH2Cl2 solution. 
 
Figure 53: Hydrogen bond formation analysis of peptide 79 
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Furthermore, when the NH-stretch IR spectrum at 10 mM in CH2Cl2 is considered, the band 
at 3418 cm–1 suggests that intermolecular interaction occurring in solution and so the 
network II is probably not the only one present. This conclusion is supported the NMR 
chemical shift data.  
In this work, cyclopropane-containing peptides have been analysed by NMR and IR 
spectroscopy. Evidence for intramolecular hydrogen bonds obtained by IR and NMR 
analysis in dipeptides and in longer peptides. However, the analogues presented in this work 
have demonstrated an interesting feature: replacement of the peptide bond with 
cyclopropane seems to favour formation of an 8-membered hydrogen-bonded ring as 
opposed to more common 10-membered cyclic system observed natural β-turns. Overall, the 
data suggest that the cyclopropyl unit is an efficient and compact tool to constrain small 
peptides to adopt a turn conformation stabilised by strong intramolecular hydrogen bonds.  
2.7.3. Use of Circular Dichroism to Probe Peptide Structure 
Circular dichroism (CD) is an essential tool for structural analysis of the secondary structure 
of peptides and proteins.175 Over the past few decades, systems that contain β-turns, 
especially type I and II turns, have been the subject of structural studies,  and characteristic 
CD spectra have been identified for these types of turn in both MeCN and H2O.176,177,178 For 
type I β-turns, two different shapes have been described: one has a negative band around 
205–210 nm, while the other has a positive band at around 195 nm and large negative band 
at around 225 nm (Figure 54). Type II turns can be identified by a positive band at around 
200 nm going to neutral ellipticity, and β-sheet structure presented the same positive band 
at 200 nm and a negative band around 210–220 nm.179  
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Figure 54: Type I, Type II and extended configuration CD spectra180 
To obtain additional information about our peptide mimics and study their secondary 
structure, the peptides previously described were analysed by circular dichroism. Previous 
conformational studies had demonstrated that turn sequence having a Gly in i + 2 position 
was more likely to produce a type II β-turn.181 The analogues designed in this work contained 
Gly mimic in i + 1 and i + 2 position, therefore it was possible to compare the results with 
those reported previously. The CD spectra were recorded and analysed with the help of Dr. 
Sharon Kelly at the University of Glasgow. 
Tri- and tetrapeptide analogues 77-80 were analysed by CD spectroscopy at 1 mg/mL in 
three solvents with differing polarity. The solvents selected were water, acetonitrile and 
trifluoroethanol (TFE). Acetonitrile was selected because the peptide should exhibit similar 
behaviour to that in CH2Cl2 (chlorinated solvents are not compatible with CD). 
Trifluoroethanol (TFE) was selected as a solvent because in enhances intramolecular 
interactions and secondary structure even in small systems. In water, the peptide was 
expected to adopt an extended conformation due to extensive solvation.   
  
Type I 
Type II 
Extended 
Type I 
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Figure 55: Far-UV CD spectrum of (S,R)-Ac-Val-{GlyΔGly}-Leu-NMe2 78 as a 1 mg/mL 
solution  in various solvents. 
The CD spectrum for tetrapeptide 78 in H2O (blue in Figure 55) was found to have a large 
positive band at 205 nm which looks similar to a type II turn shown in Figure 54. However, 
the peptide was probably sampling some other random conformations given the largely 
negative peak towards 190 nm. The peptide seems to adopt a turn structure in water, which 
was not expected for such a small peptide in a polar solvent. In MeCN (purple), the spectrum 
experienced a more intensive positive and negative peaks at 205 and 235 nm respectively. 
This CD spectrum suggests that the peptide contains features similar to a type II β-turn and 
β-sheet in this solvent. The peptide appears to be more structured in trifluoroethanol (1:1 
TFE/H2O in red and 100% TFE in green) with an ellipticity almost two times higher than 
that in H2O at 200 nm. Analysis of (S,R)-Ac-Val-{GlyΔGly}-Leu-NMe2 77 by CD suggests 
formation of a type II turn in all solvents, but the large negative peaks at around 190 nm in 
H2O and MeCN suggest that the peptide experiences other conformations so a complex 
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mixture of conformers seems to be present in solution. The same conditions were used to 
analyse (R,S)-Ac-Val-{GlyΔGly}-Leu-NMe2 77 and similar results were obtained (Figure 
56). Once again, CD data suggests that the peptide is more structured in TFE than in other 
solvents, and that it displays the characteristic features of a type II β-turn or β-sheet. The CD 
spectra obtained for samples in H2O and MeCN suggest that the peptide is probably 
experiencing another random conformation because a large negative is observed around 190 
nm.  
 
 
Figure 56: Far-UV CD spectrum of (R,S)-Ac-Val-{GlyΔGly}-Leu-NMe2  77 78 as a 1 mg/mL 
solution  in various solvents. 
The formation of turns in the cyclopropyl analogues that had been established by the 
hydrogen bonding network analysis described previously, was supported by the CD data. In 
addition, CD spectra provided supplementary information about the folding pattern of the 
tetrapeptides by displaying features found in a type II β-turn. Nevertheless, in all of the 
solvents studied, the peptides were found to adopt complex mixtures of conformations. 
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Variants of the tripeptides 79 and 80 displayed strong intramolecular hydrogen bonding as 
shown by the NMR and IR studies and so it was expected that features indicative of turn 
formation would be observed by CD spectroscopy. In this case, only solution in H2O and 
TFE (1 mg/mL) were used as solvents and features of any type of β-turn were absent in the 
CD spectra obtained in both solvents (Figure 57). Even in TFE, a solvent in which peptides 
are supposed to be more structured, negative bands at 198 and 215 nm were observed in the 
CD spectra of both isomers. These bands correspond to π-π* and n- π transitions and are 
usually assigned to random coil formation.182  
 
Figure 57: CD Spectra of variants of 79 and 80 in TFE (red) and H2O (blue) (1 mg/mL) 
However, the peaks were more intense in TFE than in H2O and, given the small size of the 
peptides and the intramolecular interactions observed by NMR and IR spectroscopy, we can 
assume that the peptide is adopting a turn structure but that it is not the preferred 
conformation adopted by the peptide within the whole population in solution. An 
equilibrium with a disordered conformation would display this type of spectrum.  
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2.7.4. NMR analysis of tetrapeptides 77 and 78 
In addition to chemical shift analysis, information can be obtained about molecular 
conformation by the use of 2D NMR experiments. The compounds described here were 
analysed by a variety of 2D experiments (COSY, TOSCY, HSQC, HMBC and NOESY). 
These experiments were performed by Dr Brian Smith at the University of Glasgow. 
Previous studies have allowed to determine and assign various NOE cross peaks depending 
on the type of β-turn that was present (figure 58).178,183  
 
Figure 58: Characteristic NOE cross peaks found in type I (red), I' (blue), II (green) and II' 
(orange) turn  
It is important to remember that in the analogues synthesised for this work a cyclopropane 
is employed as a peptide bond isostere. As a consequence, the bonds of one NH and one CO 
have been replaced by CC and CH bonds (that cannot be used to study β-turn) and two atoms 
in the amide that have sp2 character have been replaced by a sp3 atoms, which can alter the 
dihedral angles significantly and thus change the turn adopted. Cross peaks observed with 
CH protons cannot be used as evidence for β-turn formation. (R,S)-77 and (S,R)-78 were 
prepared and analysed. The same cross peaks were observed in the two variants and the 
absolute configuration of the stereocenters in the trans-cyclopropane did not influence the 
folding pattern of the peptide, a finding that supports the data obtained by IR and CD 
spectroscopy. 
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Figure 59: NOE Cross peaks of 77 measured in 1 mM in CD2Cl2 at 293 K (red) and in 1mM 
H2O/5 % D2O at 278 K (blue) 
Two interesting cross peaks were observed, NHi-NHi+1 and NHi+1-NHi+3 in TFE (Figure 59). 
These peaks do not correspond to any features of natural peptides described in literature, but 
the last interaction establishes the close proximity between Gly-NH and Leu-NH in space 
and provides further evidence for formation of an 8-membered ring that stabilises the folded 
conformation of the tetrapeptide. This is also supported by an NH-CHi+2 cross peak that is 
observed in spectrum obtained in CD2Cl2. Sequential cross peaks NHi-Hαi–1 were observed 
in water and CD2Cl2. These cross peaks are characteristic features of β-hairpin strands and 
of a type II turn (green in Figure 58). This supported the data obtained by CD spectroscopy 
which showed that the peptide adopts a type II or II’ turn (as they differ by rotation of 180° 
the CD spectrum would be identical). Nevertheless, a NHi-NHi+3 interaction cannot be 
observed because the peaks for these two NHs have very similar chemical shifts (6.67 and 
6.47 ppm respectively), and it was difficult to identify cross peaks in this region.  
The NOE interactions within peptide 77 were studied as TFE-d3 solution. This solvent 
promotes formation of the strongest intramolecular interactions. The NMR experiments 
were also performed at a lower temperature (278 K) to further enhance intramolecular 
interactions and obtain clearer signals. It was observed that Leu-NH and Val-NH were 
exchanging with the deuterium of TFE-d3 slowly over time (Figure 60, blue t = 0, red t = 20 
min, green t = 8 h), whereas Gly-NH exchanged immediately. This can be explained if the 
Leu-NH and Val-NH are protected from exchange with the solvent because they form 
intramolecular hydrogen bonds, while the Gly-NH was exposed to solvent. This suggested 
intramolecular hydrogen bonding to form of a 10-membered ring, which contrasts with the 
findings of the NMR shift experiments that had been performed in CH2Cl2 described earlier. 
This finding suggests that intramolecular interactions and the conformation adopted by our 
analogues are highly dependent on the solvent used.  
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Figure 60: NMR Spectrum of 77 at 10 mM in TFE-d3 showing H/D exchange of Leu-NH and 
Val-NH. t = 0 min (blue), t = 20 min (red), t = 8 h (green) at 278 K.  
2D NOESY spectra of 77 were also acquired in TFE-d2 because substrate cannot undergo 
deuterium exchange with the solvent. The same cross peaks that had been observed in 
CD2Cl2 were observed in this solvent, which was not surprising considering that the CD 
spectra were similar in all solvents, and suggests the same conformation is adopted. 
Nevertheless, the intramolecular hydrogen bonding pattern is different (Figure 61).  
 
Figure 61: NOE Cross peak of 77 observed at 10 mM in TFE-d2 at 278 K. 
Results were inconclusive and suggested that a defined, exclusive and stable type of turn 
was not being adopted by these peptides. The spectroscopic data provided evidence for 
intramolecular hydrogen bond formation and suggested that structured and folded 
conformations are formed but that this varied depending on the solvent. Consequently, it had 
been demonstrated that replacement of a planar peptide bond by a non-planar cyclopropane 
was an efficient way to constrain the system and form intramolecular hydrogen bonds in 
organic solvents even in small dipeptide mimics.  
  
O
HN
NH
O
HN
N
O
O
i
i+1
i+2 i+3
Leu-NH 
Val-NH 
  110 
2.8. Towards Leu-Enkephalin Mimicry 
Leu-enkephalin is a pentapeptide that binds to opioid receptors, with a particular affinity for 
the δ-opioid receptor.184 Leu-enkephalin can adopt a β-turn at two different positions with 
the formation of two hydrogen bonds and so is simple yet biologically important system in 
which the effectiveness of the cyclopropane dipeptide mimetics in promoting β-turns could 
be explored (Figure 62). The intention at the outset was to prepare two Leu-enkephalin 
analogous in which the Gly-Gly or the Tyr-Gly peptide units were replaced with a suitable 
cyclopropyl mimic.  
 
 
Figure 62: Leu-enkephalin and cyclopropyl analogues 
 
  
2 HN
O 3
N
O
4
NH
O
HOOC
HN
1
O
HN
HO
H
3 HN
O 4
N
O
HN
2
O
NH
1
O
N
H
HO H
OH
O
H
H
β-turn with Gly-Gly central residues β-turn with Gly-Phe central residues
H2N NH
O H
N
O
N
H
O
COOH
OH
H2N
H
N
O
H
N N
H
O
COOH
OH
O
(R,S)-{GlyΔGly}-Leu-enkephalin 132
(S,R)-{GlyΔGly}-Leu-enkephalin 133
(R,S)-{TyrΔGly}-Leu-enkephalin 134
(S,R)-{TyrΔGly}-Leu-enkephalin 135
  111 
2.8.1. Synthesis of {GlyΔGly}-Leu-enkephalin 132 and 133  
The first targets – {GlyΔGly}-Leu-enkephalin 132 and 133 – were synthesised from the 
Boc2-{GlyΔGly}-OH 107 building block. Boc-Phe-Leu-OMe 135 was first obtained in 88% 
yield by peptide coupling using HATU and DIPEA at rt (Scheme 38a). 
 
Scheme 38: {GlyΔGly}-Leu-enkephalin Analogues synthesis 
The synthesis commenced with Boc removal from dipeptide 136 using TFA and then 
coupling to the acid (R,S)- or (S,R)-107 using HATU to give respectively 137 and 138 
following the same scheme described for the synthesis of the other analogues (Scheme 38b). 
Removal of both Boc groups and coupling of the resulting amine to Boc-protected tyrosine 
afforded the protected analogues 139 and 140 respectively in good yield. The protected 
peptides were fully deprotected in one pot using 4 M HCl to give (R,S)-{GlyΔGly}-Leu-
enkephalin 132 and (S,R)-{GlyΔGly}-Leu-enkephalin 133 after purification by semi-
preparative HPLC in yields of 40% and 48% respectively.  
For comparison purposes, natural Leu-enkephalin 141 was also synthesised on a peptide 
synthesiser using Fmoc-Leu Wang resin (0.84 mmol/g loading) in a 0.1 mmol scale. The 
peptide was obtained in 43% yield after purification on semi-preparative HPLC.  
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2.8.2. Conformational Analysis of {GlyΔGly}-Leu-enkephalin 132 and 
133  
The conformational studies of the Leu-enkephalin analogues were performed in order to 
explore whether a β-turn was formed. CD spectra were recorded of solutions in H2O and 
TFE at 1 mg/mL (Figure 63). The CD spectra of (R,S)-{GlyΔGly}-Leu-enkephalin 132 in 
water showed a large negative around 190 nm that suggests a random conformation (green, 
Figure 63). The random population of conformations might be increased by the presence of 
the free N- and C- termini. The peptide displayed a more ordered structure in TFE, but it did 
not correspond to any type of β-turn described previously. This does not mean that the 
peptide is not adopting the expected conformation but it might adopt a different, currently 
undefined arrangement at equilibrium. Furthermore, the peptide contains two chromophore 
residues (Phe and Tyr) which could modify the CD signal due to their intermolecular and / 
or intramolecular interactions resulting in a unique CD profile. Nevertheless, the positive 
and negative peaks were observed at around 198 and 220 nm in TFE and H2O, which 
suggests similar conformational features are formed in both solvents.  
The diastereoisomeric compound, (S,R)-{GlyΔGly}-Leu-enkephalin 133 displayed a similar 
CD spectrum in water, which again suggests that the peptide does not adopt a well-defined 
structure due to interactions with the solvent (blue, Figure 63). The spectrum obtained from 
a sample in TFE was slightly different with three sharper positive peaks at 192, 205 and 223 
nm, suggesting a better-defined structure in this isomer when compared to the diastereomeric 
compound.  
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a)  
b)  
Figure 63: Far-UV CD comparison in a) TFE and b) H2O of Leu- enkephalin 141 (orange), 
(R,S)-132 (green) and (S,R)-133 (blue) 
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Comparison of the data obtained for the two analogues with the data for the native peptide 
in TFE (Figure 63a) and H2O (Figure 63b) was undertaken with a sample concentration of 
1 mg/mL. Similar features were evident in the spectra of all three peptides in water, with a 
large negative peak at 190 nm (suggestive of a random conformation) and a positive peak at 
around 220 nm was common to all peptides, which suggests that they adopt similar 
conformations in water. In TFE, the positive peaks at 192 and 220 nm were preserved in all 
of the peptides, which is evidence for a structure that is better defined for all peptides. 
However, differences between the conformations were clearly observable in the region of 
the spectrum around 200 nm. These results indicated that cyclopropane-containing 
analogues adopted similar conformational features to those found in the native peptide and 
demonstrated that the cyclopropane moiety is able to stabilise the conformation adopted by 
the peptide.   
Conformational NMR studies were undertaken in order to identify secondary structures that 
could be adopted by the peptides. Only sequential cross peaks (i.e. those between adjacent 
residues) were observed for the three peptides, providing no evidence to support any 
secondary structure adopted by Leu-enkephalin and its analogues. The Leu-NH, Gly2-NH 
and Phe-NH had similar chemical shifts in both solvents showing that they are in the very 
similar chemical environment (Figure 64). However, the downfield shift of the NH peaks 
when the spectra were recorded in TFE suggests a more ordered conformation. Both isomers 
of {GlyΔGly}-Leu-enkephalin 132, 133 and Leu-enkephalin 141 did not exhibit the 
characteristic features of β-turn when analysed by either NMR or CD spectroscopy. Indeed, 
no evidence of typical NOE crosspeaks of turns were shown and the CD spectra did not 
correspond to any type of turn described in literature.  
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a)              
 
b)   
Figure 64: NH Chemical shifts for (R,S)-132, (S,R)-133 and 141 in a) TFE and b) H2O/5 % D2O 
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2.8.3. Towards the Synthesis of {TyrΔGly}-Leu-enkephalin 134 and 
135 
Leu-enkephalin contains two glycine residues and the CH2 bonds within the residues allow 
free rotation about these bonds. The replacement of glycine with more substituted tyrosine 
restricts the number of accessible conformations of the molecule. The cyclopropane-
containing mimic with a Tyr side chain was also investigated to see if location of the mimic 
in a different position within the hybrid structure would have an effect. The synthesis 
commenced with the intermediate alkene 142 which was subjected to stereoselective 
cyclopropanation reaction (Scheme 39). It was expected that diastereoisomers of 143 would 
be formed and that separation of the diastereoisomers would be possible. The isomers could 
then be submitted to peptide coupling to obtain compound 144 and subsequent deprotection 
in order to obtain Leu-enkephalin analogues. Another approach was to proceed a 
cyclopropanation on terminal alkene using carbenes chemistry. Once the carboxylic acid 
143 obtained, it be submitted to Arndt-Eister homologation to produce the amide 144.185,186 
Finally, a standard peptide coupling procedure would be used to deliver the mimic 
{TyrΔGly}-Leu-enkephalin 134 and 135. 
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Scheme 39: Initial strategy for the synthesis of {TyrΔGly}-Leu-enkephalin 134 and 135 
Alkene 142 was obtained following the synthesis described by Dory et al..85 It consisted of 
sequential PMB protection of the Tyr, DiBAl-H reduction of the ester and Wittig reaction of 
the aldehyde to give a terminal alkene. This alkene was then subjected to a cross metathesis 
reaction with benzyl but-3-enoate.  
It was expected that cyclopropanation of the alkene would be unselective leading to a 
mixture of diastereoisomers that could be separated for further study. 
  
BocHN
Tyr(PMB)
CO2H
BocHN
Tyr(PMB)
O
O
R
O
BocHN
Tyr(PMB)
O
N2
H2N
X
O
R
10% Ag benzoate/Et3N
BocHN
Tyr(PMB)
N
H
O R
X
O
144
BocHN
Tyr(PMB)
CO2BnBocHN
Tyr
OMe
O
4 steps cyclopropanation
BocHN
Tyr(PMB)
CO2Bn
142 143
H2N NH
O H
N
O
N
H
O
COOH
OH
(R,S)-{TyrΔGly}-Leu-enkephalin 134
(S,R)-{TyrΔGly}-Leu-enkephalin 135
CH2N2
BocHN
Tyr(PMB)
BocHN
Tyr(PMB)
N
H
O R
X
O
144
H2N NH
O H
N
O
N
H
O
COOH
OH
(R,S)-{TyrΔGly}-Leu-enkephalin 134
(S,R)-{TyrΔGly}-Leu-enkephalin 135
145 146
  118 
 
Table 17: Cyclopropanation conditions on alkene 142 
 Entry Conditions Results 
1 Et2Zn, CH2I2, CH2Cl2 –78 °C to rt 20% conversion 
2 CH2N2, Et2O, Pd(OAc)2 Decomp. 
The general procedure for Simmons-Smith cyclopropanation, in which diethyl zinc is used 
in combination with diiodomethane, was employed in an attempt to cyclopropanate the 
alkene 142 but there was poor conversion and the expected product was not obtained (Table 
17 entry 1).187  The use of diazomethane to cyclopropanate vinyl amides has been 
described.188 The reaction was attempted on allylic ester 142 using Pd(OAc)2 as the catalyst 
(Table 17, entry 2). TLC analysis of the reaction showed that multiple products had been 
generated but the cyclopropane 143 was not isolated following column chromatography. 
After the failure of the reactions above, an alternative cyclopropanation method was 
explored. Following the success of cyclopropanation of a terminal alkene by a Rh2(OAc)4-
catalysed reaction with ethyldiazoacetate, these conditions were applied to the 
functionalisation of the alkene 145 (Table 18, entry 1). A solution of ethyl diazoacetate was 
added slowly to a solution of the alkene and the catalyst at low temperature and the mixture 
was stirred for 18 h. The crude product was purified by column chromatography and traces 
of compound 146 were detected by mass spectroscopy, but the compound could not be 
further purified to give the required product. 
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Table 18: Cyclopropanation on terminal alkene 
Entry Diazoester Cat. Ligand Diazoester:143 Results 
1 Ethyl Rh(OAc)2 
3 wt% 
- 2:1 Traces of 146a 
2 Ethyl CuOTf 
1 mol% 
147 
1 mol% 
2:1 Traces of 146a 
3 BHT CuOTf 1 mol% 
147 
1 mol% 5:1 - 
4 BHT CuOTf 5 mol% 
147 
5 mol% 5:1 - 
aDetermined by low res. MS 
In 1991, Evans et al. described the use of a chiral copper(I) bisoxazoline complex to perform 
the asymmetric cyclopropanation of alkenes with good enantioselectivity.189 This reaction 
required the formation of the copper-ligand complex prior to addition of the alkene and 
diazoester under an inert atmosphere (Table 18, entry 2). This reaction was attempted and a 
trace of the desired product was detected but it could not be isolated.  
 
Scheme 40: Synthesis of the BHT diazoester 150 
The diazoacetic acid ester derived from BHT has been described as a good substrate for 
carbene reactions (Scheme 26).190 The synthesis of the reagent commenced with the 
treatment of BHT with 2,2,6-trimethyl-4H-1,3-dioxin-4-one. The keto ester 148 was 
obtained in 44% yield from this reaction as a mixture of keto and enol tautomers (45:55 
keto/enol). This compound was then submitted to a reaction with tosyl azide to give 
intermediate 149, which was not isolated but instead submitted to a hydrolysis reaction in 
8% aq. KOH to produce the diazoester 150 in 66% yield. The cyclopropanation reaction was 
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performed on alkene 145 using diazoester 150. The copper sources CuOTf or Cu(OTf)2 were 
used along with the ligand 143 and catalyst loadings of 1 and 5 mol% were employed (Table 
18, entries 3 and 4). Unfortunately, poor conversion was observed and the required 
cyclopropane was not obtained.  
Cyclopropanation can be accelerated by the presence of an allylic alcohol in the substrate. 
The presence of a polar group results in coordination between the alcohol and the catalyst 
complex or reagent which delivers the reactant in an intramolecular fashion.191 In an attempt 
to exploit this reactivity, the allylic alcohol 151 and its corresponding protected version 152 
were synthesised from alkene 145, a compound obtained previously, by cross metathesis 
using Hoveyda-Grubbs second generation catalyst (Scheme 41). This reaction gave only the 
(E)-alkene isomer in modest yield and silyl protection afforded the alkene 152 
 
Scheme 41: Cross metathesis and subsequent cyclopropanation 
The Simmons-Smith cyclopropanation reaction was performed on free alcohol 151 and on 
the protected alcohol 152. Unfortunately, complex mixtures of products were obtained and 
neither of the required cyclopropanes 153 and 154 was obtained even after purification.  
The final attempt to perform a cyclopropanation reaction involved the acrylate substrate 155 
(Scheme 42). The substrate was synthesised from alkene 145 by cross metathesis using 
Grubbs II catalyst.  
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Scheme 42: Corey Chaykovsky Cyclopropanation 
The (E)-alkene 155 was obtained in 40% yield and this compound was then submitted to a 
Corey-Chaykovsky cyclopropanation reaction.192 This procedure can be used for the 
synthesis of epoxides, aziridines and cyclopropanes and a chiral or achiral ylide salt can be 
reacted with α,β-unsaturated esters. Unfortunately, when alkene 155 was submitted to the 
cyclopropanation reaction, only traces of the compound 156 were detected by LCMS after 
column chromatography. Due to the failure of all routes to required cyclopropyl 
intermediate, this approach was abandoned.  
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Chapter 3  
Tryptophan Zipper, turn replacement and 
analysis  
3.1. Introduction 
Results obtained by incorporation of cyclopropyl amide bond isosteres into small peptides 
were promising and there was evidence that {Gly∆Gly} mimic was enhancing the formation 
a β-turn in some cases. However, short peptides rarely adopt stable secondary structure in 
solution.193 and so was essential to identify a better system to evaluate the mimic. An ideal 
peptide would be longer, more stable, well-defined and fully characterised in literature, in 
order to evaluate the conformation adopted by the new peptide following incorporation of 
the dipeptide mimic and compare it to the native peptide.  
To this end, the TrpZip peptide 157 was selected and its analogues were investigated. TrpZip 
stands for Tryptophan Zipper, a system designed by Cochran at al.194 that is a water soluble 
12-residue peptide (H-SWTWEGNKWTWK-NH2). This peptide adopts a stable and 
monomeric β-hairpin, which is the minimal structural unit of an antiparallel β-sheet.195 The 
hairpin is stabilised by two cross-strand Trp-Trp pairs,  the indole groups of which stack in 
an edge-to-face manner (Figure 65).196 Aromatic stacking is one of the strongest side-chain 
interactions in tertiary structure adopted by peptides and proteins.197,198 These interactions 
along with multiple intramolecular hydrogen bonds make the structure remarkably stable 
(Tm = 323 K) and TrpZip 153 has been reported to be the smallest peptide to adopt an unique 
tertiary structure without additional metal binding or formation of a disulfide bridge.194  
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Figure 65: TrpZip 157 and Trp interactions 
The interactions between indoles are considered to be hydrophobic in nature.199 Folding of 
a β-hairpin can be initiated in two different ways: either the residues present in the peptide 
have a high propensity to form a turn structure which then brings the β-strands into close 
proximity (hydrogen bonds or side-chain interactions), or hydrophobic interactions between 
complementary residues on each strand allow formation of cross-strand hydrogen bonds 
which results in turn formation.200  Hydrophobic interactions are known to be a powerful 
driving force for formation of secondary structure201 and TrpZip 157 has features which 
make it an excellent model for hydrophobic collapse and contribute to the structural stability 
of the β-hairpin.  
Due to interactions between the indoles, its 3D structure and its overall sequence, TrpZip 
157 displays a unique circular dichroism (CD) spectrum with intense positive-negative 
exciton coupled bands (Figure 66) in the far UV at 228 and 214 nm.202  
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Figure 66: Far-UV CD spectrum of TrpZip 157 
Because of the strong coupling of the chromophores in this region, the CD spectrum arising 
from their π–π* transitions masks the weaker amide CD bands that are usually used for the 
determination of the secondary structure (positive bands at 195–220 nm).203 Which is why, 
the spectrum does not show the usual features expected of a β-sheet or a β-turn.  
TrpZip and three analogues that vary in their turn sequence were synthesised and analysed 
(Figure 67). TrpZip was used as a reference peptide and GG-TrpZip 158 was synthesised in 
order to see the effect of replacing the Asn residue by a more flexible and achiral Gly residue. 
A new hybrid peptide 159 and 160 was then synthesised in which the turn sequence was 
replaced by the {Gly∆Gly} dipeptide mimic described previously. The TrpZip analogues 
158-160 were analysed and compared with the native form.  
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Figure 67: TrpZip and analogues synthesised 
TrpZip was reported to fold to give a β-hairpin with a type II’ turn involving the E-G-N-K 
amino acid sequence.194 The aim of this study was to understand what happens when one or 
more of the amino acids is replaced in the turn sequence and to determine whether this is 
detrimental to β-hairpin formation.194,197,201,204 In particular, replacement of a peptide bond 
by a cyclopropane was to be explored to discover whether it stabilises the system or 
destabilises the β-hairpin to produce a random coil. To this end, all peptides were synthesised 
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and then analysed under the same conditions to obtain results that would permit direct 
comparison.  
3.2. Synthesis of the TrpZip and its analogues 
Microwave assisted solid phase peptide synthesis was used to synthesise the four compounds 
of interest. TrpZip 157 and GG-TrpZip 158 were synthesised using Tentagel S RAM resin 
(0.24 mmol/g loading) and Fmoc chemistry. A total of 4 equivalents of Fmoc protected L-
amino acids and 4 equivalents of HCTU as coupling agent were used for the coupling 
reaction. After purification by reverse phase HPLC and lyophilisation, peptide content was 
determined by measuring the absorbance in 300 μL of H2O using a Nanodrop at 280 nm. 
The cycle in the synthesiser includes: Swelling of the resin, deprotection of the resin, 
coupling at 75 °C, deprotection of the amino acid that has been coupled, washing after each 
coupling and deprotection step, and precleavage in CH2Cl2. The resin was cleaved using 
TFA/TIS/H2O (95:2.5:2.5) cocktail, which was then removed with a flow of N2.  
The synthesis of the {G∆G} analogues 159 and 160 was slightly different. H-KWTWK-
Tentagel first sequence was synthesised on the peptide synthesiser using the method 
described before. Once the last Lys residue had been deprotected, (R,S)-Fmoc-{Gly∆Gly}-
OH 161 and (S,R)- Fmoc-{Gly∆Gly}-OH 162 were coupled manually (1.1 and 2 equivalents 
respectively of dipeptide and 2 equivalents of HATU were used). The coupling was mixed 
overnight at rt for maximal conversion. Unreacted peptide was capped using acetic 
anhydride to avoid further coupling on it (truncated product was determined by LC-MS). 
The resin was then put in the synthesiser and the rest of the sequence was constructed 
following the same procedure as described previously.  
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3.3. Circular dichroism 
3.3.1. Materials and methods 
Far- and near-UV spectra were acquired with a Jasco J-810 spectropolarimeter using 
respectively a 0.01 cm and 0.1 cm pathlength cell. Peptide concentrations were determined 
by measuring the absorbance at 280 nm using a Nanodrop instrument (0.77–0.93 mg/mL in 
20 mM phosphate buffer, pH 7). Thermal denaturation was measured in the near UV, using 
a 0.1 cm pathlength cell and the temperature varied from 5 °C to 80 °C in steps of 5 °C. 
Melting curves were acquired at 295 nm.  
3.3.2. Results and discussion 
TrpZip 157 exhibited a unique CD spectrum in near- and far-UV due to the interactions 
between the Trp residues. Two aromatic rings can interact to form a chiral pair of 
chromophores, which can be seen in the near UV (characteristic bands are observed between 
250 and 320 nm),9 which indicated that the pairs of Trp of the peptides were in a chiral 
environment and in a well-defined tertiary structure. It was apparent that two cross-strand 
pairs of Trp were stacking with each other in this peptide resulting in bands at 287 and 295 
nm. Bands in this region are generally taken as evidence for presence of a fixed and stable 
tertiary structure in proteins. 
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Figure 68: Near- and far-UV CD spectra, TrpZip 157 (blue), GG-TrpZip 158 (red), (R,S)-
{G∆G}-TrpZip 159 (pink), (S,R)-{G∆G}-TrpZip 160 (green) 
The CD spectra were normalised at the most intense peak for both regions (Figure 68). The 
exciton bands at 214 and 228 nm were observed in the far-UV as well as the two negative 
bands at 287 and 295nm in the near-UV that were conserved in all the peptides. The 
interactions between the Trp were maintained and they were in the same environment. 
Comparison of the CD data for the analogues with that of the native form showed that the 
interactions were not changing in their nature; even though the turn sequence was modified, 
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either by swapping one residue or by replacing a planar peptide bond by a chiral non-planar 
cyclopropane unit. It was clear that cross-strand Trp pairs were still interacting with each 
other in the analogues 158, 159 and 160. Because this kind of interaction stabilises the β-
hairpin and initiates the formation of it, it was possible to state that the analogues were also 
forming the β-hairpin. However, it was not clear whether they are as stable as the TrpZip 
157.  
TrpZip peptide 157 had been reported to exhibit a reversible thermal unfolding. The CD 
spectra in the near-UV were recorded at 5 °C (blue), prior heating to 80 °C at which stage 
the peptide will be unfolded, and once it had been cooled back to 5 °C (red) (Figure 69). 
a)  
b)  
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c)  
d)  
Figure 69: Near UV CD of a) TrpZip 157, b) GG-TrpZip 158, c) (S,R)-{G∆G}-TrpZip 160 and d) 
(R,S)-{G∆G}-TrpZip 159 at 5 °C, prior  prior (blue) and following heating to 80 °C and cooling 
to 5 °C (red).  
Following unfolding, the analogues behaved in a similar manner to the TrpZip 157 and they 
refolded to give exactly the same structure. The analogues all exhibited reversible thermal 
unfolding because the curves matched perfectly before and after heating. The near-UV CD 
spectrum is influenced by the behaviour of the side chains with regard to their position before 
and after heating. The data show that the interactions between the side chains were not 
modified after refolding. The analogues and the native peptide exhibited very similar 
stabilities in terms of their folding, which means they adopt the same preferred and stable 
conformation.  
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The evidence that the Trp side chains of the analogues were in a similar arrangement to those 
of the native form of TrpZip 157 prompted a more detailed study of the stability. The melting 
temperature (Tm) is the temperature at which 50% of the peptide is in an unfolded state. The 
higher it is, the greater the stability of the peptide. The data were acquired from 5 to 80 °C 
in increments of 5 °C for each peptide in the near UV (Figure 70). The arrow indicates the 
trend as a function of increasing temperature.  
 
Figure 70: Thermal denaturation monitored by near-UV CD of TrpZip 157, GG-TrpZip 158, 
(S,R)-{G∆G}-TrpZip 160 and (R,S)-{G∆G}-TrpZip 159 
All peptides followed the same trend and the CD intensities decreased upon heating, which 
indicates a secondary structural change from the hairpin to a disordered conformation by 
destabilising the intramolecular interactions. The data suggest a loss of the Trp cross-strand 
pairs interactions resulting in conformational mobility and a loss of signal. With this data it 
was possible to plot the thermal denaturation at a specific wavelength, which was chosen to 
be 295 nm (the most intense negative peak in near-UV, Figure 70), and also the fraction of 
peptide that is folded as function of the temperature, and thereby establish the stability of 
the peptides. Both sets of data demonstrated that the three analogues follow the same trend 
as the native peptide because the slope was similar for all peptides which indicates similar 
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stability (and consequently Tm). The two graphs allowed the degree of folding and the Tm 
to be estimated.  
 
Figure 71: Thermal denaturation at 295 nm and fraction folded as function of the temperature 
of TrpZip 157 (blue), GG-TrpZip 158 (red), (R,S)-{G∆G}-TrpZip 159 (pink), (S,R)-{G∆G}-
TrpZip 160 (green) 
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The fraction folded at any given temperature α was calculated by use of the following 
(equation 1):205  
𝜶 =	 𝜽𝒕 − 𝜽𝑼𝜽𝑭 − 𝜽𝑼 
Equation 1: fraction folded equation 
Where θt is the observed ellipticity at any temperature, θF is the ellipticity of the fully folded 
form (chosen to be that at 278K), and θU is the ellipticity of the unfolded form (chosen to be 
that at 353 K, the highest temperature used). Subsequently, the Tm was calculated from the 
graph, it corresponds to the temperature where α = 0.5. For the TrpZip native form 157, the 
Tm was calculated to be 316.8 K (43.7 °C) which is similar to that reported in literature.194 
The GG-TrpZip analogue 158 showed slightly higher stability than the native peptide, with 
a Tm of 319.8 K (46.7 °C)  i.e. 3 K higher than the original peptide. The Gly residue that 
had been used to replace the Asn residue in this analogue gave more flexibility in the turn 
sequence than that in the native peptide which results in less constraint in the interaction 
between the side chains of the peptide allowing it to adopt the most favourable and stable 
conformation. Both (R,S)-159 and (S,R)-160 (pink and green respectively in  Figure 71) of 
the {G∆G} surrogate were incorporated into the peptide. The resulting analogues had similar 
stability with a Tm differing of less than 1.5 K (respectively 311.6 K/38.5 °C and 312.9 
K/39.8 °C). Both of calculated Tm values were lower than for the native peptide and so they 
are slightly less stable than either the native or GG-TrpZip peptide 158. This outcome is 
expected because replacement of the peptide bond with a cyclopropane delivers a  more 
constrained system in which there is likely to be a difference in the strength or in the angle 
of the Trp interactions because the rings don’t have the same degree of liberty to stack in the 
edge-to-face approach.  
The results described above showed that there are stability differences between the various 
peptides but they adopt very similar conformations. The GG analogue 158 was found to have 
a higher stability than the native form, whereas the {G∆G} analogues 159 and 160 were 
found to be slightly less stable, suggesting a change in the interactions between the Trp, or 
a difference in the free energy of folding of the peptides (in ∆S or ∆H, and therefore in ∆G) 
MD calculations were undertaken in order to understand the differences in the interactions 
(and thus the stability) and if these have an impact on the type of β-turn formed. Dr Drew 
Thomson has kindly provided all this data as part of a collaboration on this project.  
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3.4. MD calculation, a tool to understand the 
stability and folding pattern of peptides  
The small size of this peptide allowed full-atom computation to be carried out. MD 
calculations have been performed in order to predict the conformation of the TrpZip 157 and 
its analogues 158-160. Moreover, the measurements gave information on the nature of the 
β-turn formed. In this case, the turn sequence was examined closely by measuring the 
distance between the Glu-CO and Lys-NH and calculating the associated N-H-O angle 
(Figure 72), thus evaluating the formation of a crucial hydrogen bond within the turn or not. 
 
Figure 72: NH--OC distance and NHO angle within the turn studied 
In proteins and peptides, the hydrogen bond between the COi and NHi+3 residues of the turn, 
has a length of 2.5 to 3.2 Å, the N-H-O angle from the same residues is about 130–180 °.206 
Distance and angle were recorded for every 10th frame and plotted for each peptide (Figure 
73). The red line corresponds to the maximum length of a hydrogen bond (3.2 Å).  
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Figure 73: NH-CO distance in the turn for TrpZip 157, GG-TrpZip 158, (S,R)-{G∆G}-TrpZip 
160 and (R,S)-{G∆G}-TrpZip 159 
The distance between the Glu-CO and Lys-NH for the TrpZip peptide 157 (Figure 73, top 
graph), were within the range expected for a hydrogen bond (with an average distance of 
2.91 Å within the 50000 frames). This vindicated our choice of the peptide as a reference 
because a β-turn was undoubtedly formed in this model system. GG-TrpZip 158 (Figure 73, 
2nd graph) was for most of the frame within the hydrogen bond distance range (with an 
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average distance of 2.75 Å). It had been shown already that changing a residue within the 
turn was not detrimental to β-hairpin formation, but the results presented here supported this 
finding and showed that the crucial hydrogen bond is formed within the turn. (S,R)-{G∆G}-
TrpZip 160 (Figure 73, 3rd graph) showed a slightly different pattern and on average the 
distance was 3.07 Å (still within the range), but the graph showed more variation out of the 
range of distance with most of the frames having a distance smaller than 2.8 Å. This isomer 
brought the HBA and HBD groups into closer proximity than in the native peptide and thus 
enhanced hydrogen bond formation. In the case of (R,S)-{G∆G}-TrpZip 159 (Figure 73, 
bottom graph), the simulation showed that the distance is out of the range for most of the 
frames (4.88 Å on average), suggesting that hydrogen bond could not be formed for this 
analogue. It corresponded to the analogue having the lowest Tm as measured by CD and so 
it is the least stable peptide (cf figure 71). Hydrogen bonds stabilise the secondary structure 
of peptides/proteins and so the higher the degree of hydrogen bonding, the higher will be the 
Tm because it will take more energy to break all of them when unfolding the peptide/protein. 
In a small system like TrpZip peptide, if a single hydrogen bond is missing, less energy is 
required to destabilise the whole system and so the Tm is lower. The lower stability of the 
system could be because the cyclopropane has separated the hydrogen bond donor and 
acceptor groups compared to native TrpZip 157 and so they might not be aligned with the 
required angle (between 130 and 180°). In order to explore this issue, the N-H-O angle of 
the hydrogen bond was measured (see Figure 72) for all peptides and they were shown to be 
within the expected range (Figure 74, only (R,S)-159 peptide is shown as they are all similar).  
 
Figure 74: N-H-O angle within turn of (R,S)-{G∆G}-TrpZip 159 
Even though, (R,S)-{G∆G}-TrpZip 159 had the correct angle in most of the frames of the 
simulation, the hydrogen bond donor and acceptor groups were located too far away in space. 
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Nevertheless, when the CD results are considered, the reduced hydrogen-bonding 
capabilities of the system did not appear to have any consequences with regard to formation 
of the β-hairpin (as the CD was very similar to that of the native peptide, see Figure 68). 
This finding supports the argument that the turn was not initiating the formation of the β-
hairpin, but instead Trp-Trp interactions were initiating and stabilising the secondary 
structure leading to formation of the β-turn. The next challenge was to discover whether 
different types of turn were formed by determining the torsion angles within the turn.  
The torsion angles (φ, ψ and ω) are the main factors in dictating how the protein folds.  As 
already described in the introduction chapter, the φ angle of the i residue is defined by the 
torsion Ci–1-Ni-Cαi-Ci, ψ by the torsion Ni-Cαi-Ci-Ni+1, and ω by the torsion Cαi-Ci-Ni+1-
Cαi+1 (Figure 75).207 The φ and ψ angles provide the flexibility required for the fold, ω is 
restricted due to the planarity of the peptide bond and is set to 180 °.  
 
Figure 75: torsion angles in a peptide chain 
Ramachandran plots are a convenient way in which to visualise the distribution of the 
dihedral angles (or torsion angles) of every amino acid in a protein structure (Figure 76).208 
They are used to identify the secondary structure of a peptide or a protein.  Ramachandran 
plots of a particular protein can also provide a good indication on the stability of its 3D 
structure.209 It is a PDB (protein data bank) distribution based on energy for all residues that 
comprise proteins.  
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Figure 76: Ramachandran plot.210 
The plots are typically split in two regions: the forbidden and allowed regions. The forbidden 
region corresponds to the combination of angles where there would be unfavourable steric 
interactions between the atoms in the chain (white “background” in the figure). The allowed 
region represents the distribution of torsion angles favourable for formation of a stable 
secondary structure (black dots).211  
β-Turns are classified according to the value of the dihedral angles of the central residues 
(in our case, Gly-6 and Gly-7, Asn-7 or ∆Gly-7). Three rules need to be respected for the 
system to be classified as a β-turn: the distance between the i and i + 3 Cαs is less than 7 Å, 
the two central residues (i + 1 and i + 2) should not show helical properties (determined  by 
their torsion angles), and a cross-strand hydrogen bond between residue i and i + 3 should 
be present.212   
 
Figure 77: Dihedral angles in TrpZip and analogues 
For the the {G∆G} analogues 159 and 160, the angles were measured following the same 
rules as for native peptides (i.e. defined by four points in space, through the atoms on the 
main chain of the turn, not through the methylene group of the cyclopropane); φ67  by the 
torsion CE-NG-Cα-CH, ψ67  by the torsion NG-Cα-CH-CH, φ97  by the torsion CH-CH-Cα-CG 
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and ψ97  by the torsion CH-Cα-CG-NK). de Brevern has described and created Ramachandran 
plots for various types of β-turn (figure 78). The arrows represent the direction going from 
the i+1 residue’s dihedral angle (φ1, ψ1) to the i + 2 angles (φ2, ψ2). It is important to note 
that the dihedral angles chosen for the cyclopropane mimics cannot be used as a proof for β-
turn formation. In the case of the analogues, a planar moiety has been replaced by a non-
planar cyclopropane (sp2 hybridized atoms are replaced by sp3 centres) and so their physical 
and chemical properties are different. Consequently, the Ramachandran plots for the {G∆G} 
analogues 159 and 160 provide qualitative rather than quantitative information.  
 
Figure 78: Ramachandran plot for different type of turn212 
The MD calculations provided by Dr. Drew Thomson, allowed the dihedral angles of the 
central residues of the turn to be measured for 5000 frames i.e. every 10th frame among 
50,000. This allowed prediction of the type of turn adopted by the native form (and whether 
it corresponds to that reported by Cochran et. al.) and by the GG-TrpZip 158. The black dots 
correspond to the φ1, ψ1 angles (i+1 residue) and the blue dots to the φ2, ψ2 angles (i + 2 
residue).  
The Ramachandran plot of TrpZip 157 (Figure 56) showed that a type II’ β-turn is formed, 
a finding that agrees with the finding of Cochran et al.. The CD spectrum of GG-TrpZip 158 
(see Figure 68) overlays closely with the native form of the TrpZip, and consequently they 
adopt the same conformation. However, the Ramachandran plots for the peptides are 
different which indicates that GG-TrpZip 158 adopts another type of turn. The φ1, ψ1 angles 
were found to be in the same region, which was expected as is it the unchanged Gly residue, 
and the rotations around the bonds (thus the torsion angles) were not impacted by 
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replacement of the adjacent residue. While, φ2 and ψ2 were found to have almost opposite 
values when compared to those of TrpZip 157.  
 
Figure 79: Ramachandran plots for TrpZip 157 and GG-TrpZip 158 
The direction taken did not correspond to any of the types of turn that had been described by 
de Brevern. Several hypotheses may be ventured to explain this finding: another type of β-
turn, not described in literature, could have been formed (possibly a new type IV turn); a 
turn other than a β-turn could have been formed (e.g., a γ-turn); or a turn has not been formed 
because the two Gly residues provide too much flexibility and so a turn is not crucial for a 
stable conformation to be adopted by the peptide.  
(S,R)-{G∆G}-TrpZip 160 (Figure 80) had φ67  and ψ67  angles that are the same region as the 
TrpZip. Pleasingly, the torsion angles measured on the C-ter of the dipeptide surrogate, φ97  
and ψ97 , were also in the same region as the native form and so it appeared that this analogue 
was forming a type II’ β-turn. This finding is in agreement with the CD spectrum in the near-
UV (see figure 68), which matched that of TrpZip 153 perfectly and thereby showed the Trp 
were in the same chiral environment and interacting in the same way in both compounds. 
Because the Trp initiate formation of the β-hairpin, if the interactions are very similar the 
same type of turn would be expected.  
For the (R,S)-159 (figure 80), the key torsion angles were rotated by 180 °. φ97  and ψ97  were 
found to have opposite values compare to the (S,R)-160. φ67  was found to be unchanged 
whereas ψ67  was also found to be the opposite. Fundamentally, all dihedral angles appear to 
be flipped except φ67 , resulting in a different type of turn that has the features of a type I’ 
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turn when compared to de Brevern’s Ramachandran plots. The stacking might be slightly 
deviating due to the rigidity of the cyclopropane. Surprisingly, despite the fact that the turn 
lacked a hydrogen bond (see Figure 73), a type of turn could still be discerned in the plot.  
 
 
Figure 80: Ramachadran plot of cyclopropane analogues 
The results presented above show that there are changes in the turn conformation of the 
analogues when compared to that of the native TrpZip 157. However, these changes did not 
have an impact on the hairpin conformation adopted by all peptides (as shown by CD 
spectroscopy). The CD spectra were obtained in the near-UV region and show the Trp side 
chain contribution. Pleasingly, all peptides have essentially the same CD spectrum, which 
proves that the Trp side chains are in the same environment and interact in the same way as 
in TrpZip. Furthermore, the non-natural unit incorporated within the peptide is equally 
stabilising the β-hairpin (Tm slightly lower, which indicates similar stability). The 
cyclopropane is a rigid and compact group and the hypothesis is that the ∆H is similar to that 
of TrpZip 157 but ∆S (defined by the side chains) varies between the peptides. As a 
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consequence, the value of ∆G would be expected to vary, which could explain why the Tm 
values for the analogues are slightly different.  
3.5. NMR conformational analysis  
3.5.1. Material and method 
NMR samples contained 0.25 to 1.30 mM peptide (measured by absorbance at 280 nm) in 
95 % H2O/5% D2O-TSP (TSP used as chemical shift reference) in 10 mM pH 5.5 acetate 
buffer (AcOD was used for the preparation of the buffer and the pH was adjusted using aq. 
10 mM KOH solution). All spectra were acquired on 600 MHz Bruker spectrometer at 
various temperatures (278–308 K). Double quantum filtered correlation spectroscopy (DQF-
COSY), total correlation spectroscopy (TOCSY), and nuclear Overhauser effect (NOESY) 
spectroscopy were acquired with gradient selection and excitation sculpting for water 
suppression. 
3.5.2. Results and discussion 
Techniques in NMR spectroscopy have been well developed rapidly over the past 40 
years.213 Secondary structure can be determined by several methods: the proton (Hα) and 
carbon (Cα) chemical shifts,214 the spin-spin coupling or 3𝐽;<=>< coupling constant and the 
Karplus equation,215 NOE cross peaks,216 etc… Furthermore, NMR spectroscopy is a great 
tool to use to determine whether the peptide is a monomer (concentration dependant study, 
chemical exchange), and to detect and differentiate between intra- and inter-molecular 
hydrogen bonds (chemical shift varying with temperature or hydrogen-deuterium 
exchange).217  
2D NOESY experiments are a convenient tool to determine the conformation adopted by a 
peptide. If the peptide adopts an antiparallel β-sheet, the NOESY spectrum shows intense 
sequential cross peaks between NHi and Hαi–1. 2D NOE experiments were investigated in 
this work in order to analyse the folding of TrpZip and its analogues. The protons were 
assigned using the sequential assignments method on 2D COSY and TOCSY spectra.218 
Characteristic sequential NOE cross peaks were observed for TrpZip 157. The presence of 
long range Hα-Hα or NH-Hα cross-peaks is a good indicator of secondary structure and 
backbone interactions that stabilise the system. It is particularly important in the case of 
TrpZip 157, because its main structural characteristic is stacking between the indole groups 
of the Trp residues bringing the Hαs of these residues in close proximity. Intense cross-peaks 
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were observed between Hαs of Trp 2-Trp 11 and Trp 4-Trp 9 (Figure 81), indicating that 
these Trp residues were interacting with each other in this order confirming the conformation 
adopted by this peptide.  
 
Figure 81: Hα-Hα cross-peaks (red) and NH-Hα cross-peaks (blue) representation in TrpZip 
157* 
*In the interests of clarity, not all cross-peaks have been represented.  
Some other Hα-Hα cross-peaks were observed between cross strand Trp-2 and Thr-10, 
supporting the interactions between Trp-4 and Trp-9. NH-Hα cross peaks were also observed 
between residues located on both strands of the peptide (e. g. NH-Trp-2 with Hα-Trp-11, 
blue in Figure 81). The observation of these cross-peaks in addition to the CD data that had 
been obtained provides conclusive confirmation that TrpZip 157 is adopting a β-hairpin 
conformation.  
The aim was then to analyse the other peptides and identify the cross peaks observed. All of 
the peptides were assigned using the same method described previously (sequential 
assignments from COSY and TOCSY spectra). Sequential NHi-Hαi–1 cross-peaks, which are 
a distinctive feature of antiparallel β-sheet, were observed for the all the analogues. 
Therefore, all analogues adopted the same conformation, which supported the the CD data 
that had been obtained. However, Hα-Hα NOESY cross-peaks for GG-TrpZip 158 were 
slightly different (Figure 82). In this case, Trp-Trp cross-peaks were present, showing that 
there are interactions between them, but there are also through-space interactions between 
Trp-4 and the two Gly residues that were not observed in TrpZip 158 (with Gly and Asn). 
The turn was more flexible due to the replacement of the Asn residue with Gly, allowing 
more interactions between the side chains around the turn and this was also showing that the 
Trp-4 is stacking on the top of Trp-9.  
NH
O
Asn NH
O
N
H
O
H
N
O
H
N
O
N
H
N
H
O
O H
N
O
H
N
O
N
H
O
N
H
O
NH2
O
NH2
Glu
Trp
Thr
Trp
Ser
Lys
Trp
Thr
Trp
Lys
TrpZip
H H H
HHH
H
H
HH
H
  144 
 
Figure 82: Hα-Hα cross-peaks (red) and NH-Hα cross-peaks (blue) representation in GG-
TrpZip 158* 
*In the interests of clarity, not all cross-peaks have been represented.  
More NH-Hα NOESY cross-peaks were observed from residues on the two strands, which 
supports the hypothesis of a more stable flexible system, as determined by the CD spectra 
obtained and the higher Tm calculated (see Figure 71). Other expected cross-strand cross-
peaks were also observed for this analogue.  
When the 2D NOESY of the {G∆G} analogues were analysed, that of (S,R)-{G∆G}-TrpZip 
160 exhibited an interesting feature (Figure 83). The NHs of the backbone, shown in the 
spectrum below, were exchanging with other NHs with smaller intensity (cross peaks 
highlighted in the figure).  
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Figure 83: NOESY spectrum in NH region of (S,R)-{G∆G}-TrpZip 160 
Two different circumstances could explain this: either the protons were exchanging with the 
protons of another molecule (intermolecular interactions), which implies dimer formation, 
or it was exchanging with another conformation adopted by the peptide. A concentration 
dependant NMR study was then undertaken to discover whether the “exchanged” peaks get 
smaller with the concentration. If the peaks are reduced in size with a decrease in the 
concentration, it means that the peptide is interacting with another molecule. To this end, 1H 
NMR of the peptide was acquired at four different concentrations, from 0.125 mM to 1 mM 
(Figure 84).  
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Figure 84: Concentration dependant NMR spectra of (S,R)-{G∆G}-TrpZip 160 
The small peak (indicated with an arrow), became smaller with the concentration, which 
meant that this peptide was interacting with another molecule at higher concentration and 
forming a dimer. This observation might explain why a lower Tm was observed for this 
peptide. The 2D NMR experiments were performed at 0.25 mM because the signals were of 
better quality than those at lower concentration. The other enantiomer (R,S)-{G∆G}-TrpZip 
159 did not show this concentration dependency and was behaving as expected for a 
monomer. Therefore, a higher concentration could be used for the 2D experiments and a 0.4 
mM sample was prepared. For both analogues, long range NH-Hα and Hα-Hα NOE cross 
peaks were not observed, but all sequential NHi-Hαi–1 were present. The intensities of long-
range NOE cross peaks are lower than those of the sequential cross peaks, so these peaks 
could probably not be observed at low concentration. It would be necessary to perform the 
NMR experiments at higher concentration in order to observe such cross peaks.  
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3.6. Conclusion  
The β-hairpin conformation adopted by TrpZip peptide 157 has been confirmed by the 
combination of CD and NMR analysis. The replacement of the Asn-6 by a Gly did not 
prevent β-hairpin formation and the analogue was found to be slightly more stable than the 
native peptide with a higher Tm calculated. The analogues (S,R)-{G∆G}-TrpZip 160 and 
(R,S)-{G∆G}-TrpZip 159 also have features consistent with a β-hairpin conformation when 
analysed by CD and have similar stabilities to the native peptide. NMR analysis of (S,R)-
{G∆G}-TrpZip 160 showed that this analogue has concentration-dependent behaviour for 
and it appears to be interacting intermolecularly with another molecule and forming a dimer 
at higher concentrations. The spectra obtained from NOESY experiments did not exhibit any 
long-range cross peaks that had been observed for TrpZip 157 and GG-TrpZip 158. 
However, characteristic sequential cross peaks were present in the spectra of both analogues. 
The promising CD data obtained for samples at higher concentration than used for NMR 
analysis, indicate that the NMR experiments would need to be performed at higher 
concentration in order to observe the expected long-range cross peaks. These experiments 
alongside other conformational analysis are currently undertaken by collaborators in order 
to better understand the folding properties of our analogues.  
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Chapter 4  
Conclusions 
In conclusion, the cyclopropane moiety was initially installed via a carbene mediated 
cyclopropanation, resulting in a mixture of cis- and trans-isomers. Epimerisation followed 
by resolution allowed to access to enantioenriched precursors 90. Due to poor reproducibility 
and low overall yield, the route was revised towards the synthesis of racemic mixture of 90 
in one step by using superbase-mediated rearrangement affording exclusively trans-90 in a 
very good yield. It was then possible to install the N-terminus under Mitsunobu conditions. 
The terminal alkene present in the molecule allowed to access to the C-terminus by 
hydroboration and successive oxidations in decent overall yield. The racemic (±)-Boc2-
{GlyΔGly}-OH 106 was obtained in 4 steps (Scheme 43). 
 
Scheme 43: (±)-Boc2-{GlyΔGly}-OH 107 synthesis 
Attempts to resolve the racemic mixture at different stage of the synthesis were investigated 
and the best route was found to be the amide coupling on carboxylic acid 85 using (R)-
phenylglycinol after optimised oxidations. The two diastereoisomers were obtained in a 
reasonable yield (Scheme 44). After hydrolysis and reduction enantioenriched alcohol 90 
was obtained, which then underwent the same reactions as the racemic mixture.  
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Scheme 44: enantioenriched 107 synthesis and crystal structure of racemic peptide 75 
This new route was designed and optimised to reduce the number of steps towards the 
synthesis of enantioenriched bisprotected Boc2-{GlyΔGly}-OH 107 in 8 steps and 8% 
overall yield. trans-Cyclopropane was assigned by the crystal structure obtained for racemic 
peptide 75, proving the exclusive formation of trans-compound in both carbene and 
LIDAKOR reaction. Once the dipeptide surrogate obtained, incorporation into various 
lengths of peptides was possible using common coupling conditions. Although the synthesis 
was not fully optimised, sufficient material was obtained for the conformational analysis. 
Eleven peptides were synthesised, including enantioenriched and racemic variants (Figure 
85)  
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Figure 85: Peptides designed during this work 
Esters (±)-iPrOCO-{GlyΔGly}-N-iPr 127 and (±)-iPrOC-{GlyΔGly}-O-iPr 129 were 
synthesised from intermediates previously obtained in this work. They allowed a better 
understanding of the hydrogen bonding network formed in the turn mimetics.  
The {GlyΔGly} surrogate was proven to promote the formation of a turn by spectroscopic 
measurements by showing evidence of strong intramolecular hydrogen bonds in dipeptides 
as well as longer peptides. Furthermore, iPrOC-{GlyΔGly}-NMe2 76 variants were shown 
to be exclusively intramolecularly hydrogen bonded, implying an 8-membered ring 
hydrogen bonded system formation. This size of hydrogen bonding network is unusual for a 
β-turn suggesting the cyclopropane has a unique ability to stabilise this type of interaction. 
CD spectra added a supplementary information about the folding pattern of the tetrapeptides 
by displaying features found in type II β-turn. Nevertheless, in all solvent studied, a complex 
mixture of folded arrangements was adopted by the peptides (conformation I-IV in Figure 
86).  
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Figure 86: possible hydrogen bonding arrangements adopted by tetrapeptide 77/78 
Further conformational NMR analysis of the tetrapeptides 77 and 78 showed folded 
conformation in CH2Cl2 and TFE but different interactions took place. As a matter of fact, 
Gly-NH was exchanging with TFE-d3 solvent immediately, so it was not protected by 
intramolecular hydrogen bond as observed in CH2Cl2. The 8-memebered ring system was 
not formed in TFE. Therefore, the folding pattern of the mimetics designed was dependent 
on the solvent used. Overall, this suggests that cyclopropyl unit is efficient and compact tool 
to constrain small peptides to adopt a turn conformation stabilised by strong intramolecular 
hydrogen bonds. Folded conformation was determined for all enantioenriched compound 
synthesised. The stereochemistry on the cyclopropane did not impact the formation of the 
turn, and do not change the hydrogen bond network formed or the general conformation 
adopted as no differences have been observed by NMR, IR or CD.  
To extend the study towards the formation of a reverse turn, dipeptide 107 was incorporated 
in the turn sequence of longer known peptides, in the 5-residue Leu-enkephalin 141 and 12-
residue TrpZip 157. {GlyΔGly}-Leu-enkephalin 132 and 133 were synthesised in 4 steps 
from enantioenriched variants of Boc2-{GlyΔGly}-OH 107. Conformational analysis did not 
reveal that these peptides adopted a defined and structured folded conformation. However, 
the analogues presented similar conformational features with the native peptide, proving the 
ability of the cyclopropane moiety to stabilise the conformation adopted by the peptide.  
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Figure 87: Leu-enkephalin and TrpZip analogues 
The β-hairpin conformation adopted by native TrpZip peptide 157 has been confirmed by 
the combination of CD and NMR analysis. The analogues (R,S)-{G∆G}-TrpZip 159 and 
(S,R)-{G∆G}-TrpZip 160 have features consistent with a β-hairpin conformation when 
analysed by CD and have similar stabilities to the native peptide (determined by calculation 
of the Tm). However, the spectra obtained from NOESY experiments were not conclusive 
but characteristic sequential cross peaks of β-hairpin were present in the spectra of both 
analogues. The analogues were adopting a β-hairpin conformation but the intramolecular 
interactions are still to be determined. The NMR experiments would need to be performed 
at higher concentration in order to observe the expected long-range cross peaks. Other 
conformational analysis, such as CD recorded in the far-UV to understand the behaviour of 
the peptide backbone, analytical ultracentrifugation and other NMR experiments need to be 
undertaken to have better comprehension on the behaviour of the analogues synthesised. As 
well as shorter peptide, the stereochemistry of the cyclopropane did not impact a change on 
the formation of the β-hairpin, and stability of both analogues 159 and 160 was identical. 
However, MD calculation showed a difference in the turn and the hydrogen bond stabilising 
it (not present in the case of (S,R)-{G∆G}-TrpZip 160). Extra NMR measurements are 
currently running to understand which type of turn is formed and to obtain a 3D structure 
extracted from the NMR and MD calculation.  
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Overall, the cyclopropane used as a peptide bond isostere is an excellent tool to constrain a 
system into a turn conformation by stabilising the system with strong intramolecular 
hydrogen bond. When placed in a peptide adopting a β-hairpin conformation stabilised by 
cross-strand indoles stacking, the general folding adopted was similar. The dipeptide 
surrogate designed during this work promoted the turn formation or stabilised it.  
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Chapter 5 
Experimental 
General information  
Air and/or moisture sensitive reactions were performed under an atmosphere of argon in 
flame dried apparatus. Tetrahydrofuran, toluene, dichloromethane, acetonitrile and diethyl 
ether were purified using a Pure-SolvTM 500 Solvent Purification System. Other dry organic 
solvents and starting materials were obtained from commercial sources and used as received. 
Petroleum ether used for column chromatography was the 40–60 ºC fraction. All reactions 
were monitored by thin layer chromatography (TLC) using Merck silica gel 60 covered 
alumina plates F254. TLC plates were visualised under UV light and stained using either 
potassium permanganate solution, acidic ethanolic anisaldehyde or ninhydrine solution. 
Flash column chromatography was performed with silica gel (Merck 40–63 μm). Peptides 
were purified using a Gilson semi-preparative HPLC system equipped with a Phenomenex 
Synergi 10μ C18 80 Å, (250 x 21.2 mm) column. Peptides were lyophilized using a Christ 
Alpha 2−4 LDplus freezedryer.  
IR spectra were recorded at ambient temperature using a Shimadzu IR instrument. All 1H 
NMR spectra were recorded on Bruker 400 MHz Spectrospin, Bruker 500 MHz Spectrospin 
and Bruker 600 MHz Ultrashield 600 Plus spectrometers at ambient temperature. Data are 
reported as follows; chemical shift in ppm relative to CDCl3 (7.26), CD2Cl2 (5.32) or D2O 
(4.80) on the d scale, integration, multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, 
m = multiplet, br = broad, app. = apparent or a combination of these), coupling constant(s) 
J (Hz) and assignment. All 13C NMR spectra were recorded on a Bruker 400 MHz 
Spectrospin, Bruker 500 MHz Spectrospin and Bruker 600 MHz Ultrashield 600 Plus 
spectrometers at 101 MHz, 126 MHz and 151 MHz at ambient temperature. Data are 
reported as follows; chemical shift in ppm relative to CHCl3 (77.16), CD2Cl2 (53.5) on the 
d scale and assignment. Mass spectra were recorded using positive chemical ionization 
(CI+), positive ion impact (EI+), positive electrospray (ESI+), negative electrospray (ESI-) 
techniques on Jeol MStation JMS-700 instrument. The intensity of each peak is quoted as a 
percentage of the largest, where this information was available.  
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(±)-Phth-{Gly∆Gly}-N-i-Pr 81  
 
A solution of (±)-NPhth-{GlyΔGly}-OH 59 (1.56 g, 6.01 mmol) in CH2Cl2 (280 mL) was 
treated with DMAP (730 mg, 6.01 mmol) at rt, EDCI (1.27 g, 6.60 mmol) and isopropyl 
amine (620 µL, 7.21 mmol) were added to the solution. The reaction mixture was stirred 
overnight at rt. The solvent was evaporated under vacuum, and the resulting oil was 
dissolved in EtOAc (50 mL), washed with H2O (50 mL), 1 м aq. HCl (50 mL), sat. aq. 
NaHCO3 (50 mL) and brine (30 mL). The organic phase was dried over MgSO4, filtered and 
concentrated under vacuum to give the title compound (657 mg, 65%) as a brown solid. 
Rf (EtOAc/PE 1:1) 0.38; m.p.: 176–177 °C; nmax 3483, 1710, 1541, 1378, 1261, 1121 cm−1; 
1H NMR (500 MHz; CDCl3): δ  7.84 (2H, d, J = 5.5, 3.0 Hz, CH-Phthalimide), 7.72 (2H, 
dd, J = 5.5, 3.0 Hz, CH-Phthalimide), 5.67 (1H,  d, J = 6.2 Hz, NH), 4.03–3.97 (1H, m, 1H, 
CH-C7), 3.71 (1H, dd, J = 14.2, 6.2 Hz, CH2-C6), 3.52 (1H, dd, J = 14.2, 7.0 Hz, CH2-C6), 
2.15 (1H, dd, J = 16.2, 6.2 Hz, CH2-C2), 2.05 (1H, dd, J = 16.2, 7.0 Hz, CH2-C2), 1.11 (3H, 
d, J = 6.6 Hz, CH3-C8), 1.07 (3H, d, J = 6.6 Hz, CH3-C8), 1.08–1.04 (2H, m, CH-C3 + CH-
C5), 0.67 (1H, ddd, J = 8.2, 5.2, 5.2 Hz, CH2-C4), 0.43 (1H, ddd, J = 8.2, 5.3, 5.3 Hz, CH2-
C4); 13C NMR (126 MHz; CDCl3): δ 170.9 (CO-C1), 168.7 (2 ´ CO-Phthalimide), 134.2 
(C-Phthalimide), 134.0 (C-Phthalimide), 132.4 (CH-Phthalimide), 132.2 (CH-Phthalimide), 
123.5 (CH-Phthalimide, 123.3 (CH-Phthalimide), 41.4 (CH-C7), 41.3 (CH2-C6), 40.8 (CH2-
C2), 22.86 (CH3-C8), 22.82 (CH3-C8), 18.1 (CH-C5), 14.1 (CH-C3), 10.6 (CH2-C4). HRMS 
(ESI+) for C17H20N2NaO3 [M+Na]+ calcd 323.1366, found 323.1353.  
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Ethyl-[(1S*,2R*)-2-ethenylcyclopropane-1-carboxylate] and ethyl-[(1R*,2R*)-2-
ethenylcyclopropane-1-carboxylate] 86 
 
At - 4 °C, a solution of ethyl diazoacetate (5.00 g, 43.8 mmol) in CH2Cl2 (25 mL) was added 
dropwise (8 mL/h with a syringe pump) to a solution of butadiene (35.0 mL, 438 mmol) and 
Rh2(OAc)4 (150 mg, 0.8 mol%) in CH2Cl2 (40 mL). The reaction mixture was stirred for one 
hour after the addition. Solvent was evaporated, and the crude material was dissolved in PE 
(100 mL) and filtered through a plug of silica gel. The solution was concentrated under 
vacuum to give the vinylcyclopropane (4.24 g, 69%) as a mixture of diastereoisomers (1:1 
dr). 
Rf (EtOAc/PE 1:1): 0.54; nmax 2983, 1722, 1637, 1381, 1163 cm−1; 1H NMR (400 MHz; 
CDCl3) δ  5.82-5.72 (0.5H, m, CH-C2 cis), 5.39 (0.5H, ddd, J = 17.1, 10.2, 8.4 Hz, CH-C2 
trans), 5.23 (0.5H, dd, J = 17.2, 1.9 Hz, CH2-C1 cis), 5.16 (0.5H, dd, J = 17.1, 0.9 Hz, CH2-
C1 trans), 5.04 (0.5H, dd, J = 10.3, 1.9 Hz, CH2-C1 cis), 4.98 (0.5H, dd, J = 10.2, 1.6 Hz, 
CH2-C1 trans), 4.15–4.10 (2H, m, CH2-C7 cis + CH2-C7 trans), 2.03–1.98 (0.5H, m, CH-
C3 trans), 1.95–1.89 (1H, m, CH-C3 cis + CH-C5 cis), 1.63 (0.5H, ddd, J = 8.4, 5.2, 4.0 Hz, 
CH-C5 trans), 1.36 (0.5H, ddd, J = 8.9, 5.2, 4.3 Hz, CH2-C4 cis), 1.26 (1.5H, t, J = 7.1 Hz, 
CH3-C8 trans), 1.25 (1.5H, t, J = 7.1 Hz, CH3-C8 trans), 1.30–1.19 (1H, m, CH2-C4 cis + 
CH2-C4 trans), 0.96 (0.5H, ddd, J = 8.3, 6.2, 4.4 Hz, CH2-C4 trans); 13C NMR (101 MHz; 
CDCl3): δ 173.5 (CO-C6 trans), 172.1 (CO-C6 cis), 138.3 (CH-C2 trans), 135.5 (CH-C2 
cis), 116.2 (CH2-C1 cis), 114.9 (CH2-C1 trans), 60.72 (CH2-C7 trans), 60.60 (CH2-C7 cis), 
25.7 (CH-C3 trans), 24.9 (CH-C3 cis), 22.0 (CH-C5 trans), 21.1 (CH-C5 cis), 15.7 (CH2-
C4 trans), 14.47 (CH2-C4 cis), 14.38 (CH3-C8 trans), 14.24 (CH3-C8 cis); m/z (CI+) 
[M+H]+ 141 (68%).* 
*molecular weight too low to get accurate mass 
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(1S*,2R*)-2-Ethenylcyclopropane-1-carboxylic acid and (1R*,2R*)-2-
ethenylcyclopropane-1-carboxylic acid 85 
 
Procedure A: 
Sodium solid (4.92 g, 214 mmol) was dissolved in anhydrous EtOH (40 mL). When the 
sodium was completely dissolved, a solution of ethyl-[(1S*,2R*)-2-ethenylcyclopropane-1-
carboxylate] and ethyl-[(1R*,2R*)-2-ethenylcyclopropane-1-carboxylate] 86 (9.08 g, 64.8 
mmol) in EtOH (20 mL) was added dropwise at rt. The reaction mixture was heated to reflux 
and stirred for 24 h. Et2O (50 mL) was added to the reaction mixture and the solution was 
washed with sat. aq. NH4Cl (3 ´ 20 mL), H2O (3 ´ 20 mL), and brine (20 mL). The organic 
phase was dried over MgSO4 and concentrated under vacuum. The aqueous phase was 
acidified to pH 1 using conc. aq. HCl and extracted with Et2O (3 ´ 40 mL). The combined 
organic extracts were dried over MgSO4, filtered and concentrated to give the carboxylic 
acid (4.22 g, 95%), as a dark oil with trans-85 as the major isomer (9:1 dr).  
Procedure B: 
(1R*,2S*)-2-ethenyl-cyclopropanemethanol 90 (1.00 g, 10.2 mmol) and NMO×H2O (11.9 g, 
102 mmol) were dissolved in MeCN (41 mL). TPAP (358 mg, 1.02 mmol, 10 mol%) was 
added portionwise (20 mg/20min) at rt. The solution was stirred overnight at rt and the 
reaction was then quenched by the addition of an excess of isopropanol. H2O (30 mL) was 
added and pH was carefully adjusted to 1 using 2 м aq. HCl. The aqueous phase was 
extracted with Et2O (3 ´ 50 mL) and the combined organic extracts were then washed with 
brine (20 mL), dried over MgSO4, filtered and concentrated under vacuum. The residue was 
purified by silica gel column chromatography (PE/EtOAc 1:1) to afford the title compound 
(371 mg, 30%) as a brown oil.  
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Procedure C: 
A solution of DMSO (10.4 mL, 146 mmol) in CH2Cl2 (70 mL) was added dropwise at –78 
°C, under Ar, to a solution of oxalyl chloride (6.1 mL, 73.1 mmol) in CH2Cl2 (50 mL). The 
solution was stirred at this temperature for 30 min and (1R*,2S*)-2-ethenyl-
cyclopropanemethanol 90 (4.78 g, 48.7 mmol) in CH2Cl2 (50 mL) was added dropwise at –
78 °C. The reaction mixture was stirred for 3 h at this temperature. Et3N (40 mL, 292 mmol) 
was carefully added at –78 °C and the solution was allowed to warm to rt. H2O (200 mL) 
and CH2Cl2 (200 mL) were added and the phases were separated. The organic phase was 
washed with 1 м aq. HCl. (3 ´ 150 mL), H2O (150 mL), sat. aq. NaHCO3 (150 mL) and 
brine (150 mL). The organic phase was dried over MgSO4 and CH2Cl2 was removed by 
distillation. The resultant aldehyde was used without further purification. 
The aldehyde (48.7 mmol), 2-methyl-2-butene (52 mL, 487 mmol) and NaH2PO4×2H2O 
(15.6 g, 97.4 mmol) were dissolved in t-BuOH (500 mL). The solution was cooled to 0 °C 
and NaClO2 (15.4 g, 170 mmol) was added. The reaction mixture was stirred for 2 h at rt. 
The mixture was cooled to 0 °C and 1 м aq. HCl (20 mL) was added. The solution was 
extracted with CHCl3 (3 × 60 mL). The combined organic extracts were washed with brine, 
dried over MgSO4, filtered and concentrated under reduced pressure. The residue was 
purified by silica gel column chromatography (PE/EtOAc 1:1) to afford the title compound 
(3.76 g, 69% over 2 steps) as a yellow liquid.  
Data for the major isomer is presented.  
Rf (EtOAc/PE 1:1): 0.48; nmax 2957, 1692, 1229 cm−1; 1H NMR (400 MHz; CDCl3): δ  10.99 
(1H, bs, OH), 5.39 (1H, ddd, J = 17.0, 10.2, 8.3 Hz, CH-C2), 5.18 (1H, ddd, J = 17.0, 1.4, 
0.6 Hz, CH2-C1), 5.02 (1H, ddd, J = 10.2, 1.4, 0.4 Hz, CH2-C1), 2.13–2.06 (1H, m, CH-C3), 
1.64 (1H, ddd, J = 8.3, 5.0, 4.2 Hz, CH-C5), 1.43 (1H, ddd, J = 8.6, 5.0, 4.4 Hz, CH2-C4), 
1.06 (1H, ddd, J = 8.6, 6.4, 4.2 Hz, CH2-C4); 13C NMR (126 MHz; CDCl3): δ 179.9 (CO-
C6), 137.6 (CH-C2), 115.4 (CH2-C1), 26.6 (CH-C3), 21.7 (CH-C5), 16.3 (CH2-C4). m/z 
(CI+) [M+H]+ 113 (72%).* 
*molecular weight too low to get accurate mass 
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(1R,2S)-2-ethenyl-N-[(R)-2-hydroxy-1-phenylethyl]cyclopropanecarboxamide 89a and 
(1S,2R)-2-Ethenyl-N-[(R)-2-hydroxy-1-phenylethyl]cyclopropanecarboxamide 89b 
 
To a well stirred solution of carboxylic acid (±)-85 (4.0 g, 54 mmol) in THF (160 mL) were 
added dropwise, at -20 °C, N-methylmorpholine (3.9 mL, 54 mmol), followed by i-
BuOCOCl (4.6 mL, 54 mmol). The solution was stirred at this temperature for 15 min and 
(R)-phenylglycinol (4.9 g, 54 mmol) was added portionwise over a period of 30 min. The 
reaction mixture was stirred at -20 °C for 1 h and then allowed to warm to rt. The solvent 
was removed under vacuum. The residue was then dissolved in EtOAc (70 mL) and washed 
with H2O (3 ´ 20 mL), aq. sat. NaHCO3 (3 ´ 20 mL), 2 м aq. HCl (3 ´ 20 mL) and brine (20 
mL). The organic phase was dried over MgSO4 and concentrated under reduced pressure. 
The crude product was then purified by silica gel on column chromatography (PE/EtOAc 
1:0 to 0:1) to give (R,R,S)-89a (1.53 g, 37%) and (R,S,R)-89b (1.63 g, 39%). Each product 
was then recrystallized from EtOAc to obtain colourless crystals (100% recovery for both).  
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• (R,R,S)-89a  
Rf (EtOAc/PE 1:1): 0.31; [a],9?: −17.5 (c = 1.05, in CH3Cl); νmax (CHCl3): 3310, 2961, 1634, 
1545, 1059 cm–1; 1H NMR (400 MHz; CDCl3): δ 7.40–7.36 (2H, m, 2 ´ CH-Ph), 7.34–7.30 
(3H, m, 3 ´ CH-Ph), 6.25 (1H, d, J = 5.4 Hz, NH), 5.42 (1H, ddd, J = 17.0, 10.2, 8.5 Hz, 
CH-C2), 5.18 (1H, dd, J = 17.0, 1.5 Hz, CH2-C1), 5.07 (1H, td, J = 6.2, 3.8 Hz, OH), 5.00 
(1H, dd, J = 10.2, 1.5 Hz, CH2-C1), 3.97–3.87 (2H, m, CH2-C8), 2.73 (1H, dd, J = 7.3, 5.4 
Hz, CH-C7), 2.09–2.02 (1H, m, CH-C3), 1.47–1.37 (2H, m, CH-C5, CH2-C4), 0.91 (1H, 
ddd, J = 8.0, 6.2, 4.1 Hz, CH2-C4); 13C NMR (126 MHz; CDCl3): δ 172.8 (CO-C6), 139.0 
(C-Ph), 138.6 (CH-C2), 129.1 (2 ´ CH-Ph), 128.2 (CH-Ph), 126.9 (2 ´ CH-Ph), 114.7 (CH2-
C1), 67.2 (CH-C7), 56.7 (CH2-C8), 25.0 (CH-C3), 24.1 (CH-C5), 15.0 (CH2-C4); HRMS 
(ESI–) for C14H16NO2 [M–H] calcd 230.1186 found 230.1187.  
 
• (R,S,R)-89b 
Rf (EtOAc/PE 1:1): 0.20; [a],9?: +9.89 (c = 1.05, CHCl3); νmax (CHCl3): 3298, 2959, 1634, 
1548, 1051 cm–1, 1H NMR (400 MHz; CDCl3): δ  7.40–7.37 (2H, m, 2 ´ CH-Ph), 7.34–7.30 
(3H, m, 3 ´ CH-Ph), 6.23 (1H, d, J = 5.4 Hz, NH), 5.40 (1H, ddd, J = 17.1, 10.2, 8.5 Hz, 
CH-C2), 5.14 (1H, dd, J = 17.1, 1.5 Hz, CH2-C1), 5.07 (1H, td, J = 6.4, 4.0 Hz, OH), 4.97 
(1H, dd, J = 10.2, 1.5 Hz, CH2-C1), 3.96–3.86 (2H, m, CH2-C8), 2.77 (1H, dd, J = 7.2, 5.4 
Hz, CH-C7), 2.05–2.01 (1H, m, CH-C3), 1.47–1.40 (2H, m, CH-C5, CH2-C4), 0.97–0.93 
(1H, m, CH2-C4); 13C NMR (126 MHz; CDCl3): δ 172.6 (C-C6), 139.4 (C-Ph), 138.8 (CH-
C2), 128.8 (2 ´  CH-Ph), 127.8 (CH-Ph), 126.9 (2 ´ CH-Ph), 114.4 (CH2-C1), 66.7 (CH-C7), 
56.4 (CH2-C8), 24.6 (CH-C3), 23.9 (CH-C5), 14.9 (CH2-C4); HRMS (ESI–) for C14H16NO2 
[M–H] calcd 230.1186 found 230.1187. 
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(1S,2R)-2-Ethenylcyclopropane-1-carboxylic acid 85 
 
(1S,2R)-2-Ethenyl-N-[(R)-2-hydroxy-1-phenylethyl]cyclopropanecarboxamide 89b (1.86 g, 
8.08 mmol), was dissolved in a mixture of 10% KOH in MeOH (60 mL) and H2O (30 mL). 
The solution was heated to reflux and stirred overnight. MeOH was then removed under 
vaccum and the aqueous solution was extracted with EtOAc (3 ´ 10 mL). The combined 
extracts were dried over MgSO4 and concentrated under vacuum to recover (R)-
phenyglycinol. The aqueous layer was acidified using conc. aq. HCl until pH 1, and the 
mixture was extracted with EtOAc (3 ´ 10 mL). The combined extracts were washed with 
brine (10 mL), dried over MgSO4, filtered and the solvent was removed under reduced 
pressure to give the title compound (863 mg, 95%) as a colourless oil. 
Rf (EtOAc/PE 1:1): 0.62; [𝛼],9@ +115 (c = 1.00, CHCl3); νmax 3219, 1697, 1462, 1198 cm−1; 
1H NMR (400 MHz, CDCl3): δ 11.27 (1H, bs, OH), 5.40 (1H, ddd, J = 17.0, 10.2, 8.3 Hz, 
CH-C2), 5.18 (1H, dd, J = 17.0, 1.6 Hz, CH2-C1), 5.01 (1H, dd, J = 10.2, 1.6 Hz, CH2-C1), 
2.14–2.02 (1H, m, CH-C3), 1.64 (1H, ddd, J = 8.3, 5.1, 4.2 Hz, CH-C5), 1.43 (1H, ddd, J = 
8.6, 5.1, 4.4 Hz, CH2-C4), 1.05 (2H, ddd, J = 8.6, 6.4, 4.2 Hz, CH2-C4); 13C NMR (126 MHz, 
CDCl3): δ 179.6 (CO-C6), 137.7 (CH-C2), 115.4 (CH2-C1), 26.6 (CH-C3), 21.8 (CH-C5), 
16.3 (CH2-C4); m/z (CI+) [M+H]+ 113 (80%).* 
*molecular weight too low to get accurate mass 
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(1R,2S)-2-Ethenylcyclopropane-1-carboxylic acid 85 
 
The procedure applied to the synthesis of (1S,2R)-2-ethenylcyclopropane-1-carboxylic acid 
85 was followed using (1R,2S)-2-Ethenyl-N-[(R)-2-hydroxy-1-phenylethyl]
cyclopropanecarboxamide 89a (2.43 g, 10.5 mmol) to give the title compound (964 mg, 
82%) as a yellow oil. 
Rf (EtOAc/PE 1:1): 0.62; [𝛼],9? –100 (c = 1.00, CHCl3); νmax 3219, 1697, 1462, 1198 cm−1; 
1H NMR (500 MHz, CDCl3): δ 5.40 (1H, ddd, J = 16.9, 10.2, 8.3 Hz, CH-C2), 5.18 (1H, dt, 
J = 16.9, 1.1 Hz, CH2-C1), 5.02 (1H, dd, J = 10.2, 1.1 Hz, CH2-C1), 2.17–2.03 (1H, m, CH-
C3), 1.64 (1H, ddd, J = 8.5, 5.1, 4.1 Hz, CH-C5), 1.44 (1H, ddd, J = 8.8, 5.1, 5.1 Hz, CH2-
C4), 1.06 (1H, ddd, J = 8.8, 6.4, 4.1 Hz, CH2-C4). 13C NMR (126 MHz, CDCl3): δ 180.0 
(CO-C6), 137.7 (CH-C2), 115.5 (CH2-C1), 26.6 (CH-C3), 21.8 (CH-C5), 16.3 (CH2-C4); 
m/z (EI+) [M+H]+ 113 (99%).* 
*molecular weight too low to get accurate mass 
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(1S,2R)-2-Ethenyl-cyclopropanemethanol 90 
 
A solution of acid (S,R)-85 (1.50 g, 13.3 mmol) in THF (19 mL) was added dropwise, at 0 
°C, to a slurry of LiAlH4 (1.10 g, 26.6 mmol) in THF (19 mL). The mixture was heated to 
reflux for 5 h. The reaction was then quenched by the sequential addition of H2O (1 mL), 1 
м aq. NaOH (1 mL) and H2O (3 mL) at 0 °C. The resulting mixture was stirred for 15 min 
and an excess of MgSO4 was added. The resulting suspension was stirred for extra further 
15 min and filtered. The majority of the solvent was removed by distillation at atm. pressure 
to give (1S,2R)-2-ethenyl-cyclopropylmethanol 90 (1.18 g, 41 wt%, 59%) as a orange 
solution in THF.  
Rf (PE/EtOAc 1:1, Anisaldehyde): 0.75; [𝛼],9@ +51 (c = 1.0, CHCl3); νmax 3333, 2924, 1636, 
895 cm−1; 1H NMR (500 MHz, CDCl3) δ 5.38 (1H, ddd, J = 17.1, 10.2, 8.5 Hz, CH-C2), 
5.03 (1H, dd, J = 17.1, 1.6 Hz, CH2-C1), 4.84 (1H, dd, J = 10.2, 1.6 Hz, CH2-C1), 3.55–3.40 
(2H, m, CH2-C6), 1.34–1.29 (1H, m, CH-C3), 1.18–1.08 (1H, m, CH-C5), 0.70–0.56 (2H, 
m, CH2-C4); 13C NMR (126 MHz, CDCl3): δ 140.8 (CH-C2), 112.3 (CH2-C1), 66.2 (CH2-
C6), 23.0 (CH-C5), 20.6 (CH-C3), 11.7 (CH2-C4).* 
*Molecular weight too low to obtain a nominal or accurate mass.  
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(1R,2S)-2-Ethenyl-cyclopropanemethanol 90 
 
The procedure for the synthesis of the other enantiomer (S,R)-90 was followed using acid 
(R,S)-85 (1.40 g, 12.4 mmol) to give (1R,2S)-2-ethenyl-cyclopropylmethanol 90 (1.51 g, 49 
wt%, 62%) as an orange solution in THF.  
Rf (PE/EtOAc 1:1, Anisaldehyde): 0.88; [𝛼],9@ −61 (c = 1.0, CHCl3); νmax 3337, 2924, 1636, 
895 cm−1; 1H NMR (500 MHz, CDCl3) δ 5.37 (1H, ddd, J = 17.1, 10.2, 8.7 Hz, CH-C2), 
5.02 (1H, dd, J = 17.1, 1.6 Hz, CH2-C1), 4.83 (1H, dd, J = 10.2, 1.6 Hz, CH2-C1), 3.47 (1H, 
dd, J = 11.2, 6.8 Hz, CH2-C6), 3.44 (1H, dd, J = 11.2, 6.8 Hz, CH2-C6), 1.31 (1H, dddd, J = 
8.7, 8.7, 4.6, 4.6 Hz, CH-C3), 1.16–1.06 (1H, m, CH-C5), 0.67–0.57 (2H, m, CH2-C4); 13C 
NMR (126 MHz, CDCl3): δ 140.8 (CH-C2), 112.2 (CH2-C1), 66.1 (CH2-C6), 23.0 (CH-C5), 
20.6 (CH-C3), 11.6 (CH2-C4).*  
*Molecular weight too low to obtain a mass.  
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(1R*,2S*)-2-Ethenyl-cyclopropanemethanol 90 
 
 To THF (110 mL) cooled to –78 °C under Ar was added carefully, n-BuLi (40.0 mL of an 
11 м solution in hexane, 440 mmol). The resultant solution was stirred for 10 min at this 
temperature.  Diisopropylamine (62.0 mL, 440 mmol) was added dropwise followed by t-
BuOK (49.0 g, 440 mmol). The reaction mixture was stirred at –78 °C for 45 min. 1,3-
Epoxy-5-hexene (5.60 mL, 50.0 mmol) was added dropwise at –78 °C and the reaction 
mixture was allowed to stir for 15 h at –50 °C. The reaction was quenched at –50 °C with 
H2O (30 mL) and allowed to warm to rt. The solution was extracted with Et2O (3 × 15 mL), 
the combined organic layers were dried over MgSO4, and filtered. The majority of the 
solvent was removed by distillation at atm. pressure to afford (1R*,2S*)-2-ethenyl-
cyclopropanemethanol 90 (35.13 g, 68 wt%,  quant.) as a solution in THF  as an orange 
solution in THF.   
Rf (EtOAc/PE 1:1): 0.68; νmax (CHCl3): 3329, 2924, 1636, 1173, 1049, 1040 cm−1;  1H NMR 
(500 MHz; CDCl3): δ  5.41 (1H, ddd, J = 17.1, 10.3, 8.5 Hz, CH-C2), 5.06 (1H, dd, J = 17.1, 
1.6 Hz, CH2-C1), 4.88 (1H, dd, J = 10.3, 1.6 Hz, CH2-C1), 3.54–3.47 (2H, m, CH2-C6), 1.51 
(1H, bs, OH), 1.35 (1H, m, CH-C3), 1.21–1.13 (1H, m, CH-C5), 0.70–0.64 (2H, m, CH2-
C4) ; 13C NMR (126 MHz; CDCl3): δ 140.7 (CH2-C2), 112.5 (CH-C1), 66.4 (CH2-C6), 23.1 
(CH-C3), 20.7 (CH-C5), 11.7 (CH2-C4). 
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2-[(1R*,2S*)-2-Ethenylcyclopropyl]methyl-2,3-dihydro-1H-isoindole-1,3-dione 94 
 
DEAD (3.60 mL, 22.8 mmol) was added dropwise at 0 °C to a solution of alcohol (±)-90 
(893 mg, 9.10 mmol), PPh3 (5.98 g, 22.8 mmol) and phthalamide (3.35 g, 22.8 mmol) in dry 
THF (91 mL). The reaction mixture was heated to reflux and stirred overnight. Solvent was 
removed and the resulting residue was purified by silica gel column chromatography in 
PE/EtOAc (10:1 to 9:1) to afford the title compound (2.11 g, quant.) as an orange oil. 
Rf (EtOAc/PE 1:1): 0.34; nmax (CHCl3): 3466, 3080, 3001, 1771, 1709, 1635, 1393, 1037 
cm–1; 1H-NMR (400 MHz; CDCl3): δ 7.80–7.75 (2H, m, 2 ´ CH-Phth), 7.68–7.63 (2H, m, 
2 ´ CH- Phth), 5.28 (1H, ddd, J = 17.1, 10.2, 8.6 Hz, CH-C2), 4.98 (1H, dd, J = 17.1, 1.7 
Hz, CH2-C1), 4.77 (1H, dd, J = 10.2, 1.7 Hz, CH-C1), 3.58 (1H, dd, J = 14.1, 7.1 Hz, CH2-
C6), 3.50 (1H, dd, J = 14.1, 7.3 Hz, CH2-C6), 1.46 (1H, dddd, J = 8.6, 8.6, 4.9, 4.9 Hz, CH-
C3), 1.26–1.19 (1H, m, CH-C5), 0.77 (1H, ddd, J = 8.5, 4.9, 4.9 Hz, 1 ´ CH2-C4), 0.57 (1H, 
ddd, J = 8.5, 5.0, 5.0 Hz, CH2-C4). 13C NMR (126 MHz; CDCl3): δ 168.2 (2 ´ CO- Phth), 
140.2 (CH-C2), 133.8 (4 ´ CH-Phth), 123.2 (2 ´ C-Phth), 112.5 (CH2-C1), 41.4 (CH2-C6), 
21.6 (CH-C3), 19.7 (CH-C5), 12.6 (CH2-C4). HRMS (ESI+) for C14H13NNaO2 [M+Na]+ 
calcd 250.0838, found 250.0829. 
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Ethyl 2-isocyanato-2-oxoacetate 96 
 
Oxalyl chloride (863 µL, 10.2 mmol) was added to a suspension of ethyl oxamate (1.00 g, 
8.54 mmol) in CH2Cl2 (13 mL) at rt. The reaction mixture was heated to reflux and stirred 
overnight. The solvent was removed under vacuum to afford the isocyanate 96 (1.30 g, 
100%) as a white solid. 
Rf (EtOAc/PE 1:1) 0.15; νmax 1790, 1732, 1713, 1306 cm−1; 1H NMR (400 MHz; CDCl3) δ 
4.46 (2H, q, J = 7.2 Hz, CH2-Et), 1.43 (3H, t, J = 7.2 Hz, CH3-Et). 13C (126 MHz, CDCl3) δ 
158.1 (CO-CONCO), 157.6 (CO-COOEt), 134.3 (NCO), 65.7 (CH2-Et), 14.0 (CH3-Et).* 
*Product decomposed quickly, unable to obtain a mass of pure product without 
decomposition at rt and atm. pressure. 
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Ethyl 2-(t-butoxycarbonyl)amino-2-oxoacetate 97 
 
A solution of t-BuOH (1.23 mL, 12.8 mmol) in toluene (5 mL) was added to a solution of 
ethyl 2-isocyanato-2-oxoacetate 96 (8.54 mmol) in toluene (9 mL). The solution was heated 
to reflux and stirred for 24 h. The solvent was removed, and crude purified by silica gel 
column chromatography (PE/EtOAc from 9:1 to 1:1) affording the title compound (519 mg, 
28%) as a colourless oil. 
Rf (EtOAc/PE 1:1): 0.83; nmax (CHCl3): 1734, 1705, 1248, 1152 cm−1; 1H NMR (400 MHz; 
CDCl3): δ  10.42 (1H, bs, NH), 4.42 (2H, q, J = 7.1 Hz, CH2-Et), 1.59 (9H, s, t-Bu), 1.41 
(3H, t, J = 7.1 Hz, CH3-Et); 13C NMR (126 MHz; CDCl3): δ 158.4 (COOEt + CONHBoc), 
157.5 (CO-Boc), 86.4 (C-Boc), 63.5 (CH2-Et), 27.8 (3 ´ CH3-Boc), 14.0 (CH3-Et).* 
*Values match what is reported in literature 
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Ethyl 2-{(t-butoxycarbonyl)[(1R*,2S*)-2-ethenylcyclopropyl]methylamino}-2-
oxoacetate 99  
 
DEAD (2.17 mL, 13.8 mmol) was added dropwise at 0 °C to a solution of (±)-90 (723 mg, 
5.53 mmol), PPh3 (3.62 g, 13.8 mmol) and ethyl 2-[(t-butoxy)carbonyl]amino-2-oxoacetate 
(3.00 g, 13.8 mmol) in  THF (14 mL). The reaction mixture was heated to reflux and stirred 
overnight. Solvents were removed under vacuum and the resulting residue was purified by 
silica gel column chromatography in PE/EtOAc (10:1 to 9:1) to give the title compound 
(1.47 g, 90%) as an orange oil.  
Rf (EtOAc/PE 1:1): 0.95; νmax (CHCl3): 2982, 2938, 1740, 1698, 1636, 1369, 1145, 1024 
cm−1; 1H NMR (400 MHz; CDCl3): δ 5.35 (1H, ddd, J = 17.1, 10.2, 8.4 Hz, CH-C2), 5.04 
(1H, dd, J = 17.1, 1.6 Hz, CH2-C1), 4.86 (1H, dd, J = 10.2, 1.6 Hz, CH2-C1), 4.34 (2H, q, J 
= 7.2 Hz, CH2-Et), 3.64 (1H, dd, J = 14.0, 7.0 Hz, CH2-C6), 3.59 (1H, dd, J = 14.0, 7.2 Hz, 
CH2-C6), 1.52 (9H, s, t-Bu), 1.48-1.42 (1H, m, CH-C3), 1.36 (3H, t, J = 7.2 Hz, CH3-Et), 
1.10–1.02 (1H, m, CH-C5), 0.77 (1H, ddd, J = 8.6, 5.2, 5.2 Hz, CH2-C4), 0.63 (1H, ddd, J 
= 8.6, 5.2, 5.2 Hz, CH2-C4).  13C NMR (126 MHz; CDCl3): 163.7 (COCOOEt), 162.0 
(COCOOEt), 151.9 (CO-Boc), 140.4 (CH-C2), 112.7 (CH2-C1), 85.3 (CH-Boc), 62.2 (CH2-
Et), 46.6 (CH2-C6), 28.0 (3 ´ CH3-Boc), 21.6 (CH-C3), 19.5 (CH-C5), 14.0 (CH3-Et), 12.6 
(CH2-C4). HRMS (ESI+) for C15H23NNaO5 [M+Na]+ calcd 320.1468, found 320.1460. 
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t-Butyl-N-[(1R*,2S*)-2-ethenylcyclopropyl]methylcarbamate  93 
 
A solution of 4 м aq. LiOH (6.2 mL) was added dropwise to a solution of (±)-99 (1.47 g, 
4.95 mmol) in THF (2.20 mL). The reaction mixture was stirred overnight at rt. The solvent 
was then removed under reduced pressure and the residue was dissolved in CH2Cl2 (20 mL) 
and washed with sat. aq. NaHCO3 (7 mL) and brine (7 mL). The organic phase was dried 
over MgSO4, filtered and concentrated under vacuum to afford the title compound (801 mg, 
82%) as a colourless liquid.  
Rf (EtOAc/PE 1:1): 0.83; nmax (CHCl3): 3356, 2083, 2001, 2978, 2934, 2877, 1694, 1636, 
1368, 1169, 1030 cm−1; 1H NMR (500 MHz; CDCl3): δ 5.37 (1H, ddd, J = 17.1, 10.2, 8.6 
Hz, CH-C2), 5.04 (1H, dd, J = 17.1, 1.6, CH2-C1), 4.86 (1H, dd, J = 10.2, 1.6 Hz, CH2-C1), 
4.62 (1H, s, NH), 3.10–2.98 (2H, m, CH2-C6), 1.44 (9H, s, t-Bu), 1.30 (1H, dddd, J = 8.6, 
8.6, 4.4, 4.4 Hz, CH-C3), 1.04–0.98 (1H, m, CH-C5), 0.65–0.59 (2H, m, CH2-C4). 13C NMR 
(126 MHz; CDCl3): δ 156.0 (CO-Boc), 140.8 (CH-C2), 112.4 (CH2-C1), 79.3 (C-Boc), 44.5 
(CH2-C6), 28.6 (3 ´ CH3-Boc), 21.2 (CH-C3), 20.7 (CH-C5), 12.6 (CH2-C4). HRMS (ESI+) 
for C11H19NNaO2 [M+Na]+ calcd 220.1308, found 220.1275. 
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Ethyl 2-{(t-butoxycarbonyl)[(1S,2R)-2-ethenylcyclopropyl]methylamino}-2-oxoacetate 
99 
 
The procedure applied to the synthesis of (±)-99 (AN-01-83) was followed using (S,R)-90 
(159 mg, 1.62 mmol), and ethyl 2-(t-butoxycarbonyl)amino-2-oxoacetate (879 mg, 4.05 
mmol). The title compound (289 mg, 59%) was obtained as an orange oil.  
Rf (EtOAc/PE 1:1): 0.95; [𝛼],96 +73 (c = 0.01, in CH3Cl); nmax (CHCl3): 2982, 2938, 1740, 
1698, 1636, 1369, 1145, 1024 cm−1; 1H NMR (500 MHz; CDCl3): δ 5.35 (1H, ddd, J = 17.1, 
10.2, 8.4 Hz, CH-C2), 5.04 (1H, dd, J = 17.1, 1.1 Hz, CH2-C1), 4.86 (1H, dd, J = 10.2, 1.1 
Hz, CH2-C1), 4.34 (2H, q, J = 7.2 Hz, CH2-Et), 3.64 (1H, dd, J = 14.1, 7.0 Hz, CH2-C6), 
3.59 (1H, dd, J = 14.1, 7.2 Hz, CH2-C6), 1.52 (9H, s, t-Bu), 1.46–1.43 (1H, m, CH-C3), 1.36 
(3H, t, J = 7.2 Hz, CH3-Et), 1.20–1.17 (1H, m, CH-C5), 0.77 (1H, ddd, J = 8.6, 5.2, 5.2 Hz, 
CH2-C4), 0.63 (1H, ddd, J = 8.6, 5.2, 5.2 Hz, CH2-C4); 13C NMR (126 MHz; CDCl3): δ 
163.7 (CO-C7), 162.0 (CO-C8), 151.9 (CO-Boc), 140.4 (CH-C2), 112.7 (CH2-C1), 85.3 (C-
Boc), 62.3 (CH2-Et), 46.7 (CH2-C6), 28.6 (C-Boc), 28.0 (3 ´ CH3-Boc), 24.0 (CH-C3), 19.5 
(CH-C5), 14.0 (CH3-Et), 12.6 (CH2-C4); HRMS (ESI+) for C15H23NNaO5 [M+Na]+ calcd 
320.1468, found 320.1459. 
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t-Butyl-N-[(1S,2R)-2-ethenylcyclopropyl]methylcarbamate 93  
 
The procedure applied to the synthesis of (±)-93 was followed using (S,R)-99 (285 mg, 0.96 
mmol). The title compound (99 mg, 32%) was obtained as a clear oil.  
Rf (EtOAc/PE 1:1): 0.85; [a],96: +73 (c = 0.10, in CH3Cl); nmax (CHCl3): 3348, 3078, 3003, 
1695, 1636, 1366, 1271 cm−1; 1H NMR (400 MHz; CDCl3): δ 5.37 (1H, ddd, J = 17.1, 10.2, 
8.5 Hz, CH-C2), 5.05 (1H, dd, J = 17.1, 1.6 Hz, CH2-C1), 4.86 (1H, dd, J = 10.2, 1.6 Hz, 
CH2-C1), 4.62 (1H, s, NH), 3.10–2.98 (2H, m, CH2-C6), 1.44 (9H, s, t-Bu), 1.34–1.27 (1H, 
m, CH-C3), 1.05–0.97 (1H, m, CH-C5), 0.66–0.59 (2H, m, CH2-C4); 13C NMR (126 MHz; 
CDCl3): δ 156.0 (CO-Boc), 140.8 (CH-C2), 112.4 (CH2-C1), 79.3 (C-Boc), 44.5 (CH2-C6), 
28.6 (3 ´ CH3-Boc), 21.2 (CH-C3), 20.7 (CH-C5), 12.6 (CH2-C4); HRMS (ESI+) for 
C11H19NNaO2 [M+Na] calcd 220.1308, found 220.1302. 
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Ethyl 2-{(t-butoxycarbonyl)[(1R,2S)-2-ethenylcyclopropyl]methylamino}-2-oxoacetate 
99 
 
The procedure applied to the synthesis of (±)-99 was followed using (R,S)-2-90 (100 mg, 
1.02 mmol), and ethyl 2-(t-butoxycarbonyl)amino-2-oxoacetate (879 mg, 4.05 mmol). The 
title compound (300 mg, 99%) was obtained as an orange oil.  
Rf (EtOAc/PE 1:1): 0.95; [a],9A: –374 (c = 0.032, in CHCl3); nmax: 2982, 2938, 1740, 1698, 
1636, 1369, 1145, 1024 cm-1; 1H NMR (500 MHz; CDCl3): δ 5.35 (1H, ddd, J = 17.0, 10.2, 
8.4 Hz, CH-C2), 5.04 (1H, dd, J = 17.0, 1.6 Hz, CH2-C1), 4.86 (1H, dd, J = 10.2, 1.6 Hz, 
CH2-C1), 4.34 (2H, q, J = 7.2 Hz, CH2-Et), 3.64 (1H, dd, J = 14.1, 7.0 Hz, CH2-C6), 3.59 
(1H, dd, J = 14.1, 7.1 Hz, CH2-C6), 1.52 (9H, s, t-Bu), 1.46–1.43 (1H, m, CH-C3), 1.36 (3H, 
t, J = 7.2 Hz, CH3-Et), 1.21–1.16 (1H, m, CH-C5), 0.77 (1H, ddd, J = 8.6, 5.2, 5.2 Hz, CH2-
C4), 0.63 (1H, ddd, J = 8.6, 5.2, 5.2 Hz, CH2-C4); 13C NMR (126 MHz; CDCl3): δ 163.7 
(CO-C7), 162.0 (CO-C8), 151.9 (CO-Boc), 140.4 (CH-C2), 112.7 (CH2-C1), 85.3 (C-Boc), 
62.3 (CH2-Et), 46.6 (CH2-C6), 28.0 (3 ´  CH3-Boc), 21.6 (CH-C3), 19.5 (CH-C5), 14.0 (CH3-
Et), 12.6 (CH2-C4); HRMS (ESI+) for C15H23NNaO5 [M+Na] calcd 320.1468, found 
320.1455. 
 
  
Boc
10
9 O
O
8
O
7 N
(R,S)-99
6
5
4
3
2
1
  174 
t-Butyl-N-[(1R,2S)-2-ethenylcyclopropyl]methylcarbamate 93 
 
The procedure applied to the synthesis of (±)-91 was followed using (R,S)-2-99 (300 mg, 
1.01 mmol). The title compound (132 mg, 66%) was obtained as a yellow oil.  
Rf (EtOAc/PE 1:1): 0.85; [a],96: –374 (c = 0.028, in CH3Cl); nmax (CHCl3): 3348, 3078, 3003, 
1695, 1636, 1366, 1271 cm−1; 1H NMR (400 MHz; CDCl3): δ 5.37 (1H, ddd, J = 17.1, 10.2, 
8.6 Hz, CH-C2), 5.04 (1H, dd, J = 17.1, 1.6 Hz, CH2-C1), 4.86 (1H, dd, J = 10.2, 1.6 Hz, 
CH2-C1), 4.62 (1H, s, NH), 3.09–3.02 (2H, m, CH2-C6), 1.44 (9H, s, t-Bu), 1.34–1.27 (1H, 
m, CH-C3), 1.04–0.98 (1H, m, CH-C5), 0.65–0.59 (2H, m, CH2-C4); 13C NMR (126 MHz; 
CDCl3): δ 156.0 (CO-Boc), 140.8 (CH-C2), 112.4 (CH2-C1), 79.3 (C-Boc), 44.5 (CH2-C6), 
28.6 (3 ´ CH3-Boc), 21.2 (CH-C3), 20.7 (CH-C5), 12.3 (CH2-C4); HRMS (ESI+) for 
C11H19NNaO2 [M+Na] calcd 220.1308, found 220.1300. 
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t-Butyl-N-(t-butoxycarbonyl-N-[(1R*,2S*)-2-ethenylcyclopropyl]methylcarbamate 
100  
 
(±)-90 (3.00 g, 30.6 mmol), HN(Boc)2 (16.6 g, 76.5 mmol) and PPh3 (20 g, 76.5 mmol) were 
dissolved in  THF (310 mL). DEAD (12.1 mL, 76.5 mmol) was added dropwise at 0 °C. The 
mixture was warmed to rt and stirred for 12 h. The solvent was removed under vacuum, and 
the residue was purified by silica gel column chromatography (PE/EtOAc 10:0 to 9:1) to 
afford the title compound (6.05 g, 61%) as an orange oil.  
Rf (EtOAc/PE 1:1): 0.96; nmax (CHCl3): 3080, 2980, 2934, 1732, 1694, 1635, 1366, 1175, 
1034 cm−1; 1H NMR (500 MHz; CDCl3): δ 5.35 (1H, ddd, J = 17.1, 10.2, 8.6 Hz, CH-C2), 
5.01 (1H, dd, J = 17.1, 1.6 Hz, CH2-C1), 4.83 (1H, dd, J = 10.2, 1.6 Hz, CH2-C1), 3.53 (2H, 
d, J = 7.5 Hz, CH2-C6), 1.51 (18H, s, 2 ´  t-Bu), 1.47–1.40 (1H, m, CH-C3), 1.21 (1H, ddddd, 
J = 7.5, 5.0, 4.0, 1.1, 1.1 Hz, CH-C5), 0.73 (1H, ddd, J = 8.5, 5.2, 5.2 Hz, CH2-C4), 0.58 
(1H, ddd, J = 8.5, 5.0, 4.9 Hz, CH2-C4); 13C NMR (126 MHz; CDCl3): δ 152.9 (2 ´ CO-
Boc), 141.0 (CH-C2), 112.2 (CH2-C1), 82.3 (2 ´ C-Boc), 49.5 (CH2-C6), 28.2 (6 ´ CH3-
Boc), 21.5 (CH-C3), 20.4 (CH-C5), 12.3 (CH2-C4); HRMS (ESI+) for C16H27NNaO4 
[M+Na]+ calcd 320.1832, found 320.1819. 
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t-Butyl N-(t-butoxycarbonyl)-N-[(1S,2R)-2-ethenylcyclopropyl]methylcarbamate 100 
 
The procedure applied to the synthesis of (±)-100 was followed using alcohol (S,R)-90 (213 
mg, 2.17 mmol), and DIAD (1.10 mL, 5.43 mmol) instead of DEAD. Purification by silica 
gel column chromatography (PE/EtOAc 99:1 to 85:15) afforded the title compound (412 
mg, 64%) as an orange oil.  
Rf (PE/EtOAc 1:1): 0.86; [𝛼],9@ +6.6 (c = 1.0, CHCl3); νmax 2978, 17.39, 1694, 1636, 1366, 
1173, 1130, 856 cm−1; 1H NMR (400 MHz, CDCl3) δ 5.35 (1H, ddd, J = 17.1, 10.2, 8.5 Hz, 
CH-C2), 5.01 (1H, dd, J = 17.1, 1.7 Hz, CH2-C1), 4.83 (1H, dd, J = 10.2, 1.7 Hz, CH2-C1), 
3.53 (2H, d, J = 6.9 Hz, CH2-C6), 1.50 (18H, s, 2 × t-Bu), 1.46–1.40 (1H, m, CH-C3), 1.19 
(1H, ddddd, J = 8.6, 6.9, 6.9, 5.5, 4.5 Hz, CH-C5), 0.73 (1H, ddd, J = 8.6, 5.5, 4.8 Hz, CH2-
C4), 0.58 (ddd, J = 8.6, 4.9, 4.5 Hz, CH2-C4); 13C (126 MHz, CDCl3): δ 141.0 (CH-C2), 
112.2 (CH2-C1), 82.3 (2 × C-Boc), 49.5 (CH2-C6), 28.2 (6 × CH3-Boc), 21.5 14.9 (CH-C3), 
20.4 (CH-C5), 12.3 (CH2-C4); HRMS (ESI+) calcd for C16H27NO4Na [M+Na]+ 320.1832, 
found 320.1827. 
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t-Butyl N- (t-butoxycarbonyl)-N-[(1R,2S)-2-ethenylcyclopropyl]methylcarbamate 100 
 
The procedure applied to the synthesis of (±)-100 was followed using alcohol (R,S)-90 (743 
mg, 7.57 mmol). Purification by silica gel column chromatography (PE/EtOAc 99:1 to 
90:10) gave the title compound (1.50 mg, 59%) as an orange oil.  
Rf (PE/EtOAc 1:1): 0.86; [𝛼],9@ –6.3 (c = 1.0, CHCl3); νmax 2978, 1748, 1694, 1366, 1173, 
1126, 853 cm−1; 1H NMR (500 MHz, CDCl3) δ 5.35 (1H, ddd, J = 17.1, 10.2, 8.5 Hz, CH-
C2), 5.01 (1H, ddd, J = 17.1, 1.7, 0.6 Hz, CH2-C1), 4.83 (1H, dd, J = 10.2, 1.7 Hz, CH2-C1), 
3.53 (2H, d, J = 6.9 Hz, CH2-C6), 1.50 (18 H, s, 2 × t-Bu), 1.46–1.39 (1H, dddd, J = 8.6, 
8.5, 5.1, 4.9 Hz, CH-C3), 1.19 (1H, ddddd, J = 8.6, 6.9, 6.9, 5.1, 4.9 Hz, CH-C5), 0.73 (1H, 
ddd, J = 8.5, 5.1, 5.1 Hz, CH2-C4), 0.57 (1H, ddd, J =8.5, 4.9, 4.9 Hz, CH2-C4); 13C (126 
MHz, CDCl3): δ 152.9 (2 × CO-Boc), 141.0 (CH-C2), 112.2 (CH2-C1), 82.3 (2 × C-Boc), 
49.5 (CH2-C6), 28.2 (6 × CH3-Boc), 21.5 (CH-C3), 20.5 (CH-C5), 12.3 (CH2-C4); HRMS 
(ESI+) calcd for C16H27NO4Na [M+Na]+ 320.1832, found 320.1828. 
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t-Butyl-N-[(1R*,2S*)-2-(2-hydroxyethyl)cyclopropyl]methylcarbamate 103 
 
A flask with an argon inlet was charged with BH3×THF (1 м in THF, 2.60 mL, 2.60 mmol). 
A solution of (±)- 93 (340 mg, 1.71 mmol) in THF (2.10 mL) was added dropwise at rt. The 
reaction mixture was stirred overnight at rt. H2O (4 mL) was then added carefully followed 
by pH 7 phosphate buffer solution (4 mL). Sodium perborate (526 mg, 3.42 mmol) was 
added and the reaction mixture was stirred for a further 2 h. The excess of sodium perborate 
was removed by filtration and the filtrate was concentrated under vacuum. The aqueous 
residue was extracted with Et2O (3 × 10 mL). The combined organic extracts were washed 
with brine (10 mL), dried over MgSO4, filtered and concentrated under vacuum to give the 
corresponding alcohol (379 mg, quant.) as a colourless liquid.  
Rf (EtOAc/PE 1:1): 0.51; nmax (CHCl3): 3329, 2976, 2928, 2874, 1688, 1366, 1171, 1042, 
1020 cm−1; 1H NMR (500 MHz; CDCl3): δ 4.89 (1H, s, NH), 3.67 (2H, t, J = 6.4 Hz, CH2-
C1), 3.59 (1H, t, J = 6.4 Hz, OH), 3.11 (1H, ddd, J = 13.7, 5.6, 5.6 Hz, CH2-C6), 2.84–2.80 
(1H, m, CH2-C6), 1.65–1.61 (1H, m, 1H ´ CH2-C2), 1.43 (9H, s, t-Bu), 1.27–1.25 (1H, m, 
CH2-C2), 0.72–0.67 (2H, m, CH-C5 + CH-C3), 0.37–0.33 (1H,  m, CH2-C4), 0.31-0.27 (1H, 
m, CH2-C4). 13C NMR (126 MHz; CDCl3): δ 156.4 (CO-Boc), 79.3 (C-Boc), 62.8 (CH2-
C1), 45.0 (CH2-C6), 36.5 (CH2-C2), 28.5 (3 ´  CH3-Boc), 18.4 (CH-C5), 15.0 (CH-C3), 10.0 
(CH2-C4). HRMS (ESI+) for C11H21NNaO3 [M+Na]+ calcd 238.1419 found, 238.1442. 
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t-Butyl-N-[(1R,2S)-2-(2-hydroxyethyl)cyclopropyl]methylcarbamate 103  
 
The procedure used for the hydroboration of (±)-103 was followed using (R,S)-93 (440 mg, 
1.72 mmol). The title compound (379 mg, quant.) was obtained without any further 
purification as a colourless liquid.  
Rf (EtOAc/PE 1:1): 0.51; nmax: 3354, 2928, 1715, 1514, 1244, 1173, 1022 cm–1; 1H-NMR 
(500 MHz; CDCl3): δ 4.95 (1H, s, NH), 3.64 (2H, t, J = 6.3 Hz, CH2-C1), 3.59 (1H, t, J = 
6.6 Hz, OH), 3.13–3.04 (1H, m, CH2-C6), 2.85–2.77 (1H, m, CH2-C6), 1.68–1.57 (1H, m, 
CH2-C2), 1.40 (9H, s, t-Bu), 1.30–1.22 (1H, m, CH2-C2), 0.72–0.62 (2H, m, CH-C5 + CH-
C3), 0.35–0.30 (1H, m, CH2-C4), 0.29–0.24 (1H, m, CH2-C4). 13C NMR (126 MHz; CDCl3): 
δ 156.4 (CO-Boc), 79.3 (C-Boc), 62.7 (CH2-C1), 44.9 (CH2-C6), 36.5 (CH2-C2), 28.5 (3 ´ 
CH3-Boc) 18.3 (CH-C5), 14.9 (CH-C3), 10.3 (CH2-C4). HRMS (ESI+) for C25H21NNaO6 
[M+Na] calcd 464.2044 found 464.2041 
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t-Butyl-N-[(1S,2R)-2-(2-hydroxyethyl)cyclopropyl]methylcarbamate 103 
 
The procedure used for the hydroboration of (±)-103 was followed using (S,R)-93 (99.0 mg, 
0.50 mmol). The title compound (66 mg, 61%) was obtained without any further purification 
as a colourless liquid.  
Rf (EtOAc/PE 1:1): 0.54; [a],96: +0.52 (c = 0.05, in CH3Cl); nmax (CHCl3): 3329, 2976, 2928, 
2874, 1688, 1366, 1171, 1042, 1020 cm−1; 1H NMR (500 MHz; CDCl3): δ 4.99 (1H, s, NH), 
3.61 (2H, t, J = 6.2 Hz, CH2-C1), 3.56 (1H, t, J = 6.2 Hz, OH), 3.09–3.03 (1H, m, 1 ´ CH2-
C6), 2.80–2.78 (1H, m, CH2-C6), 1.60–1.56 (1H, m, CH2-C2), 1.38 (9H, s, t-Bu), 1.26–1.21 
(1H, m, CH2-C2), 0.68–0.63 (2H, m, CH-C5 + CH-C3), 0.32–0.29 (1H, m, CH2-C4), 0.26–
0.22 (1H, m, CH2-C4); 13C NMR (126 MHz; CDCl3): δ 156.4 (CO-Boc), 79.2 (C-Boc), 62.5 
(CH2-C1), 44.9 (CH2-C6), 36.5 (CH2-C2), 28.4 (3 ´  CH3-Boc) 18.3 (CH-C5), 14.9 (CH-C3), 
10.2 (CH2-C4); HRMS (ESI+) for C11H21NNaO3 [M+Na] calcd 238.1419, found 238.1439. 
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  181 
[(1R*,2S*)-(2-(2-Hydroxyethyl)cyclopropyl]methyl-2,3-dihydro-1H-isoindole-1,3-
dione 104 
 
The procedure applied to the synthesis of compound (±)-103 was followed using (±)-94 
(2.10 g, 9.23 mmol). The title compound (1.81 g, 80%) was obtained without any further 
purification as a as a yellow oil. 
Rf (EtOAc/PE 1:1): 0.12; nmax (CHCl3): 3381, 2930, 2874, 1771, 1705, 1395, 1059, 1042 
cm–1; 1H-NMR (500 MHz; CDCl3): δ 7.85–7.82 (2H, m, 2 ´ CH-Pht), 7.72–7.69 (2H, m, 2 
´ CH-Phth), 3.70–3.56 (3H, m, CH2-C1 + 1 ´  CH2-C6), 3.44 (1H, dd, J = 14.1, 7.5 Hz, CH2-
C6), 1.39–1.31 (2H, m, CH2-C2), 0.94–0.84 (2H, m, CH-C3 + CH-C5), 0.57 (1H, ddd, J = 
8.3, 4.6, 4.6 Hz, CH2-C4), 0.35 (1H, ddd, J = 8.3, 5.1, 5.1 Hz, CH2-C4). 13C NMR (126 
MHz; CDCl3): δ 168.7 (2 ´ CO-Phth), 134.1 (2 ´ CH-Phth), 132.2 (2 ´ C-Phth), 123.4 (2 ´ 
CH-Pht), 62.8 (CH2-C1), 42.1 (CH2-C6), 19.0 (CH2-C2), 17.5 (CH-C5), 15.3 (CH-C3), 10.5 
(CH2-C4). HRMS (ESI+) for C14H15NNaO3 [M+Na]+ calcd 268.0944, found 268.0948.  
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  182 
t-Butyl-N-(t-butoxycarbonyl)-N-[(1R*,2S*)-2-(2-
hydroxyethyl)cyclopropyl]methylcarbamate 105 
 
The procedure applied to the synthesis of (±)-103 (AN-II-75) was applied using (±)-100 
(12.9 g, 43.6 mmol). The title compound (13.3 g, 97%) was obtained as a colourless liquid.  
Rf (EtOAc/PE 1:1): 0.63; nmax (CHCl3): 3464, 2980, 2934, 2674, 1732, 1692, 1368, 1172, 
1126,  1096, 1036 cm−1; 1H NMR (500 MHz; CDCl3): δ 3.66–3.64 (3H, m, CH2-C1 + OH), 
3.62–3.60 (1H, m, CH2-C6), 3.34 (1H, dd, J = 14.3, 7.5 Hz, CH2-C6), 1.63 (1H, dq, J = 13.6, 
6.7 Hz, CH2-C2), 1.50 (18H, s, 2 ´ t-Bu), 1.30–1.24 (1H, m, CH2-C2), 0.90–0.87 (1H, m, 
CH-C5), 0.82–0.75 (1H, m, CH-C3), 0.47 (1H, ddd, J = 8.5, 4.8, 4.8 Hz, CH2-C4), 0.31 (1H, 
ddd, J = 8.5, 5.0, 5.0 Hz, CH2-C4); 13C NMR (126 MHz; CDCl3): δ 153.3 (2 ´ CO-Boc), 
82.4 (2 ´ C-Boc), 63.0 (CH2-C1), 50.1 (CH2-C6), 36.8 (CH2-C2), 28.2 (6 ´ CH3-Boc), 17.9 
(CH-C5), 14.9 (CH-C3), 10.2 (CH2-C4); HRMS (ESI+) for C16H29NNaO5 [M+Na]+ calcd 
338.1943, found 338.1917. 
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t-Butyl N-(t-butoxycarbonyl)-N-[(1R,2S)-2-(2-hydroxyethyl)cyclopropyl]methylcarbamate 105 
 
The procedure used for the hydroboration of (±)-103 (AN-04-70) was applied using alkene 
(R,S)-100 (1.32 g, 4.44 mmol). The mixture was stirred for 2 h before the oxidation reaction. 
The desired compound (1.27 g, 91%) was obtained as a colourless oil and used without 
further purification. 
Rf (PE/EtOAc 1:1): 0.59; [𝛼],9B +0.10 (c = 1.0, CHCl3); νmax 3522, 2978, 2932, 1732, 1694, 
1366, 1173, 1130, 856 cm−1; 1H NMR (400 MHz, CDCl3) δ 3.69−3.61 (3H, m, CH2-C1 + 1 
× CH2-C6), 3.34 (1H, dd, J = 14.3, 7.5 Hz, CH2-C6), 1.67−1.60 (1H, m, CH2-C2), 1.50 (18H, 
s, 2 × t-Bu), 1.32−1.23 (1H, m, CH2-C2), 0.94–0.85 (1H, m, CH-C5), 0.82–0.76 (1H, m, 
CH-C3), 0.47 (1H, ddd, J = 8.6, 4.8 Hz, 4.8 CH2-C4), 0.31 (1H, ddd, J = 8.6, 5.0, 5.0 Hz, 
CH2-C4); 13C (126 MHz, CDCl3): δ 153.3 (2 × CO-Boc), 82.4 (2 × C-Boc), 63.0 (CH2-C1), 
50.1 (CH2-C6), 36.8 (CH2-C2), 28.2 (6 × CH3-Boc), 17.9 (CH-C5), 14.9 (CH-C3), 10.2 
(CH2-C4); HRMS (ESI+) calcd for C16H29NO5Na [M+Na]+ 338.1938 found 338.1937.  
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  184 
t-Butyl N-(t-butoxycarbonyl)-N-[(1S,2R)-2-(2-hydroxyethyl)cyclopropyl]methylcarbamate 105 
 
The procedure used for the hydroboration/oxidation of (±)-103 was applied using alkene 
(S,R)-100 (1.01 g, 3.40 mmol). The reaction mixture was stirred for 2 h before the oxidation. 
The title compound (970 mg, 91%) was obtained as a colourless oil without any further 
purification. 
Rf (PE/EtOAc 1:1): 0.59; [𝛼],9B +0.5 (c = 1, CHCl3); νmax 3522, 2978, 2931, 1732, 1685, 
1366, 1172, 1126, 853 cm−1; 1H NMR (400 MHz, CDCl3) δ 3.69–3.59 (3H, m, CH2-C1 + 
CH2-C6), 3.61 (1H, dd, J = 8.5, 5.6 Hz, CH2-C6), 3.34 (1H, dd, J = 14.3, 7.5 Hz, CH2-C2), 
1.66–1.60 (1H, m, CH2-C2), 1.50 (18H, s, 2 × t-Bu), 1.31–1.21 (1H, m, CH2-C2), 0.91–0.85 
(1H, m, CH-C5), 0.81–0.73 (1H, m, CH-C3), 0.47 (1H, ddd, J = 8.5, 4.8, 4.8 Hz, CH2-C4), 
0.31 (ddd, J = 8.5, 5.0, 5.0 Hz, CH2-C4); 13C (126 MHz, CDCl3): δ 153.3 (2 × CO-Boc), 
82.4 (2 × C-Boc), 63.0 (CH2-C1), 50.1 (CH2-C6), 36.8 (CH2-C2), 28.2 (6 × CH3-Boc), 17.9 
(CH-C5), 14.9 (CH-C3), 10.19 (CH2-C4); HRMS (ESI+) calcd for C16H29NO5Na [M+Na]+ 
338.1938, found 338.1932. 
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t-Butyl [(1R,2S*)-2-(2-oxoethyl)cyclopropyl]methylcarbamate 102  
 
(±)-103 (545 mg, 2.53 mmol) was dissolved in CH2Cl2 (13 mL). DMP (1.61 g, 3.80 mmol) 
was added to the solution at 0 °C. The reaction mixture was stirred overnight at rt. CH2Cl2 
(10 mL) was added to the reaction mixture and the solution was washed with 1 м aq. NaOH 
(10 mL), aq. sat. NaHCO3 (10 mL), and brine (10 mL). The organic phase was dried over 
MgSO4, filtered and concentrated under vacuum. The crude was then purified by silica gel 
column chromatography (PE/EtOAc 1:1) to give the title compound (212 mg, 40%) as a 
yellow oil.  
Rf (EtOAc/PE 1:1): 0.67; nmax (CHCl3): 3360, 2978, 2930, 2726, 1695, 1366, 1169, 1051 
cm−1; 1H NMR (500 MHz; CDCl3): δ 9.79 (1H, t, J = 1.4 Hz, CHO-C1), 5.01 (1H, s, NH), 
3.29–3.24 (1H, m, CH2-C6), 2.85–2.80 (1H, m, CH2-C6), 2.56 (1H, dd, J = 18.0, 5.5 Hz, 
CH2-C2), 2.21 (1H, dd, J = 18.0, 7.1 Hz, CH2-C2), 1.44 (9H, s, t-Bu), 0.88–0.81 (1H, m, 
CH-C3), 0.77 (1H, ddddd, J = 12.8, 11.0, 8.3, 5.5, 5.1 Hz, CH-C5), 0.53 (1H, ddd, J = 8.4, 
5.1, 5.1 Hz, CH2-C4), 0.40 (1H, ddd, J = 8.4, 5.5, 5.5 Hz, CH2-C4); 13C NMR (126 MHz; 
CDCl3): δ 202.1 (CO-C1), 156.1 (CO-Boc), 79.3 (C-Boc), 47.8 (CH2-C2), 44.8 (CH2-C6), 
28.6 (3 ´ CH3-Boc), 18.4 (CH-C5), 10.7 (CH-C3), 10.0 (CH2-C4); HRMS (ESI+) for 
C11H19NNaO3 [M+Na]+ calcd 236.1257, found 236.1252. 
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{(1R*,2S*)-2-([(t-butoxycarbonyl)amino]methylcyclopropyl}acetic acid [(R*,S*)-Boc-
{Gly∆Gly}-OH] 106   
 
(±)-102 (212 mg, 0.99 mmol), 2-methyl-2-butene (2.10 mL, 19.8 mmol) and NaH2PO4×2H2O 
(308 mg, 1.98 mmol.) were dissolved in t-BuOH (10 mL) and the resultant solution cooled 
to 0 °C. To the mixture was added NaClO2 (313 mg, 3.47 mmol). The reaction mixture was 
stirred overnight at rt. The mixture was cooled down to 0 °C and 1 м aq. HCl was added to 
the solution until pH 1. The solution was extracted with CHCl3 (3 × 15mL). The combined 
organic extracts were washed with brine, dried over MgSO4, filtered and concentrated under 
reduced pressure. The residue was purified by silica gel column chromatography (PE/EtOAc 
1:1) to afford (±)-106 (176 mg, 77%) as a yellow oil. 
Rf (EtOAc/PE 1:1): 0.55; nmax (CHCl3): 3350, 2978, 1694, 1638, 1169 cm−1. 1H NMR (500 
MHz; CDCl3): δ 5.07 (1H, s, NH), 3.29 (1H, ddd, J = 12.5, 6.3, 6.3 Hz, CH2-C6), 2.80–2.72 
(1H, m, CH2-C6), 2.54 (1H, dd, J = 16.9, 5.7 Hz, CH2-C2), 2.08 (1H, dd, J = 16.9, 9.2 Hz, 
CH2-C2), 1.44 (9H, s, t-Bu), 0.93–0.85 (1H, m, CH-C3), 0.83–0.79 (1H, m, CH-C5), 0.52 
(1H, ddd, J = 8.4, 5.1, 5.1 Hz, CH2-C4), 0.43 (1H, ddd, J = 8.4, 5.2, 5.2 Hz, CH2-C4); 13C 
NMR (126 MHz; CDCl3): δ 178.3 (CO-C1), 156.2 (CO-Boc), 79.3 (C-Boc), 44.8 (CH2-C6), 
37.9 (CH2-C2), 28.6 (3 ´ CH3-Boc), 18.5 (CH-C3), 12.9 (CH-C5), 10.3 (CH2-C4); HRMS 
(ESI+) for C11H19NNaO4 [M+Na]+ calcd 252.1206, found 252.1207. 
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(R,S)-Boc-{Gly∆Gly}-OH 106 
 
To a solution of (S,R)-103 (56 mg, 0.26 mmol), DMSO (0.19 mL, 2.6 mmol) and DIPEA 
(0.18 mL, 1.04 mmol) in CH2Cl2 (3 mL) at 0 °C was added SO3·pyridine (103 mg, 0.65 
mmol) in two portions over 5 min. The reaction mixture was stirred for 15 min and then 
diluted with sat. aq. NaHCO3 (5 mL). The phases were separated, and the organic phase was 
washed with sat. aq. NaHCO3 (5 mL) and brine (5 mL), then dried over MgSO4, filtered and 
concentrated under vacuum. The crude was used directly in the next step. 
The procedure applied for the synthesis of (±)-106 was then followed using the aldehyde 
previously obtained. The residue was purified by silica gel column chromatography 
(PE/EtOAc 1:1) to yield the acid (S,R)-106 (5 mg, 22%) as dark yellow oil.  
Rf (EtOAc/PE 1:1): 0.35; [a],96: +39 (c = 0.10, CH3Cl), nmax (CHCl3): 3335, 2978, 2930, 
1711, 1368, 1171, 1026 cm−1; 1H NMR (500 MHz; CDCl3): δ 5.03 (1H, s, NH), 3.30 (1H, 
ddd, J = 12.7, 6.0, 6.0 Hz, CH2-C6), 2.83–2.73 (1H, m, CH2-C6), 2.56 (1H, dd, J = 16.8, 5.7 
Hz, CH2-C2), 2.09 (1H, dd, J = 16.8, 8.7 Hz, CH2-C2), 1.45 (9H, s,t-Bu), 0.95–0.86 (1H, m, 
CH-C3), 0.86–0.78 (1H, m, CH-C5), 0.53 (1H, ddd, J = 8.5, 5.2, 5.2 Hz, CH2-C4), 0.44 (1H, 
ddd, J = 8.5, 5.2, 5.2 Hz, CH2-C4); 13C NMR (126 MHz; CDCl3): δ 178.3 (CO-C1), 156.2 
(CO-Boc), 79.3 (C-Boc), 44.9 (CH2-C6), 37.9 (CH2-C2), 28.6 (3 ´ CH3-Boc), 18.5 (CH-
C3), 12.9 (CH-C5), 10.3 (CH2-C4); HRMS (ESI+) for C11H19NNaO4 [M+Na]+ calcd 
252.1206, found 252.1203. 
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 (±)-(Boc)2-{Gly∆Gly}-OH 107 
 
(±)-105 (1.46 g, 4.63 mmol) and NMO×H2O (6.26 g, 46.3 mmol) were dissolved in MeCN 
(19 mL). TPAP (10 mol%, 162 mg, 0.46 mmol) was added portionwise (20 mg/20min) at rt. 
The reaction mixture was stirred overnight at rt. The reaction was then quenched by the 
addition of excess of isopropanol. H2O (50 mL) was added and pH was carefully adjusted to 
1 using 2 м aq. HCl. The aqueous phase was extracted with Et2O (3 ´  20 mL). The combined 
organic extracts were washed with brine, dried over MgSO4, filtered and concentrated under 
vacuum to give the protected amino acid, which was used as crude for the next step.  
Rf (EtOAc/PE 1:1): 0.08; nmax (CHCl3): 2980, 2936, 1709, 1694, 1368, 1171, 1126, 1034 
cm−1; 1H NMR (500 MHz; CDCl3): δ 3.52 (2H, dd, J = 6.9, 1.2 Hz, CH2-C6), 2.28 (1H, dd, 
J = 16.2, 7.0 Hz, CH2-C2), 2.21 (1H, dd, J = 16.2, 7.2 Hz, CH2-C2), 1.50 (18H, s, 2 ´ t-Bu), 
1.10–1.02 (2H, m, CH-C5 + CH-C3), 0.61 (1H, ddd, J = 8.5, 5.1, 5.1 Hz, CH2-C4), 0.40 
(1H, ddd, J = 8.5, 5.1, 5.1 Hz, CH2-C4); 13C NMR (126 MHz; CDCl3): δ 178.2 (C1), 153.0 
(2 ´ CO-Boc), 82.4 (2 ´ C-Boc), 49.6 (CH2-C6), 38.4 (CH2-C2), 28.2 (6 ´ CH3-Boc), 18.3 
(CH-C5), 13.1 (CH-C3), 10.7 (CH2-C4); HRMS (ESI+) for C16H27NNaO6 [M+Na]+ calcd 
352.1736, found 352.1680.  
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(S,R)-(Boc)2-{Gly∆Gly}-OH 107 
 
The procedure applied to the synthesis of (±)-107 was followed using alcohol (S,R)-105 (646 
mg, 2.05 mmol). (S,R)-(Boc)2-{Gly∆Gly}-OH 107 (588 mg, 87%) was obtained as a black 
oil without any further purification.  
Rf (PE/EtOAc 1:1): 0.15; [𝛼],9? +0.72 (c = 1, CHCl3); νmax 2978, 2935, 1778, 1709, 1694, 
1516, 1439, 1366, 1238, 1173, 1130, 853 cm−1; 1H NMR (400 MHz, CDCl3) δ 3.52 (2H, dd, 
J = 6.9, 5.6 Hz, CH2-C6), 2.30 (1H, dd, J = 16.2, 6.7 Hz, CH2-C2), 2.19 (1H, dd, J = 16.2, 
7.3 Hz, CH2-C2), 1.50 (18H, s, 2 × t-Bu), 1.11–1.02 (2H, m, CH-C3 + CH-C5), 0.61 (1H, 
ddd, J = 8.4, 5.2, 5.2 Hz, CH2-C4), 0.40 (1H, ddd, J = 8.4, 5.2, 5.2 Hz, CH2-C4); 13C (126 
MHz, CDCl3): δ 177.9 (CO-C1), 152.9 (2 × CO-Boc), 82.4 (2 × C-Boc), 49.7 (CH2-C6), 
38.4 (CH2-C2), 28.2 (6 × CH3-Boc), 18.3 (CH-C5), 13.1 (CH-C3), 10.7 (CH2-C4); HRMS 
(ESI+) for C16H27NO6Na [M+Na]+ calcd 352.1731, found 352.1716.   
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 (R,S)-(Boc)2-{Gly∆Gly}-OH 107 
 
The procedure used for the synthesis of (±)-106 was applied using alcohol (R,S)-105 (970 
mg, 3.08 mmol) affording (R,S)-(Boc)2-{Gly∆Gly}-OH 107 (1.04 g, quant.) as a black oil. 
The compound was used without any further purification. 
Rf (PE/EtOAc 1:1): 0.65; [𝛼],9B −0.34 (c = 1.0, CHCl3); νmax 3233, 2978, 2936, 1778, 1709, 
1694, 1516, 1366, 1234, 1173, 1126, 853 cm−1; 1H NMR (400 MHz, CDCl3) δ 3.52 (2H, dd, 
J = 6.9, 1.6 Hz, CH2-C6), 2.29 (1H, dd, J = 16.2, 6.9 Hz, CH2-C2), 2.21 (1H, dd, J = 16.2, 
7.1 Hz, CH2-C2), 1.50 (18H, s, 2 × t-Bu), 1.13–1.01 (2H, m, CH-C5 + CH-C3), 0.61 (1H, 
ddd, J = 8.4, 5.2, 5.2 Hz, CH2-C4), 0.40 (1H, ddd, J = 8.4, 5.1, 5.1 Hz, CH2-C4); 13C (126 
MHz, CDCl3): δ 178.4 (CO-C1), 153.0 (2 × CO-Boc), 82.4 (2 × C-Boc), 49.6 (CH2-C6), 
38.5 (CH2-C2), 28.2 (6 × CH3-Boc), 18.3 (CH-C5), 13.1 (CH-C3), 10.7 (CH2-C4); HRMS 
(ESI+) for C16H27NO6Na [M+Na]+ calcd 352.1731, found 352.1719.   
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 (±)-(Boc)2-{Gly∆Gly}-OMe 117  
 
To a suspension of (±)-(Boc)2-{Gly∆Gly}-OH 107 (789 mg, 2.40 mmol) and NaHCO3 (403 
mg, 4.80 mmol) in anhydrous DMF (7.10 mL) was added MeI (750 µL, 12.0 mmol). The 
reaction mixture was stirred overnight at rt. H2O (10.0 mL) was added dropwise and the 
mixture was then extracted with Et2O (3 ´ 10 mL). The combined organic extracts were 
washed with H2O (10 mL) and brine (10 mL), dried over MgSO4, filtered and concentrated 
under vacuum. The residue was then purified by silica gel on column chromatography 
(PE/EtOAC, 95:5 to 85:15) to give (±)-(Boc)2-{Gly∆Gly}-OMe 117 (359 mg, 47%) as a 
yellow oil. 
Rf (EtOAc/PE 1:1): 0.15; nmax (CHCl3): 2980, 2934, 2849, 1749, 1694, 1234, 1171, 1128, 
1034 cm−1; 1H NMR (400 MHz; CDCl3): δ 3.67 (3H, s, CH3-OMe), 3.51 (2H, dd, J = 6.9, 
3.6 Hz, CH2-C6) [?], 2.25 (1H, dd, J = 15.7, 6.9 Hz, CH2-C2), 2.17 (1H, dd, J = 15.7, 7.2 
Hz, CH2-C2), 1.51 (18H, s, 2 ´ t-Bu), 1.10–1.00 (2H, m, CH-C5 + CH-C3), 0.59 (1H, ddd, 
J = 8.5, 5.1, 5.1 Hz, CH2-C4), 0.37 (1H, ddd, J = 8.5, 5.1, 5.1 Hz, 1 ´ CH2-C4); 13C NMR 
(101 MHz; CDCl3): δ 173.3 (CO-C1), 152.9 (2 ´ CO-Boc), 82.3 (2 ´ C-Boc), 51.8 (CH3-
OMe), 49.7 (CH2-C6), 38.7 (CH2-C2), 28.2 (6 ´ CH3-Boc), 18.3 (CH-C3), 13.4 (CH-C5), 
10.8 (CH2-C4); HRMS (ESI+) for C17H29NNaO6 [M+Na]+ calcd 366.1893, found 366.1883. 
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(±)-(Boc)2-{Gly∆Gly}-N-iPr 118  
 
(±)-(Boc)2-{Gly∆Gly}-OH 107 (700 mg, 2.13 mmol), i-PrNH2 (370 μL, 4.26 mmol) and 
Et3N (1.00 mL, 7.46 mmol) were dissolved in CH2Cl2 (11 mL). The solution was stirred for 
15 min at rt and T3P (1.90 mL, of a 50% solution in EtOAc, 3.20 mmol) was added dropwise. 
The reaction mixture was stirred for 18 h at rt. The solution was washed with H2O (3 ´ 10 
mL) and the phases were separated. The organic phase was dried over MgSO4, filtered and 
concentrated under vacuum. The residue was purified by silica gel on column 
chromatography (PE/EtOAc 1:1) to give the title compound (365 mg, 46%) as a colourless 
oil.  
Rf (EtOAc/PE 1:1): 0.41; nmax (CHCl3): 3287, 2976, 2934, 2874, 1694, 1651, 1366, 1175, 
1132, 1032 cm−1; 1H-NMR (400 MHz; CDCl3): δ 5.91 (1H, d, J = 7.6 Hz, NH), 4.15–4.04 
(1H, m, CH-C7), 3.63 (1H, dd, J = 14.4, 6.0 Hz, CH2-C6), 3.52 (1H, dd, J = 14.4, 6.3 Hz, 
CH2-C6), 2.19 (1H, dd, J = 16.3, 6.7 Hz, CH2-C2), 2.07 (1H, dd, J = 16.3, 6.9 Hz, CH2-C2), 
1.50 (18H, s, 2 ´ t-Bu), 1.16 (6H, d, J = 6.6 Hz, 2 ´ CH3-C8), 1.01–0.88 (2H, m, CH-C5 + 
CH-C3), 0.58 (1H, ddd, J = 8.6, 4.8, 4.8 Hz, CH2-C4), 0.37 (1H, ddd, J = 8.6, 4.8, 4.8 Hz, 
CH2-C4); 13C NMR (126 MHz; CDCl3): 171.2 (CO-C1), 153.2 (2 ´ CO-Boc), 82.7 (2 ´ C-
Boc), 49.1 (CH2-C6), 41.3 (CH-C7), 41.1 (CH2-C2), 28.2 (6 ´ CH3-Boc), 22.9 (2 ´ CH3-
C8), 18.4 (CH-C5), 13.1 (CH-C3), 10.4 (CH2-C4); HRMS (ESI+) for C19H34N2NaO5 
[M+Na]+ calcd 393.2365 found, 397.2337.  
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(±)-(Boc)2-{Gly∆Gly}-OH 107 (1.00 g, 3.04 mmol), HNMe2 (1.60 mL of a 2 м solution in 
THF, 3.19 mmol) and Et3N (1.50 mL, 10.6 mmol) were dissolved in CH2Cl2 (15 mL). The 
solution was stirred for 15 min at rt and T3P (2.70 mL of a 50% solution in EtOAc, 4.56 
mmol) was added dropwise. The reaction mixture was stirred for 18 h at rt. The solution was 
washed with H2O (3 ´ 10 mL) and phases separated. The organic phase was dried over 
MgSO4, filtered and concentrated under vacuum. The residue was purified by silica gel 
column chromatography (PE/EtOAc 1:1) to give the title compound (400 mg, 37%) as a 
colourless oil.  
Rf (EtOAc/PE 1:1): 0.17; nmax (CHCl3): 2978, 1740, 1694, 1649, 1368, 1132 cm−1; 1H NMR 
(500 MHz; CDCl3): δ 3.58 (1H, dd, J = 14.4, 6.7 Hz, CH2-C6), 3.46 (1H, dd, J = 14.4, 7.2 
Hz, CH2-C6), 2.97 (3H, s, CH3-C7), 2.93 (3H, s, CH3-C7), 2.43 (1H, dd, J = 15.3, 5.8 Hz, 
CH2-C2), 2.11 (1H, dd, J = 15.3, 7.6 Hz, CH2-C2), 1.50 (18H, d, J = 1.7 Hz, 2´ t-Bu), 1.13–
1.05 (1H, m, CH-C3), 1.04–0.97 (1H, m, CH-C5), 0.62 (1H, ddd, J = 8.5, 5.1, 5.1 Hz, CH2-
C4), 0.38 (1H, ddd, J = 8.5, 5.1, 5.1 Hz, CH2-C4); 13C NMR (126 MHz; CDCl3): δ 172.3 
(CO-C1), 152.9 (CO-Boc), 82.3 (C-Boc), 49.9 (CH2-C6), 37.9 (CH2-C2), 37.5 (CH3-C7), 
35.4 (CH3-C7), 28.2 (6 ´ CH3-Boc), 18.2 (CH-C5), 13.8 (CH-C5), 10.9 (CH2-C4); HRMS 
(ESI+) for C18H32N2NaO5 [M+Na]+ calcd 379.2203, found 379.2190. 
  
7
7N
O
(Boc)2N
(±)-119
6
5
4
3
2
1
  194 
(±)-iPrOC-{Gly∆Gly}-N-iPr 75  
 
A solution of (±)-(Boc)2-{Gly∆Gly}-iPr 118 (57 mg, 0.15 mmol) in CH2Cl2 (1.5 mL) was 
treated with TFA (115 μL, 9.90 mmol) dropwise at rt. The reaction mixture was stirred for 
3 h at rt and solvent was removed under vacuum.  
The resulting TFA salt (0.15 mmol) was dissolved in CH2Cl2 (380 μL) and Et3N (40 μL, 
0.28 mmol) was added. Isobutyric anhydride (46 μL, 0.28 mmol) was added dropwise at rt 
and the reaction mixture was stirred for 36 h. H2O (10 mL) was added and phases were 
separated. The organic phase was washed with aq. sat. NaHCO3 (3 ´ 10 mL) and brine (10 
mL). The organic phase was dried over MgSO4, filtered and concentrated under vacuum. 
The crude product was purified by silica gel column chromatography (PE/EtOAc 9:1 to 2:3) 
to afford the title compound (25 mg, 69% over two steps) as a white powder. 
Rf (EtOAc/PE 1:1): 0.45; m.p.: 107–108 °C; νmax (10 mM, CH2Cl2) 3429, 3325, 2974, 2932, 
1663, 1516, 1277, 1265, 1258 cm−1; 1H NMR (400 MHz; CDCl3): δ 6.77 (1H, s, NH-Gly), 
5.42 (1H, s, NH-iPr), 4.09 (1H, m, CH-C7), 3.72 (1H, ddd, J = 13.5, 6.0, 4.7 Hz, CH2-C6), 
2.61–2.47 (2H, m, CH2-C6 + CH2-C2), 1.18 (3H, d, J = 6.9 Hz, CH3-C11), 1.17 (3H, d, J = 
6.9 Hz, CH3-C11), 1.17 (3H, d, J = 6.5 Hz, CH3-C8), 1.16 (3H, d, J = 6.5 Hz, CH3-C8), 2.43 
(1H, hept, J = 6.9 Hz, CH-C10), 1.70 (1H, dd, J = 16.2, 9.4 Hz, CH2-C2), 0.83–0.70 (2H, 
m, CH-C5 + CH-C3), 0.52 (1H, ddd, J = 8.2, 5.2, 5.2 Hz, CH2-C4), 0.42 (1H, ddd, J = 8.2, 
5.2, 5.2 Hz, CH2-C4); 13C NMR (101 MHz; CDCl3): δ 177.5 (CO-C1), 171.7 (CO-C9), 43.9 
(CH2-C6), 41.6 (CH-C7), 40.0 (CH2-C2), 35.7 (CH-C10), 23.0 (2 ´  CH3-C8), 19.8 (2 ´  CH2-
C11), 18.1 (CH-C3/5), 13.6 (CH-C3/5), 10.2 (CH2-C4); HRMS (ESI+) for C13H24N2NaO2 
[M+Na]+ calcd 262.1730, found 262.1727. 
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 (±)-iPrOC-{Gly∆Gly}-NMe2 76  
  
(±)-(Boc)2-{Gly∆Gly}-NMe2 119 (400 mg, 1.12 mmol) was dissolved in CH2Cl2 (11 mL) 
and treated with TFA (860 μL, 11.2 mmol). The reaction mixture was stirred for 3 h and 
solvent was removed under vacuum.  
The resulting TFA·(±)-H-{Gly∆Gly}-NMe2 salt and Et3N (164 μL, 1.18 mmol) were 
dissolved in CH2Cl2 (1.6 mL). Isobutyric anhydride (196 μL, 1.18 mmol) was added 
dropwise to the solution at rt. The reaction mixture was stirred for 18 h at rt. H2O (10 mL) 
was added and the phases were separated. The organic phase was washed with sat. aq 
NaHCO3 (3 ´ 10 mL), 1 м aq. NaOH (3 ´ 10 mL), 1 м aq.  HCl (10 mL) and brine (10 mL), 
dried over MgSO4, filtered and concentrated under vacuum. The residue was purified by 
silica gel column chromatography (CH2Cl2/MeOH 99:1 to 97:3) to afford the title compound 
(17 mg, 7% over 2 steps) as a colourless semi-solid. 
Rf (PE/EtOAc 1:1): 0.08; νmax (c = 10 mM, CH2Cl2) 3306, 3048, 2963, 2928, 2855, 1636, 
1535 cm−1; 1H NMR (500 MHz, CDCl3) δ 7.57 (1H, br s, NH), 3.91 (1H, ddd, J = 13.5, 6.3, 
4.8 Hz, CH2-C6), 2.96 (3H, s, CH3-C7), 2.94 (3H, s, CH3-C7), 2.88 (1H, dd, J = 17.0, 4.3 
Hz, CH2-C2), 2.46 (1H, hept, J = 6.9 Hz, CH-C9), 2.31 (1H, ddd, J = 13.5, 10.4, 1.9 Hz, 
CH2-C6), 1.65 (1H, dd, J = 17.0, 10.1 Hz, CH2-C2), 1.19 (3H, d, J = 6.9 Hz, CH3-C10), 1.17 
(3H, d, J = 6.9 Hz, CH3-C10), 0.78 (1H, ddddd, J = 10.1, 8.4, 5.3, 5.3, 4.3 Hz, CH-C3), 0.63 
(1H, ddddd, J = 9.6, 8.6, 5.1, 5.0, 4.8 Hz, CH-C5), 0.54 (1H, ddd, J = 8.3, 5.2, 5.2 Hz, CH2-
C4), 0.44 (1H, ddd, J = 8.3, 5.2, 5.2 Hz, CH2-C4); 13C (126 MHz, CDCl3): δ 177.5 (CO-C1), 
172.9 (CO-C9), 44.5 (CH2-C6), 37.3 (CH2-C2), 36.9 (CH3-C7), 35.5 (CH-C9), 35.5 (CH3-
C7), 19.8 (2 × CH3-C10), 17.7 (CH-C5), 13.5 (CH-C3), 10.5 (CH2-C4); HRMS (ESI+) for 
C12H22N2O2Na [M+Na]+ calcd 249.1573, found 249.1570. 
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(S,R)-Boc2-{Gly∆Gly}-N-iPr 118 
 
The procedure applied to the synthesis of (±)-(Boc)2-{Gly∆Gly}-iPr 118 was followed using 
(S,R)-(Boc)2-{Gly∆Gly}-OH 107 (50 mg, 0.15 mmol). The crude was purified by silica gel 
column chromatography (PE/EtOAc 1:1) to give (S,R)-118 (29 mg, 52%) as a colourless oil.    
Rf (PE/EtOAc 1:1): 0.44; [𝛼],6B +8.28 (c = 1.45, CHCl3); νmax 3308, 2975, 2934, 1728, 1700, 
1642, 1368, 1174, 1132, 853 cm−1; 1H NMR (500 MHz, CDCl3) δ 5.91 (1H, d, J = 6.8 Hz, 
NH), 4.15–4.05 (1H, m, CH-C7), 3.63 (1H, dd, J = 14.4, 6.1 Hz, CH2-C6), 3.52 (1H, dd, J 
= 14.4, 6.4 Hz, CH2-C6), 2.19 (1H, dd, J = 16.5, 6.8 Hz, CH2-C2), 2.07 (1H, dd, J = 16.5, 
7.5 Hz, CH2-C2), 1.50 (18H, s, 2 × t-Bu), 1.16 (3H, d, J = 6.3 Hz, CH3-C8), 1.16 (3H, d, J 
= 6.6 Hz, CH3-C8), 1.01–0.88 (2H, m, CH-C5 + CH-C3), 0.59 (1H, ddd, J = 8.5, 5.0, 5.0 
Hz, CH2-C4), 0.38 (1H, ddd, J = 8.5, 5.0, 5.0 Hz, CH2-C4); 13C (126 MHz, CDCl3): δ 171.3 
(CO-C1), 153.2 (2 × CO-Boc), 82.7 (C-Boc), 49.1 (CH2-C6), 41.4 (CH-C7), 41.1 (CH2-C2), 
28.2 (6 × CH3-Boc), 22.9 (CH3-C8), 22.9 (CH3-C8), 18.4 (CH-C5), 13.1 (CH-C3), 10.4 (CH2-
C4); HRMS (ESI+) for C19H34N2O5Na [M+Na]+ calcd 393.2360 found 393.2356. 
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The procedure applied to the synthesis of (±)-(Boc)2-{Gly∆Gly}-NMe2 119 was followed 
using (S,R)-(Boc)2-{Gly∆Gly}-OH 107 (130 mg, 0.39 mmol). 2 equiv. of HNMe2 (2 м in 
THF) were used in this case. The residue was purified by silica gel column chromatography 
(PE/EtOAc 1:1) to give (S,R)-(Boc)2-{Gly∆Gly}-NMe2 119 as a yellow oil (67 mg, 48%).  
Rf (PE/EtOAc 1:1): 0.34; [𝛼],99 +9.8 (c = 0.50, CHCl3); νmax 2977, 2932, 1744, 1734, 1693, 
1646, 1368, 1171, 1131, 853 cm−1; 1H NMR (500 MHz, CDCl3) δ 3.56 (1H, dd, J = 14.4, 
6.6 Hz, CH2-C6), 3.44 (1H, dd, J = 14.4, 7.2 Hz, CH2-C6), 2.95 (3H, s, CH3-C7), 2.91 (3H, 
s, CH3-C7), 2.41 (1H, dd, J = 15.3, 5.8 Hz, CH2-C2), 2.09 (1H, dd, J = 15.3, 7.5 Hz, CH2-
C2), 1.48 (18H, s, 2 × t-Bu), 1.10–1.03 (1H, m, CH-C3), 1.01–0.96 (1H, m, CH-C5), 0.60 
(1H, ddd, J = 8.4, 5.0, 5.0 Hz, CH2-C4), 0.36 (1H, ddd, J = 8.4, 5.1, 5.1 Hz, CH2-C4); 13C 
(126 MHz, CDCl3): δ 172.2 (CO-C1), 152.9 (2 × CO-Boc), 82.2 (CH-Boc), 49.9 (CH2-C6), 
37.8 (CH2-C2), 37.4 (CH3-C7), 35.4 (CH3-C7), 28.2 (6 × CH3-Boc), 18.2 (CH-C5), 13.8 
(CH-C3), 10.8 (CH2-C4); HRMS (ESI+) for C18H32N2O5Na [M+Na]+ calcd 379.2203, found 
379.2201. 
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 (S,R)-iPr-{Gly∆Gly}-N-iPr 75 
 
The procedure applied to the synthesis of (±)-iPr-{Gly∆Gly}-N-iPr 75 was followed using 
(S,R)-(Boc)2-{Gly∆Gly}-N-iPr 118 (74 mg, 0.20 mmol). After deprotection, 1.5 equiv. of 
Et3N and isobutyric anhydride were used. Trituration of the residue with cold pentane and 
cold Et2O in EtOAc afforded the title compound as a white solid (8 mg, 17% over 2 steps).  
Rf (PE/EtOAc 1:1): 0.08; [𝛼],96 −43 (c = 0.28, CHCl3); m.p.: 134–135 °C; νmax 3300, 2970, 
2924, 1639, 1547, 1238 cm−1; 1H NMR (500 MHz, CDCl3) δ 6.78 (1H, br s, NH-C6), 5.39 
(1H, br s, NH-C7), 4.10 (1H, dh, J = 7.9, 6.5 Hz, CH-C7), 3.73 (1H, ddd, J = 13.5, 5.9, 4.8 
Hz, CH2-C6), 2.60–2.50 (2H, m, CH2-C6 + CH2-C2), 2.43 (1H, h, J = 7.0 Hz, CH-C10), 
1.70 (1H, dd, J = 16.2, 9.4 Hz, CH2-C2), 1.18 (3H, d, J = 7.0 Hz, CH3-C11), 1.18 (3H, d, J 
= 7.0 Hz, CH3-C11), 1.17 (3H, d, J = 6.5 Hz, CH3-C8), 1.16 (3H, d, J = 6.5 Hz, CH3-C8), 
0.83–0.71 (2H, m, CH-C3 + CH-C5), 0.53 (1H, ddd, J = 8.1, 5.3, 5.3 Hz, CH2-C4), 0.42 
(1H, ddd, J = 8.1, 5.3, 5.3 Hz, CH2-C4); 13C (126 MHz, CDCl3): δ 177.5 (CO-C9), 171.7 
(CO-C1), 43.9 (CH2-C6), 41.6 (CH-C7), 39.9 (CH2-C2), 35.7 (CH-C10), 22.9 (CH3-C8), 
22.9 (CH3-C8), 19.8 (2 × CH3-C11), 18.0 (CH-C5/3), 13.5 (CH-C3/5), 10.2 (CH2-C4); 
HRMS (ESI+) for C13H24N2O2Na [M+Na]+ calcd 263.1730, found 263.1725. 
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 (S,R)-iPr-{Gly∆Gly}-NMe2 76 
 
The procedure applied to the synthesis of (±)-iPr-{Gly∆Gly}-NMe2 76 was followed using 
(1R,2S)-(Boc)2-Gly∆Gly}-NMe2 119 (90 mg, 0.25 mmol). After deprotection, 1.5 equiv. of 
Et3N and isobutyric anhydride were used. The residue was purified by silica gel column 
chromatography (CH2Cl2/MeOH 100:0 to 97:3) to afford the title compound (37 mg, 65% 
over 2 steps) as a colourless semi-solid.  
Rf (PE/EtOAc 1:1): 0.08; [𝛼],9C –57 (c = 0.50, CHCl3); νmax 3480, 3295, 2967, 2932, 1636, 
1535, 1265, 1238 cm−1; 1H NMR (500 MHz, CDCl3) δ 7.57 (1H, br s, NH), 3.92 (1H, ddd, 
J = 13.3, 6.3, 4.8 Hz, CH2-C6), 2.97 (3H, s, CH3-C7), 2.94 (3H, s, CH3-C7), 2.88 (1H, dd, J 
= 17.0, 4.0 Hz, CH2-C2), 2.46 (2H, h, J = 6.9 Hz, CH2-C9), 2.32 (1H, ddd, J = 13.3, 10.2, 
2.0 Hz, CH2-C6), 1.65 (1H, dd, J = 17.0, 10.3 Hz, CH2-C2), 1.18 (3H, d, J = 6.9 Hz, CH3-
C10), 1.17 (3H, d, J = 6.9 Hz, CH3-C10), 0.78 (1H, ddddd, J = 10.3, 8.6, 5.3, 5.1, 4.0 Hz, 
CH-C3), 0.63 (1H, ddddd, J = 10.2, 8.6, 5.3, 5.1, 4.8 Hz, CH-C5), 0.55 (1H, ddd, J = 8.3, 
5.1, 5.1 Hz, CH2-C4), 0.45 (1H, ddd, J = 8.3, 5.3, 5.3 Hz, CH2-C4); 13C (126 MHz, CDCl3): 
δ 177.6 (CO-C1), 172.9 (CO-C8), 44.5 (CH2-C6), 37.3 (CH2-C2), 36.9 (CH3-C7), 35.7 (CH-
C9), 35.5 (CH3-C7), 19.8 (2 × CH3-C10), 17.7 (CH-C5), 13.5 (CH-C3), 10.5 (CH2-C4); 
HRMS (ESI+) for C12H22N2O2Na [M+Na]+ calcd 249.1573, found 249.1575. 
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(R,S)-Boc2-{Gly∆Gly}-N-iPr 118 
 
The procedure applied to the synthesis of (±)-(Boc)2-{Gly∆Gly}-N-iPr 118 was followed 
using (R,S)-(Boc)2-{Gly∆Gly}-OH 107 (92 mg, 0.28 mmol). The crude was purified by 
silica gel column chromatography (PE/EtOAc 1:1) to give (S,R)-(Boc)2-{Gly∆Gly}-N-iPr 
118 (36 mg, 35%) as a colourless oil.  
Rf (PE/EtOAc 1:1): 0.35; [𝛼],6B –8.63 (c = 1.80, CHCl3); νmax 3294, 2971, 2929, 1732, 1693, 
1640, 1366, 1173, 1129, 853 cm−1; 1H NMR (400 MHz, CDCl3) δ 5.96 (1H, d, J = 8.1 Hz, 
NH), 4.17–4.04 (1H, m, CH-C7), 3.60 (1H, dd, J = 14.4, 6.0 Hz, CH2-C6), 3.50 (1H, dd, J 
= 14.4, 6.2 Hz, CH2-C6), 2.16 (1H, dd, J = 16.5, 6.7 Hz, CH2-C2), 2.04 (1H, dd, J = 16.5, 
7.2 Hz, CH2-C2), 1.48 (18H, s, 2 × t-Bu), 0.92 (3H, d, J = 6.5 Hz, CH3-C8), 0.92 (3H, d, J 
= 6.5 Hz, CH3-C8), 0.99–0.81 (2H, m, CH-C5 + CH-C3), 0.55 (1H, ddd, J = 8.4, 5.0, 5.0 
Hz, CH2-C4), 0.35 (1H, ddd, J = 8.4, 5.1, 5.1 Hz, CH2-C4); 13C (101 MHz, CDCl3): δ 171.2 
(CO-C1), 153.2 (2 × CO-Boc), 82.6 (C-Boc), 49.1 (CH2-C6), 41.3 (CH-C7), 41.0 (CH2-C2), 
28.2 (6 × CH3-Boc), 22.8 (CH3-C8), 22.8 (CH3-C8), 18.4 (CH-C5), 13.1 (CH-C3), 10.4 (CH2-
C4); HRMS (ESI+) for C19H34N2O5Na [M+Na]+ calcd 393.2360, found 393.2359. 
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 (R,S)-(Boc)2-{Gly∆Gly}-NMe2 119 
 
The procedure applied to the synthesis of (±)-(Boc)2-{Gly∆Gly}-NMe2 119 was followed 
using (R,S)-(Boc)2-{Gly∆Gly}-OH 107 (110 mg, 0.33 mmol). 2 equiv. of HNMe2 (2 м 
solution in THF) were used in this case. The residue was purified by silica gel column 
chromatography (PE/EtOAc 1:1) to give (S,R)-(Boc)2-{Gly∆Gly}-NMe2 119 (87 mg, 74%) 
as a yellow oil.   
Rf (PE/EtOAc 1:1): 0.27; [𝛼],9D –16 (c = 0.50, CHCl3); νmax 2981, 2943, 1736, 1692, 1646, 
1368, 1171, 1131, 853 cm−1; 1H NMR (500 MHz, CDCl3) δ 3.58 (1H, dd, J = 14.4, 7.1 Hz, 
CH2-C6), 3.46 (1H, dd, J = 14.4, 7.1 Hz, CH2-C6), 2.97 (3H, s, CH3-C7), 2.93 (3H, s, CH3-
C7), 2.44 (1H, dd, J = 15.3, 5.0 Hz, CH2-C2), 2.11 (1H, dd, J = 15.3, 7.6 Hz, CH2-C2), 1.50 
(18H, s, 2 × t-Bu), 1.09 (1H, ddddd, J = 7.6, 7.1, 5.0, 5.0, 5.0 Hz, CH-C3), 1.01 (1H, ddddd, 
J = 7.1, 7.1, 7.1, 5.0, 5.0 Hz, CH-C5), 0.62 (1H, ddd, J = 8.5, 5.0, 5.0 Hz, CH2-C4), 0.39 
(1H, ddd, J = 8.5, 5.0, 5.0 Hz, CH2-C4); 13C (126 MHz, CDCl3): δ 172.3 (CO-C1), 153.0 (2 
× CO-Boc), 82.3 (CH-Boc), 49.9 (CH2-C6), 37.9 (CH2-C2), 37.5 (CH3-C7), 35.4 (CH3-C7), 
28.2 (6 × CH3-Boc), 18.3 (CH-C5), 13.9 (CH-C3), 10.9 (CH2-C4); HRMS (ESI+) for 
C18H32N2O5Na [M+Na]+ calcd 379.2203, found 379.2200. 
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The procedure applied to the synthesis of (±)-iPrOC-{Gly∆Gly}-N-iPr 75 was followed 
using (R,S)-(Boc)2-{Gly∆Gly}-N-iPr 118 (70 mg, 0.19 mmol). After deprotection, 1.5 equiv. 
of Et3N and isobutyric anhydride were used. Trituration of the residue with cold Et2O in 
EtOAc yielded the title compound (15 mg, 31% over 2 steps) as a white solid.  
Rf (PE/EtOAc 1:1): 0.08; [𝛼],96 +48 (c = 0.30, CHCl3); m.p.: 134–135 °C; νmax (10 mM, 
CH2Cl2) 3429, 3325, 2974, 2932, 1663, 1516, 1277, 1265, 1258 cm−1; 1H NMR (500 MHz, 
CDCl3) δ 6.78 (1H, br s, NH-C6), 5.40 (1H, br s, NH-C7), 4.10 (1H, dq, J = 7.6, 6.5 Hz, 
CH-C7), 3.73 (1H, ddd, J = 13.5, 6.0, 4.7 Hz, CH2-C6), 2.60–2.48 (2H, m, CH2-C6 + CH2-
C2), 2.43 (1H, h, J = 6.9 Hz, CH-C10), 1.70 (1H, dd, J = 16.2, 9.4 Hz, CH2-C2), 1.18 (3H, 
d, J = 6.9 Hz, CH3-C11), 1.18 (3H, d, J = 6.9 Hz, CH3-C11), 1.17 (3H, d, J = 6.5 Hz, CH3-
C8), 1.16 (3H, d, J = 6.5 Hz, CH3-C8), 0.83–0.71 (2H, m, CH-C3 + CH-C5), 0.53 (1H, ddd, 
J = 8.1, 5.3, 5.3 Hz, CH2-C4), 0.42 (1H, ddd, J = 8.1, 5.3, 5.3 Hz, CH2-C4); 13C (126 MHz, 
CDCl3): δ 177.5 (CO-C9), 171.7 (CO-C1), 43.9 (CH2-C6), 41.6 (CH-C7), 39.9 (CH2-C2), 
35.7 (CH-C10), 23.0 (CH3-C8), 22.9 (CH3-C8), 19.8 (2 × CH3-C11), 18.0 (CH-C5/3), 13.5 
(CH-C3/5), 10.2 (CH2-C4); HRMS (ESI+) for C13H24N2O2Na [M+Na]+ calcd 263.1730, 
found 263.1726. 
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 (R,S)-iPr-{Gly∆Gly}-NMe2 76 
 
The procedure applied to the synthesis of (±)-iPr-{Gly∆Gly}-NMe2 76 was followed using 
(R,S)-(Boc)2-{Gly∆Gly}-NMe2 119 (122 mg, 0.34 mmol). After deprotection, 1.5 equiv. of 
Et3N and isobutyric anhydride were used. The residue was purified by silica gel column 
chromatography (CH2Cl2/MeOH 100:0 to 97:3) to afford the title compound (31 mg, 40 % 
over 2 steps) as a colourless semi-solid.  
Rf (PE/EtOAc 1:1): 0.08; [𝛼],9C +68 (c = 0.50, CHCl3); νmax (10 mM, CH2Cl2) 3287, 2967, 
2928, 1637, 1539, 1261, 1238 cm−1; 1H NMR (500 MHz, CDCl3) δ 7.57 (1H, br s, NH), 3.92 
(1H, ddd, J = 13.5, 6.4, 4.9 Hz, CH2-C6), 2.97 (3H, s, CH3-C7), 2.95 (3H, s, CH3-C7), 2.89 
(1H, dd, J = 17.0, 3.8 Hz, CH2-C2), 2.47 (1H, h, J = 7.0 Hz, CH-C9), 2.32 (1H, ddd, J = 
13.5, 10.0, 2.0 Hz, CH2-C6), 1.65 (1H, dd, J = 17.0, 10.5 Hz, CH2-C2), 1.18 (3H, d, J = 7.0 
Hz, CH3-C10), 1.18 (3H, d, J = 7.0 Hz, CH3-C10), 0.83–0.75 (1H, m, CH-C3), 0.63 (1H, 
ddddd, J = 10.0, 8.2, 4.9, 4.9, 4.9 Hz, CH-C5), 0.55 (1H, ddd, J = 8.3, 4.9, 4.9 Hz, CH2-C4), 
0.45 (1H, ddd, J = 8.3, 4.9, 4.9 Hz, 1H × CH2-C4); 13C (126 MHz, CDCl3): δ 177.6 (CO-
C1), 173.0 (CO-C8), 44.5 (CH2-C6), 37.3 (CH2-C2), 36.9 (CH3-C7), 35.7 (CH-C9), 35.5 
(CH3-C7), 19.8 (2 × CH3-C10), 17.7 (CH-C5), 13.5 (CH-C3), 10.5 (CH2-C4); HRMS (ESI+) 
for C12H22N2O2Na [M+Na]+ calcd 249.1573 found 249.1566.  
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Boc-Gly-NMe2 121  
 
Boc-Gly-OH (3.00 g, 17.1 mmol), HNMe2 (17.1 mL of a 2 м solution in THF, 34.2 mmol) 
and Et3N (8.30 mL, 70.0 mmol) were dissolved in CH2Cl2 (100 mL). The solution was stirred 
for 15 min at rt and T3P (8.90 mL, of a 50% solution in EtOAc, 30.0 mmol) was added 
dropwise at 0 °C. H2O (20 mL) was added and the phases were separated. The organic phase 
was washed with sat. aq. NaHCO3 (20 mL), 1 м aq. HCl (20 mL), and brine (15 mL). The 
organic phase was dried over MgSO4, filtered and concentrated under vacuum affording 
Boc-Gly-NMe2 121 (2.96 g, 86%) as a colourless solid.  
Rf (EtOAc/PE 1:1): 0.27; m.p.: 129–130 °C, nmax (CHCl3): 3418, 1974, 1713, 1645, 1167 
cm−1; 1H-NMR (500 MHz; CDCl3): δ 5.51 (1H, s, NH), 3.94 (2H, d, J = 4.3 Hz, CH2-C7), 
2.97 (3H, s, CH3-C9), 2.95 (3H, s, CH3-C9), 1.44 (9H, s, t-Bu); 13C NMR (126 MHz; 
CDCl3): δ 168.4 (CO-Boc), 156.0 (CO-C8), 79.7 (C-Boc), 42.4 (CH2-C7), 36.0 (CH3-C9), 
35.7 (3 ´ CH3-Boc), 28.5 (CH3-C9); HRMS (ESI+) for C9H18N2NaO3 [M+Na]+ calcd 
225.1210, found 225.1207. 
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Boc-Leu-NMe2 122 
 
To a solution of Boc-Leu-OH (1.55 g, 6.70 mmol) in CH2Cl2 (10 mL) was added DCC (1.66 
g, 8.04 mmol) portionwise at 0 °C, followed by HNMe2 (6.70 mL of a 2 м solution in THF, 
13.4 mmol). The mixture was heated to reflux and stirred for 8 h. The solid formed was 
filtered and washed with CH2Cl2, the filtrate was concentrated under vacuum. The resulting 
solid was purified by silica gel column chromatography (PE/EtOAc 1:1) to give Boc-Leu-
NMe2 122 (1.12 g, 65%) as a white solid.  
Rf (PE/EtOAc 1:1): 0.65; [𝛼],96 +30 (c = 1.0, CHCl3); m.p.: 54–55 °C; νmax 3314, 2969, 1712, 
1642, 1498, 1397, 1367, 1247, 1193 cm−1; 1H NMR (400 MHz, CDCl3) δ  5.25 (1H, d, J = 
9.5 Hz, NH), 4.64 (1H, ddd, J = 9.5, 9.5, 3.9 Hz, CH-C7), 3.07 (3H, s, CH3-C12), 2.94 (3H, 
s, CH3-C12), 1.80–1.65 (1H, m, CH-C9), 1.47 (1H, ddd, J = 13.9, 9.5, 4.4 Hz, CH2-C8), 
1.42 (9H, s t-Bu), 1.34 (1H, ddd, J = 13.9, 9.3, 3.9 Hz, CH2-C8), 0.99 (3H, d, J = 6.5 Hz, 
CH3-C10), 0.91 (3H, d, J = 6.7 Hz, CH3-C10); 13C (126 MHz, CDCl3): δ 173.1 (CO-C11), 
155.8 (CO-Boc), 79.5 (C-Boc), 48.8 (CH-C7), 42.9 (CH2-C8), 37.1 (CH3-C12), 35.9 (CH3-
C12), 28.5 (3 × CH3-Boc), 24.8 (CH-C9), 23.6 (CH3-C10), 21.9 (CH3-C10); HRMS (ESI+) 
for C13H26N2O3Na [M+Na]+ calcd 281.1836, found 281.1833. 
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 (±)-(Boc)2-{Gly∆Gly}-Gly-NMe2 123  
 
Boc-Gly-NMe2 121 (2.96 g, 14.6 mmol) was dissolved in CH2Cl2 (150 mL) and TFA (11.0 
mL, 146 mmol) was added dropwise at rt. The reaction mixture was stirred overnight at rt 
and then the solvent was removed under vacuum to give TFA·H-Gly-NMe2.  
(±)-(Boc)2-{Gly∆Gly}-OH 107 (2.87 g, 8.72 mmol), TFA·H-Gly-NMe2 (2.91 g, 14.6 mmol) 
and Et3N (4.30 mL, 30.5 mmol) were dissolved in CH2Cl2 (43 mL). The solution was stirred 
for 15 min at rt and T3P (50% in EtOAc, 7.80 mL, 13.1 mmol) was added 0 °C. The reaction 
mixture was stirred for 16 h at rt. The solution was washed with H2O (3 ´ 10 mL), sat. aq. 
NaHCO3 (3 ´ 10 mL) and brine (10 mL). The phases were separated, and the organic phase 
was dried over MgSO4, filtered and concentrated under vacuum. The residue was purified 
by silica gel column chromatography (PE/EtOAc 1:1) to give the title compound (3.26 mg, 
63%) as a colourless oil.  
Rf (EtOAc/PE 1:1): 0.22; nmax (CHCl3): 3312, 2978, 2933, 1690, 1644, 1366, 1125, 1030, 
853 cm−1; 1H-NMR (500 MHz; CDCl3): δ 6.90 (1H, t, J = 4.0 Hz, NH), 4.03 (2H, d, J = 4.0 
Hz, CH2-C7), 3.62 (1H, dd, J = 14.4, 6.0 Hz, CH2-C6), 3.45 (1H, dd, J = 14.4, 6.9 Hz, CH2-
C6), 2.98 (3H, s, CH3-C9), 2.97 (3H, s, CH3-C9), 2.37 (1H, dd, J = 16.0, 5.7 Hz, CH2-C2), 
2.01 (1H, dd, J = 16.0, 7.8 Hz, CH2-C2), 1.48 (18H, s, 2 ´ t-Bu), 1.07–0.97 (2H, m, CH-C3 
+ CH-C5), 0.68 (ddd, J = 8.0, 5.1, 5.1 Hz, CH2-C4), 0.42 (ddd, J = 8.0, 5.1, 5.1 Hz, CH2-
C4); 13C NMR (126 MHz; CDCl3): δ 172.2 (CO-C1), 168.1 (CO-C8), 152.9 (CO-Boc), 82.3 
(C-Boc), 49.5 (CH2-C6), 41.4 (CH2-C7), 40.6 (CH2-C2), 36.0 (CH3-C9), 35.7 (CH3-C9), 
28.2 (6 ´ CH3-Boc), 18.4 (CH-C5), 13.8 (CH-C3), 10.8 (CH2-C4); HRMS (ESI+) for 
C20H35N3NaO6 [M+Na]+ calcd 436.2418, found 436.2402. 
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 (±)-Ac-Gly-{Gly∆Gly}-Gly-NMe2 120  
 
(±)-(Boc)2-{Gly∆Gly}-Gly-NMe2 123 (2.26 g, 5.47 mmol) was dissolved in CH2Cl2 (55 
mL) and TFA (4.20 mL, 54.7 mmol) was added dropwise at rt. The reaction mixture was 
stirred overnight at rt and the solvent was then removed under vacuum. The resulting TFA 
salt was then used without further purification in the next coupling.  
TFA·(±)-H-{Gly∆Gly}-Gly-NMe2 (200 mg, 0.61 mmol), Et3N (300 μL, 2.14 mmol) and 
Ac-Gly-OH (143 mg, 1.22 mmol) were dissolved in CH2Cl2 (3.00 mL). The solution was 
stirred for 15 min at rt and T3P (550 μL of a 50% solution in EtOAc, 0.92 mmol) was added 
dropwise. The reaction mixture was heated to reflux and stirred overnight. The reaction 
mixture was then cooled and washed with H2O (3 × 5 mL). The organic phase was dried 
over MgSO4, filtered and concentrated under vacuum. The residue was triturated with cold 
PE in EtOAc to afford (±)-Ac-Gly-{Gly∆Gly}-Gly-NMe2 120 (100 mg, 52% over two steps) 
as a white solid.  
Rf (EtOAc/PE 1:1): 0.19; m.p.: 138–140 °C; nmax (20 mM in CHCl3): 3408, 3319, 1053, 
2984, 1659, 1651, 1514, 1271, 1263 cm−1; 1H-NMR (400 MHz; CDCl3): δ 7.68 (1H, s, NH-
C6), 6.75 (1H, s, NH-C7), 6.56 (1H, s, NH-C11), 4.10 (1H, dd, J = 17.4, 4.3 Hz, CH2-C7), 
4.04 (1H, dd, J = 17.4, 4.4 Hz, CH2-C7), 3.95 (2H, d, J = 4.8 Hz, CH2-C11), 3.93–3.86 (1H, 
m, CH2-C6), 3.03 (6H, s, 2 ´ CH3-C9), 2.79 (1H, dd, J = 16.6, 3.4 Hz, CH2-C2), 2.45 (1H, 
ddd, J = 13.7, 10.0, 3.2 Hz, CH2-C6), 2.03 (3H, s, CH3-C13), 1.68 (1H, dd, J = 16.6, 10.4 
Hz, CH2-C2), 0.86–0.78 (2H, m, CH-C5 + CH-C3), 0.56 (1H, ddd, J = 8.2, 5.3, 5.3 Hz, CH2-
C4), 0.47 (1H, ddd, J = 8.2, 5.4, 5.4 Hz, CH2-C4); 13C NMR (126 MHz; CDCl3): δ 172.6 
(CO-C1), 170.4 (CO-C12), 168.9 (CO-C10), 168.4 (CO-C8), 44.2 (CH2-C6), 42.9 (CH2-
C11), 41.3 (CH2-C7), 39.7 (CH2-C2), 36.2 (CH3-C9), 35.9 (CH3-C9), 23.2 (CH3-C13), 18.1 
(CH-C5), 14.0 (CH-C3), 10.4 (CH2-C4); HRMS (ESI+) for C14H24N4NaO4 [M+Na]+ calcd 
335.1690, found 335.1688. 
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(R,S)-Ac-Val-{Gly∆Gly}-NMe2 79 
 
(R,S)-(Boc)2-{Gly∆Gly}-NMe2 119 (87 mg, 0.24 mmol) was dissolved in CH2Cl2 (3 mL) 
and TFA (184 µL, 2.40 mmol) was added to the solution. The reaction mixture was stirred 
at rt for 8 h. The solvent was then removed, and the compound was used for the subsequent 
coupling without purification.  
To a solution of TFA·(R,S)-H-{Gly∆Gly}-NMe2 (0.24 mmol) in CH2Cl2 (1 mL), was added 
DIPEA (125 µL, 1.35 mmol) dropwise. Ac-Val-OH (38 mg, 0.24 mmol) was added, 
followed by HATU (91 mg, 0.24 mmol). The reaction mixture was stirred overnight at rt. 
The solution was washed with H2O (3 × 5 mL). The organic phase was dried over MgSO4 
and filtered. The solvent was removed under vacuum and the resulting brown oil was 
purified by silica gel column chromatography (CH2Cl2/MeOH 99:1 to 96:4) to afford (R,S)-
Ac-Val-{Gly∆Gly}-NMe2 79 (10 mg, 14%) as a white powder. 
Rf (CH2Cl2/MeOH 9:1):0.57; [𝛼],96 +41 (c = 0.13, CH2Cl2); m.p.: 123–125 °C; νmax (c = 10 
mM, CH2Cl2) 3410, 3306, 2963, 2932, 1678, 1659, 1632, 1551, 1513, 1269, 1261 cm−1; 1H 
NMR (500 MHz, CD2Cl2) δ 8.16 (1H, s, NH-Gly), 6.70 (1H, d, J = 9.2 Hz, NH-Val), 4.34 
(1H, dd, J = 9.2, 5.0 Hz, CHα -Val), 3.98 (1H, ddd, J = 13.4, 7.0, 4.4 Hz, CH2-C6), 2.97 
(3H, s, CH3-C7), 2.93 (3H, s, CH3-C7), 2.97–2.92 (1H, m, CH2-C2), 2.24–2.15 (2H, m, CH2-
C6 + CHβ -Val), 2.03 (3H, s, CH3-Ac), 1.63 (1H, dd, J = 17.5, 10.5 Hz, CH2-C2), 0.93 (3H, 
d, J = 6.9 Hz, CH3γ-Val), 0.86 (3H, d, J = 6.9 Hz, CH3γ-Val), 0.77–0.71 (1H, m, CH-C3), 
0.62–0.56 (2H, m, CH-C5 + CH2-C4), 0.52–0.47 (1H, m, CH2-C4); 13C (126 MHz, CD2Cl2): 
δ 173.6 (CO-C1), 171.5 (CO-Ac), 170.6 (CO-Val), 59.0 (CHα -Val), 44.6 (CH2-C6), 37.5 
(CH2-C2), 37.3 (CH3-C7), 35.9 (CH3-C7), 31.5 (CHβ -Val), 23.6 (CH3-Ac), 19.7 (CH3γ-
Val), 18.5 (CH3γ-Val), 17.8 (CH-C5), 13.6 (CH-C3), 10.8 (CH2-C4); HRMS (ESI+) for 
C15H27N3O3Na [M+Na]+  calcd 320.1945, found 320.1934. 
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(S,R)-Ac-Val-{Gly∆Gly}-NMe2 80 
 
The procedure applied to the synthesis of (R,S)-Ac-Val-{Gly∆Gly}-NMe2 79 was followed 
using (S,R)-(Boc)2-{Gly∆Gly}-NMe2 119 (161 mg, 0.45 mmol). After the work up, cold 
Et2O (5 mL) was added to the residue and a precipitate was formed. Et2O was filtered and 
this was repeated another time to give (S,R)-Ac-Val-{Gly∆Gly}-NMe2 80 (16 mg, 12%) as 
a white powder.  
Rf (CHCl3/MeOH 95:5): 0.69; [𝛼],96 −39 (c = 0.55, CHCl3); m.p.: 130–131 °C; νmax (c = 10 
mM, CH2Cl2) 3418, 3294, 2963, 2932, 1678, 1659, 1632, 1547, 1504, 1273, 1265, 1258 
cm−1; 1H NMR (500 MHz, CD2Cl2) δ 8.18 (1H, bs, NH-Gly), 6.51 (1H, d, J = 9.3 Hz, NH-
Val), 4.33 (1H, dd, J = 9.3, 5.3 Hz, CHα -Val), 3.80 (1H, dd, J = 13.1, 5.2, 5.2 Hz, CH2-C6), 
2.96 (3H, s, CH3-C7), 2.98–2.95 (1H, m, CH2-C2), 2.93 (3H, s, CH3-C7), 2.32 (1H, ddd, J 
= 13.1, 10.6, 2.1 Hz, CH2-C6), 2.17–2.09 (1H, m, CHβ -Val), 2.02 (3H, s, CH3-Ac), 1.63 
(1H, dd, J = 17.3, 11.2 Hz, CH2-C2), 0.93 (3H, d, J = 6.9 Hz, CH3γ-Val), 0.88 (3H, d, J = 
6.9 Hz, CH3γ-Val), 0.74–0.68 (1H, m, CH-C3), 0.68–0.63 (1H, m, CH-C5), 0.58 (1H, ddd, 
J = 8.3, 5.1, 5.1 Hz, CH2-C4), 0.50 (1H, ddd, J = 8.3, 5.2, 5.2 Hz, CH2-C4); 13C (126 MHz, 
CD2Cl2): δ 173.5 (CO-C1), 171.6 (CO-Ac), 170.4 (CO-Val), 58.9 (CHα -Val), 45.0 (CH2-
C6), 37.5 (CH2-C2), 37.3 (CH3-C7), 35.9 (CH3-C7), 31.9 (CHβ -Val), 23.7 (CH3-Ac), 19.6 
(CH3γ-Val), 17.9 (CH3γ-Val), 17.6 (CH-C5), 13.8 (CH-C3), 11.1 (CH2-C4); HRMS (ESI+) 
for C15H27N3O3Na [M+Na]+ calcd 320.1945, found 320.1933. 
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(S,R)-(Boc)2-{Gly∆Gly}-Leu-NMe2 124 
 
Boc-Leu-NMe2 122 (1.12 g, 4.34 mmol) was dissolved in CH2Cl2 (44 mL) and TFA (1.7 
mL, 21.7 mmol) was added at rt. The reaction mixture was stirred for 8 h at this temperature. 
The solvent was removed under vacuum and the residue was used in the next step without 
further purification.  
TFA·NH2-Leu-NMe2 (130 mg, 0.39 mmol) was dissolved in CH2Cl2 (1.3 mL), DIPEA (203 
µL, 1.17 mmol) was added followed by (S,R)-(Boc)2-{Gly∆Gly}-OH 107 (106 mg, 0.39 
mmol). The mixture was stirred for 15 min and HATU (148 mg, 0.39 mmol) was added. The 
reaction mixture was stirred overnight at rt and H2O (10 mL) was added. The phases were 
separated and the organic phase was washed with sat. aq. NaHCO3 (10 mL), brine (10 mL), 
dried over MgSO4 and filtered. The solvent was removed under vacuum and the residue was 
purified by silica gel column chromatography (PE/EtOAc 1:1) to afford (S,R)-(Boc)2-
{Gly∆Gly}-Leu-NMe2 124 (131 mg, 72%) as a yellow oil.  
Rf (PE/EtOAc 1:1): 0.35; [𝛼],99 +15 (c = 0.25, CHCl3); νmax 3287, 2926, 1711, 1634, 1506, 
1366, 1248, 1173 cm−1; 1H NMR (400 MHz, CDCl3) δ 6.52 (1H, d, J = 8.6 Hz, NH-Leu), 
5.01 (1H, ddd, J = 12.8, 8.6, 4.0 Hz, CHα-Leu), 3.66 (1H, dd, J = 14.4, 5.7 Hz, CH2-C6), 
3.47 (1H, dd, J = 14.4, 6.9 Hz, CH2-C6), 3.09 (3H, s, CH3-C7), 2.94 (3H, s, CH3-C7), 2.34 
(1H, dd, J = 15.9, 5.7 Hz, CH2-C2),1.98 (1H, dd, J = 15.9, 7.7 Hz, CH2-C2),  1.70–1.60 (1H, 
m, CHγ-Leu), 1.49 (18H, s, 2 × t-Bu), 1.45–1.36 (2H, m, CH2β-Leu), 1.02–0.95 (2H, CH-
C3 + CH-C5), 0.99 (3H, d, J = 6.5 Hz, CH3δ-Leu), 0.91 (3H, d, J = 6.8 Hz, CH3δ-Leu),  0.65 
(1H, ddd, J = 7.8, 5.1, 5.1 Hz, CH2-C4), 0.40 (1H, ddd, J = 7.8, 5.1, 5.1 Hz, CH2-C4); 13C 
(126 MHz, CDCl3): δ 172.6 (CO-C1), 171.6 (CO-Leu), 152.87 (2 × CO-Boc), 82.3 (2 × C-
Boc), 49.2 (CH2-C6), 47.3 (CHα-Leu), 42.2 (CH2β-Leu), 40.6 (CH2-C2), 37.0 (CH3-C7), 
35.7 (CH3-C7), 28.1 (6 × CH3-Boc), 24.7 (CHγ-Leu), 23.4 (CH3δ-Leu), 21.8 (CH3δ-Leu), 
18.3 (CH-C5), 13.4 (CH-C3), 10.5 (CH2-C4); HRMS (ESI+) for C24H43N3O6Na [M+Na]+ 
calcd 492.3044, found 492.3028.   
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(S,R)-Ac-Val-{Gly∆Gly}-Leu-NMe2 78 
 
(R,S)-(Boc)2-{Gly∆Gly}-Leu-NMe2 124 (310 mg, 0.66 mmol) was dissolved in CH2Cl2 (3 
mL) and TFA (505 µL, 6.60 mmol) was added to the solution. The reaction mixture was 
stirred at rt for 8 h. The solvent was then removed, and the product was used for the coupling 
reaction without purification.  
To a solution of TFA·(1R,2S)-H-{Gly∆Gly}-Leu-NMe2 (0.66 mmol) in CH2Cl2 (3 mL) was 
added DIPEA (345 µL, 1.98 mmol) dropwise. Ac-Val-OH (105 mg, 0.66 mmol) was added 
followed by HATU (251 mg, 0.66 mmol). The reaction mixture was stirred overnight at rt. 
The solution was washed with H2O (3 × 10 mL) and phases were separated. The organic 
phase was dried over MgSO4 and filtered. The solvent were removed under vacuum and the 
resulting brown oil was purified by silica gel column chromatography (CH2Cl2/MeOH 99:1 
to 90:10) to afford (S,R)-Ac-Val-{Gly∆Gly}-Leu-NMe2 78 (130 mg, 76% over two steps) 
as a white powder. 
Rf (CH2Cl2/MeOH 9:1): 0.95; [𝛼],96 −17 (c = 0.55, CHCl3); m.p.: 155–156 °C; νmax (c = 10 
mM, CH2Cl2) 3422, 3306, 2963, 2874, 1659, 1639, 1508, 1278, 1269 cm−1; 1H NMR (600 
MHz, CD2Cl2) δ 7.74 (1H, bs, NH-Gly), 6.63 (1H, d, J = 8.6 Hz, NH-Leu), 6.43 (1H, d, J = 
8.8 Hz, NH-Val), 5.01 (1H, ddd, J = 10.6, 8.6, 3.7 Hz, CHα-Leu), 4.31 (1H, dd, J = 8.8, 6.4 
Hz, CHα-Val), 3.65 (1H, ddd, J = 13.8, 4.2, 4.2 Hz, CH2-C6), 3.11 (3H, s, CH3-C7), 2.96 
(3H, s, CH3-C7), 2.74 (1H, dd, J = 17.0, 3.8 Hz, CH2-C2), 2.57 (1H, ddd, J = 13.8, 10.2, 4.2 
Hz, CH2-C6), 2.12–2.00 (1H, m, CHβ -Val), 1.97 (3H, s, CH3-Ac), 1.70–1.60 (2H, m, CHγ-
Leu + CH2-C2), 1.54 (1H, ddd, J = 14.1, 10.6, 4.3 Hz, CH2β -Leu), 1.41 (1H, ddd, J = 14.1, 
9.5, 3.7 Hz, 1H × CH2β -Leu), 0.99 (3H, d, J = 6.5 Hz, CH3δ-Leu), 0.93 (3H, d, J = 6.2 Hz, 
CH3γ-Val), 0.92 (3H, d, J = 6.2 Hz, CH3δ-Leu), 0.89 (3H, d, J = 6.9 Hz, CH3γ-Val), 0.82–
0.73 (2H, m, CH-C3 + CH-C5), 0.54 (1H, ddd, J = 10.2, 5.4, 5.4 Hz, CH2-C4), 0.46 (1H, 
ddd, J = 10.2, 5.4, 5.4 Hz, CH2-C4); 13C (151 MHz, CD2Cl2): δ 174.1 (CO-C1), 173.3 (CO-
Ac), 172.5 (CO-Leu), 171.9 (CO-Val), 58.7 (CHα-Val), 48.0 (CHα-Leu), 44.4 (CH2-C6), 
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42.3 (CH2β -Leu), 40.2 (CH2-C2), 37.5 (CH3-C7), 36.2 (CH3-C7), 32.0 (CHβ -Val), 25.3 
(CHγ-Leu), 23.7 (CH3-Ac), 23.6 (CH3δ-Leu), 22.0 (CH3δ-Leu), 19.6 (CH3γ-Val), 18.5 
(CH3γ-Val), 18.4 (CH-C5), 14.0 (CH-C3), 11.2 (CH2-C4); HRMS (ESI+) for C21H38N4O4Na 
[M+Na]+ calcd 433.2785, found 433.2782.   
  
  213 
(R,S)-(Boc)2-{Gly∆Gly}-Leu-NMe2 124 
 
Boc-Leu-NMe2 122 (1.12g, 4.34 mmol) was dissolved in CH2Cl2 (44 mL) and TFA (1.7 mL, 
21.7 mmol) was added at rt. The reaction mixture was stirred for 8 h at this temperature. The 
solvent was removed under vacuum and the residue was used in the next step without further 
purification. 
(R,S)-(Boc)2-{Gly∆Gly}-OH 107 (90 mg, 0.33 mmol) was dissolved in CH2Cl2 (1 mL). 
DIPEA (200 µL, 0.99 mmol) was added followed by TFA·H-Leu-NMe2 (110 mg, 0.33 
mmol). The mixture was stirred for 15 min and HATU (125 mg, 0.33 mmol) was added. The 
reaction mixture was stirred overnight at rt. H2O (10 mL) was added and the phases were 
separated. The organic phase was washed with sat. aq. NaHCO3 (10 mL), brine (10 mL), 
dried over MgSO4 and filtered. The solvent was removed under vacuum and the residue was 
purified by silica gel column chromatography (PE/EtOAc 1:1) to afford (S,R)-(Boc)2-
{Gly∆Gly}-Leu-NMe2 124 (131 mg, 85%) as a yellow oil.  
Rf (PE/EtOAc 1:1): 0.20; [𝛼],9D −13 (c = 0.50, CHCl3); νmax 3304, 2930, 1711, 1634, 1508, 
1366, 1248, 1173 cm−1; 1H NMR (500 MHz, CDCl3) δ  6.52 (1H, d, J = 8.6 Hz, NH), 5.02 
(1H, ddd, J = 9.5, 8.6, 3.9 Hz, CHα-Leu), 3.65 (1H, dd, J = 14.3, 5.8 Hz, CH2-C6), 3.45 (1H, 
dd, J = 14.3, 7.1 Hz, CH2-C6), 3.09 (3H, s, CH3-C7), 2.95 (3H, s, CH3-C7), 2.41 (1H, dd, J 
= 16.0, 5.3 Hz, CH2-C2), 1.92 (dd, J = 16.0, 8.0 Hz, 1H, CH2-C2), 1.71–1.61 (1H, m, CHγ-
Leu), 1.51 (18H, s, 2 × t-Bu), 1.46–1.40 (2H, m, CH2β-Leu), 1.04−0.98 (2H, m, CH-C5 + 
CH-C3), 1.00 (3H, d, J = 6.5 Hz, CH3δ-Leu), 0.92 (3H, d, J = 6.6 Hz, CH3δ-Leu), 0.70 (1H, 
ddd, J = 8.0, 5.1, 5.1 Hz, CH2-C4), 0.43 (ddd, J = 8.0, 5.2, 5.2 Hz, CH2-C4); 13C (126 MHz, 
CDCl3): δ 172.7 (CO-C1), 171.7 (CO-Leu), 153.0 (2 × CO-Boc), 82.4 (2 × C-Boc), 49.5 
(CH2-C6), 47.3 (CHα-Leu), 42.8 (CH2β-Leu), 40.8 (CH2-C2), 37.2 (CH3-C12), 35.9 (CH3-
C12), 28.2 (6 × CH3-Boc), 24.9 (CHγ-Leu), 23.6 (CH3δ-Leu), 22.1 (CH3δ-Leu), 18.4 (CH-
C5), 13.7 (CH-C3), 10.8 (CH2-C4); HRMS (ESI+) for C24H43N3O6Na [M+Na]+ calcd 
492.3044, found 492.3026.   
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 (R,S)-Ac-Val-{Gly∆Gly}-Leu-NMe2 77 
 
The procedure applied to the synthesis of (S,R)-Ac-Val-{Gly∆Gly}-Leu-NMe2 78 was 
followed using (R,S)-(Boc)2-{Gly∆Gly}-Leu-NMe2 124. The crude product was purified by 
silica gel column chromatography (CH2Cl2/MeOH 99:1 to 94:6) to afford (R,S)-Ac-Val-
{Gly∆Gly}-Leu-NMe2 77 (20 mg, 17%) as a white powder. 
Rf (CH2Cl2/MeOH 9:1): 0. 90; [𝛼],96 +47 (c = 0.90, CH2Cl2); m.p.: 95–97 °C; νmax (c = 10 
mM, CH2Cl2) 3418, 3302, 3051, 2963, 1659, 1643, 1512, 1504, 1269, 1261, 1254 cm−1; 1H 
NMR (500 MHz, CDCl3) δ 7.82 (1H, d, J = 6.7 Hz, NH-Gly), 6.44 (1H, d, J = 8.6 Hz, NH-
Leu), 6.37 (1H, d, J = 8.7 Hz, NH-Val), 5.03 (1H, ddd, J = 10.5, 8.6, 3.6 Hz, CHα-Leu), 
4.42 (1H, dd, J = 8.7, 6.0 Hz, CHα-Val), 3.97 (1H, ddd, J = 13.8, 6.7, 4.3 Hz, CH2-C6), 3.13 
(3H, s, CH3-C7), 2.98 (3H, s, CH3-C7), 2.69 (1H, dd, J = 16.3, 3.6 Hz, CH2-C2), 2.35 (1H, 
ddd, J = 13.8, 9.8, 2.7 Hz, CH2-C6), 2.14–2.02 (1H, m, CHβ -Val), 2.01 (3H, s, CH3-Ac), 
1.75–1.69 (2H, m, CHγ-Leu + CH2-C2), 1.53–1.42 (2H, m, CH2β -Leu), 1.02 (3H, d, J = 6.6 
Hz, CH3δ-Leu), 0.94 (3H, d, J = 6.8 Hz, CH3γ-Val), 0.92 (3H, d, J = 6.6 Hz, CH3δ-Leu), 
0.90 (3H, d, J = 6.8 Hz, CH3γ-Val), 0.85–0.74 (2H, m, CH-C3 + CH-C5), 0.54 (1H, ddd, J 
= 8.3, 5.2, 5.2 Hz, CH2-C4), 0.46 (1H, ddd, J = 8.3, 5.4, 5.4 Hz, CH2-C4); 13C (126 MHz, 
CD2Cl2): δ 172.9 (CO-C1), 172.4 (CO-Ac), 171.4 (CO-Leu), 169.8 (CO-Val), 58.1 (CHα-
Val), 47.6 (CHα-Leu), 44.0 (CH2-C6), 42.4 (CH2β -Leu), 39.7 (CH2-C2), 37.2 (CH3-C7), 
36.0 (CH3-C7), 32.0 (CHβ -Val), 24.9 (CHγ-Leu), 23.6 (CH3-Ac), 23.6 (CH3δ-Leu), 21.8 
(CH3δ-Leu), 19.3 (CH3γ-Val), 18.5 (CH3γ-Val), 18.3 (CH-C5), 14.2 (CH-C3), 10.2 (CH2-
C4); HRMS (ESI+) for C21H38N4O4Na [M+Na]+ calcd 433.2785, found 433.2768. 
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(1R*,2S*)-(2-Ethenylcyclopropyl)methyl isobutyrate 125  
 
To a cooled solution of DMAP (24.0 mg, 200 μmol) in pyridine (5.00 mL) a 0 °C, was added 
(±)-90 (1.00 g, 10.2 mmol). Isobutyric anhydride (3.40 mL, 20.4 mmol) was added dropwise 
to the solution and the reaction mixture was stirred for 48 h at rt. H2O (15 mL) was added 
and the resulting aqueous solution was extracted with Et2O (3 ´ 15 mL). The combined 
organic extracts were washed with sat. aq. NH4Cl (10 mL), H2O (10 mL) and brine (10 mL), 
dried over MgSO4, filtered and concentrated under vacuum. The residue was purified by 
silica gel column chromatography (PE/EtOAc 20:1) to afford the title compound (819 mg, 
48%) as a colourless liquid.  
Rf (EtOAc/PE 1:1): 0.46; nmax (CHCl3): 2972, 2362, 1732,  1190, 1152, 897 cm−1;  1H NMR 
(500 MHz; CDCl3): δ 5.39 (1H, ddd, J = 17.0, 10.3, 8.5 Hz, CH-C2), 5.05 (1H, dd, J = 17.0, 
1.5 Hz, CH2-C1), 4.87 (1H, dd, J = 10.3, 1.5 Hz, CH2-C1), 3.97 (1H, dd, J = 11.3, 6.9 Hz, 
CH2-C6), 3.94 (1H, dd, J = 11.3, 6.9 Hz, CH2-C6),  2.54 (1H, p, J = 7.0 Hz, CH-C8), 1.45–
1.34 (1H, m, CH-C3), 1.22–1.17 (1H, m, CH-C5), 1.16 (6H, d, J = 7.0 Hz, 2 ´ CH3-C9), 
0.72 (1H, ddd, J = 8.5, 5.3, 5.3 Hz, CH2-C4), 0.67 (1H, ddd, J = 8.5, 5.1, 5.1 Hz, CH2-C4); 
13C NMR (126 MHz; CDCl3): δ 177.4 (CO-C7), 140.3 (CH-C2), 112.8 (CH2-C1), 67.5 
(CH2-C6), 34.2 (CH-C8), 20.9 (CH-C3), 19.4 (CH-C5), 19.1 (2 ´ CH3-C9), 12.0 (CH2-C4); 
HRMS (ESI+) for C10H16NaO2 [M+Na]+ calcd 191.1043, found 191.1043. 
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[(1R*,2S*)-2-(2-Hydroxyethyl)cyclopropyl]methyl isobutyrate 126  
 
A flask equipped with an argon inlet was charged with BH3×THF (10.0 mL of a 1 м solution 
in THF, 10.0 mL, 9.74 mmol). A solution of (±)-125 (819 mg, 4.87 mmol) in THF (18 mL) 
was added dropwise at 0 °C. The reaction mixture was stirred for 4 h at this temperature. 
H2O (9 mL) was then added carefully followed by pH 7 phosphate buffer solution (9 mL). 
Sodium perborate (2.20 g, 14.6 mmol) was added and the reaction mixture was stirred for a 
further 2 h. The excess of sodium perborate was removed by filtration and the solvent was 
removed under vaccum. The aqueous phase was extracted with Et2O (3 × 20 mL). The 
combined organic extracts were washed with brine (20 mL), dried over MgSO4, filtered and 
concentrated under vacuum. The residue was purified by silica gel column chromatography 
(PE/EtOAc 1:1) to give the corresponding alcohol (83 mg, 9%) as a yellow oil. 
Rf (EtOAc/PE 1:1): 0.58; nmax (CHCl3): 3422, 2931, 1732, 1471, 1192, 1155, 1072, 1044 
cm−1.  1H NMR (500 MHz; CDCl3): δ 4.09 (1H, dd, J = 11.4, 6.2 Hz, CH2-C6), 3.75 (1H, 
dd, J = 11.4, 8.3 Hz, CH2-C6), 3.69 (2H, ddd, J = 6.8, 6.1, 2.4 Hz, CH2-C1), 2.55 (1H, hept, 
J = 7.0 Hz, CH-C8), 1.65 (1H, dddd, J = 13.5, 12.8, 6.1, 6.1 Hz, CH2-C2), 1.36 (1H, dddd, 
J = 14.3, 12.8, 6.8, 6.8 Hz, CH2-C2), 1.17 (3H, d, J = 7.0 Hz, CH3-C9), 1.17 (3H, d, J = 7.0 
Hz, CH3-C9), 1.00–0.87 (1H, m, CH-C5), 0.80–0.69 (1H, m, CH-C3), 0.49 (1H, ddd, J = 
8.5, 4.9, 4.9 Hz, CH2-C4), 0.42 (1H, ddd, J = 8.5, 5.1, 5.1 Hz, CH2-C4) ; 13C NMR (126 
MHz; CDCl3): δ 177.5 (CO-C7), 68.6 (CH2-C6), 63.0 (CH2-C1), 36.4 (CH2-C2), 34.2 (CH-
C8), 19.2 (2 ´ CH3-C9), 17.1 (CH-C5), 14.7 (CH-C3), 9.7 (CH2-C4); HRMS (ESI+) for 
C10H18NaO3 [M+Na]+ calcd 209.1148, found 209.1150. 
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(±)-iPrCOO-{Gly∆Gly}-OH 
 
The procedure applied to the synthesis of (±)-107 was followed using (±)-2-(2-
hydroxyethyl)cyclopropyl]methyl isobutyrate 126 (83 mg, 0.45 mmol). The title compound 
(95 mg) was obtained as a black oil and used as crude for the next step. 
Rf (EtOAc/PE 1:1): 0.38; 1H NMR (500 MHz; CDCl3): δ 3.97 (1H, dd, J = 11.5, 6.7 Hz, 
CH2-C6), 3.92 (1H, dd, J = 11.6, 7.0 Hz, CH2-C6), 2.54 (1H, hept, J = 7.0 Hz, CH-C8), 2.30 
(2H, dd, J = 14.0, 6.9 Hz, CH2-C2), 1.16 (3H, d, J = 7.1 Hz, CH3-C9), 1.16 (3H, d, J = 7.1 
Hz, CH3-C9), 1.09–1.00 (2H, m, CH-C3 + CH-C5), 0.60 (1H, ddd, J = 8.3, 5.3, 5.3 Hz, CH2-
C4), 0.50 (1H, ddd, J = 8.3, 5.3, 5.3 Hz, CH2-C4); 13C NMR (126 MHz; CDCl3): δ 178.3 
(CO-C1), 177.4 (CO-C7), 67.6 (CH2-C6), 38.1 (CH2-C2), 34.2 (CH-C8), 19.1 (CH3-C9), 
19.1 (CH3-C9), 17.4 (CH-C5), 12.9 (CH-C3), 10.2 (CH2-C4); HRMS (ESI+) for C10H16NaO4 
[M+Na]+ calcd 223.0941, found 223.0944. 
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(±)-iPrCOO-{Gly∆Gly}-iPr 127  
 
The procedure applied to the synthesis of (±)-118 was applied using (±)-126 (95 mg, 0.47 
mmol). The title compound was obtained as a white solid (55 mg, 51% over 2 steps) after 
the work up.  
Rf (EtOAc/PE 1:1): 0.41; m.p.: > 400 °C; nmax (10 mМ in CH2Cl2): 3429, 3059, 2970, 2928, 
2870, 1724, 1663, 1512, 1466, 1270, 1161, 1157 cm−1; 1H NMR (500 MHz; CDCl3): δ 5.71 
(1H, bs, NH), 4.14–4.10 (1H, m, CH-C10), 4.08 (1H, dd, J = 11.6, 6.4 Hz, CH2-C6), 3.81 
(1H, dd, J = 11.6, 7.6 Hz, CH2-C6), 2.55 (1H, hept, J = 7.0 Hz, CH-C8), 2.18 (1H, dd, J = 
16.1, 6.9 Hz, CH2-C2), 2.11 (1H, dd, J = 16.1, 7.3 Hz, CH2-C2), 1.18–1.13 (12H, m, 2 ´ 
CH3-C9 + 2 ´ CH3-C11), 1.05–0.90 (2H, m, CH-C5 + CH-C3), 0.59 (1H, ddd, J = 8.4, 5.0, 
5.0 Hz, CH2-C4), 0.48 (1H, ddd, J = 8.4, 5.1, 5.1 Hz, CH2-C4); 13C NMR (126 MHz; CDCl3): 
δ 177.4 (CO-C1), 170.9 (CO-C7), 67.8 (CH2-C6), 41.4 (CH-C10), 40.7 (CH2-C2), 34.1 (CH-
C8), 22.9 (2 ´ CH3-C9), 19.2 (2 ´ CH3-C11), 17.5 (CH-C5), 13.6 (CH-C3), 10.2 (CH2-C4); 
HRMS (ESI+) for C13H23NNaO3 [M+Na]+ calcd 264.1570, found 264.1572. 
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(±)-(Boc)2-{Gly∆Gly}-O-iPr 128  
 
(±)-(Boc)2-{Gly∆Gly}-OH 107 (90 mg, 0.27 mmol) was dissolved in CH2Cl2 (1.4 mL). 
DCC (62 mg, 0.30 mmol) and i-PrOH (23 μL, 0.30 mmol) were added to the solution. The 
reaction mixture was stirred overnight at rt. The solvent was removed under vacuum. The 
residue was purified by silica gel column chromatography (PE/EtOAc 1:1) to afford the title 
compound as a mixture 0.3:1 NHBoc/N(Boc)2 (87 mg). Only the major compound is 
reported. 
Rf (EtOAc/PE 1:1): 0.41; 1H NMR (500 MHz; CDCl3): δ 5.05 (1H, hept, J = 6.4 Hz, CH-
C7), 3.37–3.28 (1H, m, CH2-C6), 2.71 (1H, ddd, J = 13.0, 8.4, 4.0 Hz, CH2-C6), 2.48–2.44 
(1H, m, CH2-C2), 1.96 (1H, dd, J = 16.8, 9.0 Hz, CH2-C2), 1.44 (18H, s, 2 ´ t-Bu), 1.03 
(3H, d, J = 6.3 Hz, CH3-C8), 1.03 (3H, d, J = 6.3 Hz, CH3-C8), 0.88–0.82 (1H, m, CH-C3), 
0.81–0.75 (1H, m, CH-C5), 0.48 (1H, ddd, J = 8.6, 5.2, 5.2 Hz, CH2-C4), 0.40 (1H, ddd, J 
= 8.6, 5.2, 5.2 Hz, CH2-C4); 13C NMR (126 MHz; CDCl3): δ 172.7 (CO-C1), 152.9 (2 ´  CO-
Boc), 82.3 (2 ´ C-Boc), 68.0 (CH-C7), 45.0 (CH2-C6), 38.7 (CH2-C2), 28.6 (6 ´ CH3-Boc), 
22.0 (2 ´ CH3-C8), 18.3 (CH-C5), 13.3 (CH-C3), 10.2 (CH2-C4); HRMS (ESI+) for 
C19H33N2NaO6 [M+Na]+ calcd 394.2200, found 394.2186. 
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(±)-iPr-{Gly∆Gly}-OiPr 129  
 
(±)- (Boc)2-{Gly∆Gly}-OiPr 128 (88 mg, 0.24 mmol) was dissolved in CH2Cl2 (2.4 mL) and 
TFA (200 μL, 2.40 mmol) was added dropwise. The reaction mixture was stirred for 3 h and 
the solvent was removed under vacuum. The residue was taken up in CH2Cl2 (0.34 mL) and 
Et3N (50 μL, 0.36 mmol) was added followed by isobutyric anhydride (60 μL, 0.36 mmol) 
at rt. The mixture was stirred overnight at rt andH2O (5 mL) was added. The phases were 
separated and the organic phase was washed with sat. aq. NaHCO3 (5 mL), 1 м aq. HCl (5 
mL), brine (5 mL), dried over MgSO4 and concentrated under reduced pressure. The residue 
was purified by silica gel column chromatography (Et2O/PE 9:1 to 7:3) to give the title 
compound (29 mg, 65% over 3 steps) as a colourless solid.  
Rf (Et2O/PE 1:1): 0.63; m.p.: 103–104 °C; nmax (10 mМ in CH2Cl2): 3437, 3356, 3048, 2982, 
2928, 2866, 1713, 1666, 1516, 1192, 1107 cm−1; 1H NMR (500 MHz; CDCl3): δ 6.56 (1H, 
bs, NH), 5.03 (1H, hept, J = 6.6 Hz, CH-C7), 3.72 (1H, ddd, J = 13.6, 5.7, 5.7 Hz, CH2-C6), 
2.67 (1H, dd, J = 17.3, 4.6 Hz, CH2-C2), 2.51 (1H, ddd, J = 13.6, 9.6, 2.9 Hz, CH2-C6), 2.41 
(1H, hept, J = 7.0 Hz, CH-C10), 1.79 (1H, dd, J = 17.3, 9.9 Hz, CH2-C2), 1.24 (3H, d, J = 
6.6 Hz, CH3-C8), 1.24 (3H, d, J = 6.6 Hz, CH3-C8), 1.17 (3H, d, J = 7.0 Hz, CH3-11), 1.17 
(3H, d, J = 7.0 Hz, CH3-11), 0.82–0.76 (1H, m, CH-C3), 0.76–0.69 (1H, m, CH-C5), 0.53 
(1H, ddd, J = 8.5, 5.2 Hz, CH2-C4), 0.44 (1H, ddd, J = 8.5, 5.2 Hz, CH2-C4); 13C NMR (126 
MHz; CDCl3): δ 177.2 (CO-C9), 173.5 (CO-C1), 68.1 (CH-C7), 44.1 (CH2-C6), 38.2 (CH2-
C2), 35.8 (CH-C10), 22.0 (2 ´ CH3-C8), 19.8 (2 ´ CH3-C11), 17.8 (CH-C5), 13.2 (CH-C3), 
10.4 (CH2-C4); HRMS (ESI+) for C13H23NNaO3 [M+Na]+ calcd 264.1570, found 264.1563. 
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Boc-Phe-Leu-OMe 135   
 
To a solution of Boc-Phe-OH (1.00 g, 3.77 mmol) in CH2Cl2 (13 mL) was added HCl·H-
Leu-OMe (685 mg, 3.77 mmol) followed by DIPEA (1.97 mL, 3.77 mmol). The solution 
was stirred for 10 min and HATU (1.40 g, 3.77 mmol) was added. The reaction mixture was 
stirred for 6 h at rt. H2O (30 mL) was added and the phases were separated. The organic 
phase was dried over MgSO4 and filtered. The solvents were removed under vacuum and 
the resulting brown oil was purified by silica gel column chromatography (PE/EtOAc 1:1) 
to yield Boc-Phe-Leu-OMe 135 (1.30 g, 88%) as a white powder.  
Rf (PE/EtOAc 1:1): 0.88; [𝛼],99 –28 (c = 1.0, MeOH); m.p.: 109–110 °C;  νmax 3287, 2957, 
1748, 1682, 1645, 1535, 1366, 1250, 1171 cm−1; 1H NMR (500 MHz, CDCl3) δ 7.36–7.20 
(5H, m, 5 × CH-Ph), 6.23 (1H, d, J = 8.3 Hz, NH-Leu), 5.01 (1H, s, NH-Phe), 4.59 (1H, ddd, 
J = 8.6, 8.3, 4.8 Hz, CHα-Leu), 4.36 (d, J = 5.6 Hz, CHα-Phe), 3.72 (3H, s, OCH3), 3.12 
(1H, dd, J = 13.7, 6.6 Hz, CH2β-Phe), 3.08 (1H, dd, J = 13.7, 5.6 Hz, CH2β-Phe), 1.65–1.52 
(2H, m, CHγ-Leu + CH2β-Leu), 1.54–1.44 (1H, m, CH2β-Leu), 1.44 (9H, s, t-Bu), 0.93 (3H, 
d, J = 6.2 Hz, CH3δ-Leu), 0.91 (3H, d, J = 6.3 Hz, CH3δ-Leu); 13C (126 MHz, CDCl3): δ 
172.3 (CO-Phe), 171.0 (CO-Boc), 169.7 (CO-Leu), 129.5 (2 × CH-Ph), 128.8 (2 × CH-Ph), 
126. 48 (CH-Ph), 110.0 (C-Ph), 79.5 (C-Boc), 53.4 (CHα-Phe), 52.4 (OCH3), 50.9 (CHα-
Leu), 41.8 (CH2β-Leu), 39.2 (CH2β-Phe), 28.4 (3 × CH3-Boc), 24.8 (CHγ-Leu), 22.9 (CH3δ-
Leu), 22.0 (CH3δ-Leu); HRMS (ESI+) for C21H32N2NaO5 [M+Na]+ calcd 415.2203, found 
415.2197. 
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(S,R)-(Boc)2-{Gly∆Gly}-Phe-Leu-OMe 138  
 
Boc-Phe-Leu-OMe 135 (260 mg, 0.66 mmol) was dissolved in CH2Cl2 (6.6 mL) and TFA 
(100 µL, 0.99 mmol) was added. The reaction mixture was stirred for 5 h at rt and the solvent 
was removed under vacuum.  
TFA·H-Phe-Leu-OMe (122 mg, 0.30 mmol) was dissolved in CH2Cl2 (1 mL) and DIPEA 
(160 µL, 0.90 mmol) was added followed by (S,R)-(Boc)2-{Gly∆Gly}-OH 107 (100 mg, 
0.30 mmol). The mixture was stirred for 15 min and HATU (114 mg, 0.30 mmol) was added. 
The reaction mixture was stirred for 5 h at rt. H2O (10 mL) was added and the phases were 
separated. The organic phase was washed with 1 м aq. HCl (10 mL), H2O (10 mL), brine 
(10 mL), dried over MgSO4 and filtered. The solvent was removed under vacuum and the 
residue was purified by silica gel column chromatography (PE/EtOAc 9:1 to 1:1) to afford 
(S,R)-(Boc)2-Gly∆Gly}-Phe-Leu-OMe 138 (108 mg, 60%) as a colourless solid. 
Rf (PE/EtOAc 1:1): 0.68; [𝛼],6@ –10 (c = 0.40, CHCl3); m.p.: 153–154 °C; νmax 3281, 2957, 
1746, 1694, 1641, 1553, 1368, 1175, 1128 cm−1; 1H NMR (500 MHz, CDCl3) δ 7.27–7.16 
(5H, m, 5 × CH-Ph), 6.45 (1H, d, J = 7.2 Hz, NH-Phe), 6.25 (1H, d, J = 8.3 Hz, NH-Leu), 
4.64 (1H, ddd, J = 14.5, 7.2, 7.2 Hz, CHα-Phe), 4.48 (1H, ddd, J = 8.5, 8.3, 5.2 Hz, CHα-
Leu), 3.66 (3H, s, OCH3), 3.55 (1H, dd, J = 14.3, 6.0 Hz, CH2-C6), 3.42 (1H, dd, J = 14.3, 
6.8 Hz, CH2-C6), 3.07 (2H, d, J = 7.2 Hz, CH2β-Phe), 2.30 (1H, dd, J = 16.4, 6.1 Hz, CH2-
C2), 1.87 (1H, dd, J = 16.4, 8.3 Hz, CH2-C2), 1.60–1.40 (3H, m, CHγ-Leu + CH2β-Leu), 
1.46 (18H, s, 2 × t-Bu), 0.93–0.82 (2H, m, CH-C5 + CH-C3), 0.85 (6H, d, J = 6.3 Hz, 2 × 
CH3δ-Leu), 0.52 (1H, ddd, J = 8.4, 5.0, 5.0 Hz, CH2-C4), 0.23 (1H, ddd, J = 8.4, 5.1, 5.1 
Hz, CH2-C4); 13C NMR (126 MHz, CDCl3) δ 172.9 (CO-Leu), 172.3 (CO-C1), 170.7 (CO-
Phe), 153.1 (2 × CO-Boc), 136.7 (C-Ph), 129.5 (C-Ph), 128.8 (2 × Ph), 127.1 (2 × CH-Ph), 
82.5 (C-Boc), 54.4 (CHα-Phe), 52.4 (OCH3), 51.1 (CHα-Leu), 49.0 (CH2-C6), 41.5 (CH2β-
Leu), 40.7 (CH2-C2), 37.8 (CH2β-Phe), 28.2 (6 × CH3-Boc), 24.9 (CHγ-Leu), 22.8 (CH3δ-
(Boc)2N
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Leu), 22.1 (CH3δ-Leu), 18.5 (CH-C5), 13.2 (CH-C3), 10.4 (CH2-C4); HRMS (ESI+) for 
C32H49N3NaO8 [M+Na]+ calcd 626.3412, found 626.3389. 
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(S,R)-Boc-Tyr-{Gly∆Gly}-Phe-Leu-OMe 140  
 
(S,R)-(Boc)2-{Gly∆Gly}-Phe-Leu-OMe 138 (108 mg, 0.18 mmol) was dissolved in CH2Cl2 
(2 mL) and TFA (140 µL, 1.80 mmol) was added to the solution. The reaction mixture was 
stirred at rt for 12 h. The solvent was then removed, and the compounds was used for the 
coupling without purification.  
To a solution of TFA·(S,R)-H-{Gly∆Gly}-Phe-Leu-OMe (0.18 mmol) in DMF (600 µL) 
was added DIPEA (94 µL, 0.54 mmol) dropwise. Boc-Tyr-OH (76 mg, 0.27 mmol) was 
added followed by HATU (68 mg, 0.18 mmol). The reaction mixture was stirred overnight 
at rt. The solution was washed with 5% aq. LiCl (4 × 5 mL), 1 м aq. HCl (5 mL) and sat. aq. 
NaHCO3 (5 mL). The organic phase was dried over MgSO4 and filtered. The solvent was 
removed under vacuum and the resulting oil was purified by silica gel column 
chromatography (CH2Cl2/MeOH 99:1 to 95:5) to afford (S,R)-Boc-Tyr-{Gly∆Gly}-Phe-
Leu-OMe 140 (90 mg, 75%) as a white powder. 
Rf (CH2Cl2/MeOH 9:1): 0.76; [𝛼],6A +38 (c = 0.05, CHCl3); m.p.: 152–153 °C; νmax 3276, 
2955, 1732, 1701, 1656, 1519, 1342, 1172, 1129 cm−1; 1H NMR (500 MHz, CDCl3) δ 7.33–
7.18 (5H, m, 5 × CH-Ph), 7.04 (2H, bd, J = 8.3 Hz, 2 × CH-Arom-Tyr), 6.71 (2H, d, J = 8.3 
Hz, 2 × CH-Arom-Tyr), 6.68 (1H, bs, NH-Gly), 6.60 (1H, bs, NH-Phe), 6.38 (1H, bs, NH-
Leu), 5.43 (1H, d, J = 8.3 Hz, NH-Tyr), 4.68 (1H, bs, CHα-Phe), 4.56 (1H, bs, CHα-Leu), 
4.34 (1H, dd, J = 8.3, 6,7 Hz, CHα-Tyr), 3.71 (3H, s, OCH3), 3.48 (1H, bs, 1H × CH2-C6), 
3.09 (2H, bd, J = 5.7 Hz, CH2β-Phe), 3.01 (1H, bs, 1H × CH2β-Tyr), 2.92 (1H, bs, 1H × 
CH2β-Tyr), 2.67–2.59 (1H, m, 1H × CH2-C6), 2.29 (2H, bd, J = 16.7 Hz, 1H × CH2-C2), 
1.91–1.81 (1H, m, 1H × CH2-C2), 1.66–1.48 (3H, m, CHγ-Leu + CH2β-Leu), 1.41 (9H, s,t-
Bu), 0.90 (6H, d, J = 6.0 Hz, 2 × CH3δ-Leu), 0.54 (2H, m, CH-C5 + CH-C3), 0.39 (1H, bs, 
CH2-C4), 0.31 (1H, bs, CH2-C4)**; 13C (126 MHz, CDCl3): 173.0 (CO-OCH3), 172.7 (CO-
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Leu), 171.7 (CO-C1), 171.4 (CO-Phe), 155.6 (CO-Boc), 155.2 (C-Tyr), 136.5 (CH-Arom-
Phe), 130.7 (2 × CH-Arom-Tyr), 129.5 (2 × CH-Ph), 128.8 (CH-Ph), 128.6 (CH-Ph), 127.3 
(C-Ph), 115.7 (2 × CH-Arom-Tyr), 80.0 (C-Boc), 56.3 (CHα-Tyr), 54.6 (CHα-Phe), 52.6 
(OCH3), 51.3 (CHα-Leu), 43.0 (CH2-C6), 41.4 (CH2β-Leu), 39.8 (CH2-C2), 38.4 (CH2β-
Tyr), 38.2 (CH2β-Phe), 28.5 (3 × CH3-Boc), 24.9 (CHγ-Leu), 22.0 (2 × CH3δ-Leu), 18.0 
(CH-C5), 13.0 (CH-C3), 10.7 (CH2-C4); HRMS (ESI+) for C36H50N4NaO8 [M+Na]+ calcd 
689.3521, found 689.3503. 
**Most of the signal are shown broad due to exchange in conformation for this peptide.  
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(S,R)-H-Tyr-{Gly∆Gly}-Phe-Leu-OH 133   
 
(S,R)-Boc-Tyr-{Gly∆Gly}-Phe-Leu-OMe 140 (20.0 mg, 0.03 mmol) was dissolved in THF 
(0.10 mL) and 4 м aq. HCl (0.50 mL). The reaction mixture was stirred overnight at rt. The 
solution was then lyophilised. The crude peptide was purified using semi-preparative HPLC 
system with a flow rate of 8 mL/min. A linear gradient of buffer A (H2O and 0.1% TFA) to 
buffer B (MeCN and 0.1% TFA) was used over 40 min from 35 to 65%. UV detection 
wavelengths were 214 and 280 nm. The title compound was obtained as a white solid (8 mg, 
48%). 
[𝛼],9? –0.87 (c = 0.12, MeOH); HRMS (ESI+) for C28H38N5O7 [M+H]+ calcd 556.2766 found 
556.2752. HPLC: purity 92.56% (50 mins gradient), 90.29% (20 mins gradient); m.p.: 107–
108 °C.  
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(R,S)-(Boc)2-{Gly∆Gly}-Phe-Leu-OMe 137  
 
The procedure applied to the synthesis of (S,R)-(Boc)2-{Gly∆Gly}-Phe-Leu-OMe 138 on 
exactly the same scale. The residue was purified by silica gel column chromatography 
(PE/EtOAc 9:1 to 1:1) to afford (R,S)-(Boc)2-{Gly∆Gly}-Phe-Leu-OMe 137 (118 mg, 65%) 
as a white solid. 
Rf (PE/EtOAc 1:1): 0.68; [𝛼],9? –23 (c = 0.90, CHCl3); m.p.: 122–123 °C; νmax 3275, 3067, 
2957, 1746, 1694, 1639, 1553, 1437, 1368, 1238, 1128 cm−1; 1H NMR (500 MHz, CDCl3) 
δ 7.32–7.22 (5H, m, 5 × CH-Ph), 6.52 (1H, d, J = 7.4 Hz, NH-Phe), 6.23 (1H, d, J = 8.2 Hz, 
NH-Leu), 4.67 (1H, ddd, J = 14.8, 7.4, 7.4 Hz, CHα-Phe), 4.51 (1H, ddd, J = 8.2, 8.2, 5.3 
Hz, CHα-Leu), 3.70 (3H, s, OCH3), 3.60 (1H, dd, J = 14.4, 5.8 Hz, CH2-C6), 3.44 (1H, dd, 
J = 14.4, 6.8 Hz, CH2-C6), 3.12 (2H, dd, J = 7.4, 3.9 Hz, CH2β-Phe), 2.33 (1H, dd, J = 16.4, 
6.2 Hz, CH2-C2), 1.95 (1H, dd, J = 16.4, 8.1 Hz, CH2-C2), 1.65–1.41 (3H, m, CHγ-Leu + 
CH2β-Leu), 1.50 (18H, s, 2 × t-Bu), 0.95–0.82 (2H, m, CH-C5 + CH-C3), 0.89 (3H, d, J = 
6.3 Hz, CH3δ-Leu), 0.89 (3H, d, J = 6.3 Hz, CH3δ-Leu), 0.57 (1H, ddd, J = 8.5, 5.1, 5.1 Hz, 
CH2-C4), 0.31 (1H, ddd, J = 8.5, 5.1, 5.1 Hz, CH2-C4); 13C (126 MHz, CDCl3): δ 172.9 
(CO-Leu), 172.3 (CO-C1), 170.8 (CO-Phe), 153.1 (2 × CO-Boc), 136.8 (C-Ph), 129.5 (C-
Ph), 128.8 (2 × CH-Ph), 127.1 (2 × CH-Ph), 82.5 (2 × C-Boc), 54.3 (CHα-Phe), 52.4 (OCH3), 
51.1 (CHα-Leu), 48.9 (CH2-C6), 41.5 (CH2β-Leu), 40.7 (CH2-C2), 37.8 (CH2β-Phe), 28.2 
(6 × CH3-Boc), 24.9 (CHγ-Leu), 22.8 (CH3δ-Leu), 22.1 (CH3δ-Leu), 18.4 (CH-C5), 13.1 
(CH-C3), 10.4 (CH2-C4); HRMS (ESI+) for C32H49N3NaO8 [M+Na]+ calcd 626.3412, found 
626.3381. 
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(R,S)-Boc-Tyr-{Gly∆Gly}-Phe-Leu-OMe 139 
 
The procedure applied to the synthesis of (S,R)-Boc-Tyr-{Gly∆Gly}-Phe-Leu-OMe 140 was 
followed using (R,S)-(Boc)2-{Gly∆Gly}-Phe-Leu-OMe 137 (107 mg, 0.18 mmol). The 
residue was purified by silica gel column chromatography (CH2Cl2/MeOH 99:1 to 98:2) to 
afford (R,S)-Boc-Tyr-{Gly∆Gly}-Phe-Leu-OMe 139 (130 mg, 76%) as a white powder. 
Rf (CH2Cl2/MeOH 9:1): 0.93; [𝛼],9? –5.5 (c = 0.20, CHCl3); m.p.: 167–168 °C; νmax 3287, 
2953, 2926, 1725, 167, 1533, 1516, 1449, 1368, 1246, 1167 cm−1; 1H NMR (500 MHz, 
CDCl3) δ 7.33–7.19 (5H, m, 5 × CH-Ph), 7.05 (2H, d, J = 8.3 Hz, 2 × CH-Arom-Tyr), 6.72 
(2H, d, J = 8.3 Hz, 2 × CH-Arom-Tyr), 6.41 (1H, d, J = 7.2 Hz, NH-Phe), 6.38 (1H, d, J = 
8.2 Hz, NH-Leu), 6.04 (1H, bs, NH-Gly), 5.43 (1H, d, J = 8.3 Hz, NH-Tyr), 4.70 (1H, m, 
CHα-Phe), 4.60–4.51 (1H, m, CHα-Leu), 4.29–4.22 (1H, m, CHα-Tyr), 3.71 (3H, s, OCH3), 
3.49 (1H, bd, J = 13.5 Hz, CH2-C6), 3.08 (2H, d, J = 7.2 Hz, CH2β-Phe), 3.07–3.01 (1H, m, 
CH2β-Tyr), 2.80 (1H, bdd, J = 11.3, 11.3 Hz, CH2β-Tyr), 2.42 (1H, m, CH2-C6), 2.00–1.86 
(2H, m, CH2-C2), 1.65–1.45 (3H, m, CHγ-Leu + CH2β-Leu), 1.42 (9H, s, t-Bu), 0.90 (3H, 
d, J = 6.1 Hz, CH3δ-Leu), 0.89 (3H, d, J = 6.2 Hz, CH3δ-Leu), 0.57–0.33 (4H, m, CH-C5 + 
CH-C3 + CH2-C4)**; 13C (126 MHz, CDCl3): δ 172.9 (CO-OCH3), 172.5 (CO-Leu), 171.6 
(CO-C1), 171.2 (CO-Phe), 155.4 (C-Tyr), 151.8 (CO-Boc), 136.4 (CH-Ph), 130.6 (2 × CH-
Arom-Tyr), 129.5 (2 × CH-Arom-Phe), 128.8 (CH-Ph), 128.7 (CH-Ph), 127.3 (C-Ph), 115.9 
(2 × CH-Arom-Tyr), 80.0 (C-Boc), 56.6 (CHα-Tyr), 54.7 (CHα-Phe), 52.6 (OCH3), 51.2 
(CHα-Leu), 43.7 (CH2-C6), 41.5 (CH2β-Leu), 39.9 (CH2-C2), 39.0 (CH2β-Tyr), 38.4 (CH2β-
Phe), 28.5 (3 × CH3-Boc), 24.9 (CHγ-Leu), 22.9 (CH3δ-Leu), 22.0 (CH3δ-Leu), 17.2 (CH-
C5), 13.7 (CH-C3), 10.8 (CH2-C4); HRMS (ESI+) for C36H50N4NaO8 [M+Na]+ calcd 
689.3521, found 689.3493. 
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**Almost all peaks are shown broad or multiplet due to exchange in conformation for this 
peptide. 
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(R,S)-H-Tyr-{Gly∆Gly}-Phe-Leu-OH 132  
 
(R,S)-Boc-Tyr-{Gly∆Gly}-Phe-Leu-OMe 139 (59.0 mg, 0.09 mmol) was dissolved in a 
mixture of THF (2 mL) and 4 м aq. HCl (2.25 mL). The reaction mixture was stirred 
overnight at rt. The solution was then lyophilised, and the crude peptide was then purified 
using semi-preparative HPLC system with a flow rate of 8 mL/min. A linear gradient of 
buffer A (H2O and 0.1% TFA) to buffer B (MeCN and 0.1% TFA) was used over 40 min 
from 35 to 65%. UV detection wavelengths were 214 and 280 nm. The title compound (20 
mg, 40%) was obtained as a colourless solid. 
[𝛼],9? +9.5 (c = 0.22, MeOH); HRMS (ESI+) for C30H41N4O6 [M+H]+ calcd 553.3021, found 
553.3013. HPLC: purity 89.56% (50 mins gradient), 89.36% (20 mins gradient), m.p.: 129–
130 °C. 
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Microwave Assisted Solid Phase Peptide Synthesis: 
Following peptides were synthesised using an Automated Biotage Initiator + Alstra 
microwave synthesizer on 0.1 mmol scale using Tentagel S RAM resin (0.24 mmol/g 
loading) or Fmoc-Leu Wang resin (0.84 mmol/g loading). L-amino acids were used for 
peptide synthesis with N-Fmoc protecting groups (4 equiv.). Analytical HPLC was 
undertaken on a Shimadzu SIL-20AHT equipped with a dual wavelength UV detector and a 
Phenomenex Aeris 5 μm C18 (150 x 46 mm) column at a flow rate of 1 mL/min. A linear 
gradient of buffer A (95:5 H2O/MeCN and 0.1% TFA) to buffer B (95:5 MeCN/H2O and 
0.1% TFA) was used over 20 min and 50 min from 0 to 100% and 100 to 0%. UV 
measurements were recorded at 214 nm and 280 nm. Peptides were purified using a Gilson 
semi-preparative HPLC system equipped with a Phenomenex Synergi 10u C18 80 Å, (250 
x 21.2 mm) column with a flow rate of 8 mL/min. Peptides were lyophilized using a Christ 
Alpha 2−4 LDplus freezedryer. Peptide content was determined using a Nanodrop 2000c 
using UV absorbance at 280 nm when mentioned.  
Peptides were synthesised via the following general procedure on the peptide synthesiser:  
Resin Swelling – Resin swollen in DMF at 70 °C for 20 min.  
Coupling – Coupling reactions were performed using 4 equiv. of amino acid, 4 equiv. of 
HCTU (0.5 м in DMF) and 8 equiv. of DIPEA (2 м in NMP). Natural amino acids were 
coupled at 75 °C for 5 min. 
Deprotection – Fmoc deprotections were carried out using 20% piperidine in DMF, spiked 
with 5% formic acid at 75 °C for 30 s. A second deprotection was then undertaken at 70 °C 
for 3 min.  
Washing – Resin was washed with DMF after each coupling and deprotection step.  
Peptide Cleavage – Resin bound peptide was cleaved and protecting groups removed upon 
addition of 3 mL TFA/TIS/H2O (95:2.5:2.5) and spun for 3 h.  
After filtration through a sintered frit, the cleavage cocktail was evaporated using a stream 
of N2 and the peptide was precipitated with ice cold Et2O and centrifuged at 4500 rpm for 5 
min. After decanting the supernatant, the Et2O wash was repeated a further 2 times. The 
  234 
crude peptide dissolved in 50% MeCN/H2O with 0.1% TFA and was lyophilized before 
purification. 
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Leu-enkephalin 141  
 
Following the procedure described for for SPPS using Fmoc-Leu Wang resin (0.84 mmol/g 
loading), the crude peptide was purified using semi-preparative HPLC system with a flow 
rate of 8 mL/min. A linear gradient of buffer A (H2O and 0.1% TFA) to buffer B (MeCN 
and 0.1% TFA) was used over 40 min from 20 to 70%. UV detection wavelengths were 214 
and 280 nm. Leu-enkephalin 137 (24 mg, 43%) was obtained as a white solid. 
HRMS (ESI+) for C28H38N5O7 [M+H]+ calcd 556.2766, found 556.2752. HPLC: purity 
96.69% (50 min gradient), 97.18% (20 min gradient), m.p.: 157–160 °C.  
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2,6-Di-t-butyl-4-methylphenyl-3-oxobutanoate 148  
 
A mixture of 2,6-di-t-butyl-4-methylphenol (5.00 g, 22.7 mmol) and 2,2,6-trimethyl-4H-1,3-
dioxin-4-one (3.00 mL, 22.7 mL) in xylene (5 mL) was stirred at 140 °C for 2 h. Solvents 
were removed under reduced pressure and the residue was purified by silica gel column 
chromatography (PE/EtOAc 9:1) to give an orange solid which was recrystallised from PE 
to afford the title compound (3.07 g, 44%) as white solid as a mixture (45:55) of keto 
148a/enol 148b compounds. 
Rf (EtOAc/PE 1:1): 0.58; m.p.: 97–98 °C; 1H NMR (500 MHz; CDCl3): δ 12.15 (0.55H, s, 
OH enol), 7.13 (2H, s, CH-Arom), 5.33 (0.55H, d, J = 0.8 Hz, CH-C3’), 3.73 (0.9H, s, CH2-
C3), 2.40 (1.35H, s, CH3-C1), 2.33 (3H, s, CH3-C5 + CH3-C5’), 2.07 (1.65, s, CH3-C1’), 
1.34 (8.1H, s, 2 ´ tBu enol form), 1.33 (9.9H, s, 2 ´ tBu keto form); 13C NMR (126 MHz; 
CDCl3): δ 200.2 (CO-C2), 177.6 (CO-C4’), 167.8 (CO-C4), 145.5 (C-Ar), 145.1 (C-Ar), 
142.4 (C-Ar), 142.0 (C-Ar), 135.2 (C-Ar), 134.8 (C-Ar), 127.3 (C-Ar), 127.1 (C-Ar), 90.6 
(CH-C3’), 50.9 (CH2-C3), 35.4 (CH3-C1’), 34.4 (CH3-C1), 31.7 (tBu keto form), 31.6 (tBu 
keto form), 30.9 (3 ´ tBu keto form), 21.7 (tBu enol form), 21.7 (CH3-C5), 21.3 (CH3-C5’); 
HRMS (ESI+) for C19H28NaO3 [M+Na]+ calcd 327.1931 found 327.1934.* 
*Values match what has been reported in litterature. ref  
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2,6-Di-t-butyl-4-methylphenyl 2-diazoacetate 150  
 
To a solution of 2,6-di-t-butyl-4-methylphenyl-3-oxobutanoate 148 (3.07 g, 10.1 mmol) in 
MeCN (13 mL) was added Et3N (1.8 mL). The solution was cooled to 0 °C and TsN3 (2.20 
g, 11.3 mmol) in MeCN (13 mL) was added dropwise. The reaction mixture was allowed to 
warm to rt and stirred overnight at rt. The solvents were removed and the residue was 
dissolved in Et2O. The solution was washed with 8% aq. KOH solution (3 ´ 40 mL) and the 
organic phase was dried over MgSO4 and concentrated under vacuum. The residue was 
dissolved in MeCN (15 mL) and 8% aq. KOH (25 mL) was added. The mixture was stirred 
for 4 h at rt. H2O (15 mL) was added and the mixture extracted with Et2O (3 ´ 20 mL). The 
combined extracts were dried over MgSO4 and concentrated under vacuum. The crude 
product was purified by column chromatography on silica gel (PE/Et2O 30:1) to afford the 
title product (1.92 g, 66%) as a bright yellow solid. 
Rf (EtOAc/PE 1:1): 0.58; m.p.: 153–154 °C; νmax 2961, 2914, 2110, 1705, 1366, 1335, 1184, 
1144, 1107 cm−1; 1H NMR (500 MHz; CDCl3): δ 7.11 (2H, s, CH-Arom), 2.32 (3H, s, CH3-
C5), 1.35 (18H, s, 2 ´ tBu); 13C NMR (126 MHz, CDCl3) δ 142.6 (CO-C4), 134.9 (2 ´ CH-
Arom), 130.9 (C-Arom)127.2 (CH-C3), 35.4 (C-tBu), 31.7 (2 ´  tBu), 21.7 (CH3-C5); HRMS 
(ESI+) for C19H28NaO3 [M+Na]+ calcd 327.1931, found 327.1934.* 
*Values match what has been reported in litterature. ref   
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t-Butyl-(4S,E)-{5-hydroxy-1-[4-(4-methoxybenzyloxy)phenyl]pent-3-en-2-
yl}carbamate 151 
 
(4S)-t-Butyl-{1-[4-(4-methoxybenzyloxy)phenyl]but-3-en-2-yl}carbamate 145 (50.0 mg, 
0.13 mmol) previously synthesised following a known procedure, REF was dissolved in 
degassed CH2Cl2 (2 mL) and butenediol (39 μL, 0.65 mmol) was added. The solution was 
degassed and Hoveyda-Grubbs 2nd generation catalyst (3 mg, 3.5 mol%) was added. The 
reaction mixture was stirred at reflux for 18 h. The solvents were removed and the residue 
was purified by silica gel column chromatography (PE/EtOAc 9:1 to 1:1) to give the title 
compound (23 mg, 43%) as a white solid.  
Rf (PE/EtOAc 1:1): 0.38; [𝛼],6C +13 (c = 1.0, CHCl3); νmax 3294, 2971, 2929, 1732, 1693, 
1640, 1366, 1173, 1129 cm−1; 1H NMR (400 MHz, CDCl3) δ 7.35 (2H, d, J = 8.6 Hz, 2 × 
CH-Ph-PMB), 7.08 (2H, d, J = 8.6 Hz, 2 × CH-Ph-PMB), 6.90 (4H, dd, J = 10.2, 8.6 Hz, 4 
× CH-Ph), 5.75–5.62 (2H, m, CH-C2 + CH-C3), 4.96 (2H, s, CH2-PMB), 4.48 (1H, bs, NH), 
4.38 (1H, bs, CH-C1), 4.11 (2H, d, J = 3.9 Hz, CH2-C4), 3.81 (3H, s, OCH3-PMB), 2.77 
(2H, d, J = 6.3 Hz, CH2-C5), 1.40 (9H, s, CH3-Boc); 13C (101 MHz, CDCl3): δ 159.6 (CO-
Boc), 157.7 (2 × C-Ph-PMB), 155.3 (2 × C-Ph), 131.8 (CH-C3), 130.6 (2 × CH-Ph), 129.8 
(CH-C2), 129.4 (2 × CH-Ph), 114.9 (2 × CH-Ph), 114.1 (2 × CH-Ph), 80.0 (C-Boc),70.0 
(CH2-PMB), 63.2 (CH2-C4), 55.5 (OCH3-PMB), 52.9 (CH-C1), 40.9 (CH2-C5), 28.5 (3 × 
CH3-Boc); HRMS (ESI+) for C24H31NO5Na [M+Na]+ calcd, 436.2094 found 436.2088.  
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t-Butyl-(4S,E)-{5-(t-butyldiphenylsilyloxy)-1-[4-(4-methoxybenzyloxy)phenyl]pent-3-
en-2-yl}carbamate 152 
 
TPBDPSCl (15 μL, 0.06 mmol) was slowly added to a solution of t-butyl-(4S,E)-{5-
hydroxy-1-{4-(4-methoxybenzyloxy)phenyl]pent-3-en-2-yl}carbamate 151 (20 mg, 0.05 
mmol) and imidazole (7 mg, 0.09 mmol) in CH2Cl2 (0.50 mL). The reaction mixture was 
stirred for 24 h at rt. H2O (7 mL) was added and the phases were separated. The organic 
phase was dried over Na2SO4, filtered and concentrated under vacuum. The resulting oil was 
purified by silica gel column chromatography (PE/EtOAc 1:1) yielding the title compound 
(33 mg, quant.) as a clear oil  
Rf (PE/EtOAc 1:1): 0.79; νmax 2982, 2864, 1715, 1550, 1436, 1248, 1173, 1129 cm−1; 1H 
NMR (400 MHz, CDCl3) δ 7.73–7.70 (4H, m, 4 × CH-Ph-TBDPS), 7.65 (4H, ddd, J = 8.1, 
1.6, 1.6 Hz, 4 × CH-Ph-TBDPS), 7.41–7.36 (2H, m, 2 × CH-Ph-TBDPS), 7.35 (2H, d, J = 
8.7 Hz, 2 × CH-Ph-PMB), 7.17 (1H, s, NH), 7.07 (2H, d, J = 8.7 Hz, 2 × CH-Ph PMB), 6.91 
(2H, d, J = 8.6 Hz, 2 × CH-Ph), 6.87 (1H, d, J = 8.6 Hz, 2 × CH-Ph), 5.69 (1H, dd, J = 15.5, 
5.2 Hz, CH-C2), 5.59 (1H, ddd, J = 15.5, 4.8, 3.5 Hz, CH-C3), 4.94 (2H, s, CH2-PMB), 
4.42–4.36 (1H, m, CH-C1), 4.16 (2H, d, J = 3.5 Hz, CH2-C4), 3.81 (3H, s, CH3-PMB), 2.80–
2.69 (2H, m, CH2-C5), 1.42 (9H, s, t-Bu-Boc), 1.04 (9H, s, t-Bu-TBDPS); 13C NMR (126 
MHz, CDCl3) δ 159.6 (CO-Boc), 157.7 (2 × C-Ph-PMB), 135.7 (4 × CH-Ph), 134.9 (4 × 
CH-Ph), 130.7 (2 × CH-Ph), 129.8 (CH-C2 + CH-C3), 129.6 (2 × C-Ph), 129.4 (2 × CH-
Ph), 127.9 (2 × C-Ph), 114.8 (2 × CH-Ph), 114.1 (2 × CH-Ph), 83.1 (CH-Boc), 70. 0 (CH2-
PMB), 63.9 (CH2-C4), 55. 5 (OCH3-PMB), 41.0 (CH2-C5), 34.0 (C-TBDPS), 28.6 (t-Bu-
Boc), 27.0 (t-Bu-TBDPS); HRMS (ESI+) for C40H49NO5NaSi [M+Na]+ calcd 674.3272, 
found 674.3252.  
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Methyl-(4S,E)-4-[(t-butoxycarbonyl)amino]-5-[4-(4-methoxybenzyloxy)phenyl]pent-2-
enoate 155  
 
A solution of t-butyl {1-[4-(4-methoxybenzyloxy)phenyl]but-3-en-2-yl}carbamate 145 (50 
mg, 0.13 mmol) in CH2Cl2 (300 μL) and a solution of methyl acrylate (20 μL, 0.23 mmol) 
in CH2Cl2 (300 μL) were added simultaneously to a suspension of degassed Grubbs II 
catalyst (3.3 mg, 3 mol%) in CH2Cl2 (700 μL). The reaction mixture was degassed again and 
stirred for 48 h at reflux. Solvents were removed and the residue was purified by silica gel 
column chromatography (PE/EtOAc 9:1 to 1:4) to give the title compound (23 mg, 40%) as 
a clear oil.  
Rf (PE/EtOAc 1:1): 0.48; [𝛼],6C +6.2 (c = 0.75, CHCl3), νmax 3354, 2974, 2928, 1714, 1514, 
1368, 1244, 1172, 1022 cm−1; 1H NMR (500 MHz, CDCl3) 7.35 (2H, d, J = 8.7 Hz, 2 × CH-
Arom PMB), 7.07 (2H, d, J = 8.6 Hz, 2 × CH-Arom), 6.92 (2H, d, J = 6.8 Hz, 2 × CH-Arom-
PMB), 6.90 (2H, d, J = 7.1 Hz, 2 × CH-Arom), 5.85 (1H, dd, J = 15.7, 1.7 Hz, CH-C2), 4.96 
(2H, s, CH2-PMB), 4.56 (1H, bs, CH-C1), 4.49 (1H, bs, CH-C3), 3.82 (3H, s, CH3-PMB), 
3.73 (3H, s, CO2CH3), 2.83 (2H, d, J = 6.6 Hz, CH2-C5), 1.40 (9H, s, t-Bu); 13C NMR (126 
MHz, CDCl3) δ 166.8 (CO-Ac), 159.6 (2 × C-Arom-PMB), 158.0 (CO-Boc), 155.1 (2 × CH-
Arom), 130.6 (2 × CH-Arom), 129.4 (2 × CH-Arom-PMB), 129.2 (2 × C-Arom), 120.8 (CH-
C1), 115.1 (2 × CH-Arom), 114.2 (2 × CH-Arom-PMB), 83.1 (C-Boc), 67.0 (CH2-PMB), 
55.5 (CH3-PMB), 51.8 (CO2CH3), 39.5 (CH2-C5), 28.5 (t-Bu); HRMS (ESI+) for 
C25H31NO6Na [M+Na]+ calcd 464.2044, found 464.2041.  
 
  
BocHN 1
2
3
4 OMe
5
PMBO
O
151
  241 
TrpZip 157 
 
 
Following the general procedure for SPPS using TentaGel S RAM resin (0.24 mmol/g 
loading). The crude peptide was purified using semi-preparative HPLC system with a flow 
rate of 8 mL/min. A linear gradient of buffer A (H2O and 0.1% TFA) to buffer B (MeCN 
and 0.1% TFA) was used over 55 min from 20 to 70%. UV detection wavelengths were 214 
and 280 nm. TrpZip 157 (15 mg, 9%) was obtained as a colourless solid. 
HRMS (ESI+) for C78H104N20O18 [M+2H]2+ calcd 804.3913, found 804.3943. HPLC: purity 
94.58% (50 min gradient), 93.12% (20 min gradient).  
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GG TrpZip 158  
  
Following the general procedure for SPPS using TentaGel S RAM resin (0.24 mmol/g 
loading). The crude peptide was purified using semi-preparative HPLC system with a flow 
rate of 8 mL/min. A linear gradient of buffer A (H2O and 0.1% TFA) to buffer B (MeCN 
and 0.1% TFA) was used over 55 mins from 20-70%. UV detection wavelengths were 214 
and 280 nm. GG TrpZip 158 (28 mg, 18%) was obtained as a white solid. Peptide content 
was determined by measuring the absorbance at 280 nm.  
HRMS (ESI+) for C76H101N19O17 [M+2H]2+ calcd 775.8806, found 775.8832. HPLC: purity 
97.54% (50 min gradient), 95.86% (20 min gradient). 
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(R,S)-Fmoc-{GlyΔGly}-OH 161 
 
(R,S)-(Boc)2-{GlyΔGly}-OH 107 (248 mg, 0.75 mmol) was dissolved in CH2Cl2 (8 mL) and 
TFA (0.6 mL) was added. The solution was stirred for 3 h at rt and the solvent was removed. 
The resulting TFA salt was dissolved in a dioxane/H2O mixture (3:1, 13 mL) and K2CO3 
(310 mg, 2.25 mmol) was added. The solution was stirred for 30 min at rt and FmocOSu 
(304 mg, 0.900 mmol) was added. The reaction mixture was stirred overnight at rt. The 
mixture was diluted in 2 м aq. K2CO3 (5 mL) and extracted with EtOAc (3 ´ 5 mL). The aq. 
phase was then acidified carefully to pH 1 using 1 м aq. HCl and then extracted with EtOAc 
(3 ´ 5 mL). The combined extracts were dried over MgSO4, filtered and concentrated under 
vacuum. The residue was purified by silica gel on column chromatography (PE/EtOAc 1:1) 
to give the title compound (40 mg, 15%) as a yellow oil.  
Rf (Et2O/PE 1:1): 0.27; [𝛼],99 +25 (c = 0.50, CHCl3); nmax 3335, 3067, 2932, 1703, 1520, 
1450, 1242, 1034 cm–1; 1H NMR (400 MHz; CDCl3): δ 7.75 (2H, d, J = 7.5 Hz, 2 ´ CH-
Arom-Fmoc), 7.61 (2H, d, J = 7.5 Hz, 2 ´ CH-Arom-Fmoc), 7.39 (2H, t, J = 7.5 Hz, 2 ´ 
CH-Arom-Fmoc), 7.30 (2H, t, J = 7.5 Hz, 2 ´ CH-Arom-Fmoc), 5.39 (1H, bs, NH), 4.35 
(2H, d, J = 6.9 Hz, CH2-Fmoc), 4.22 (1H, t, J = 6.9 Hz, CH-Fmoc), 3.42 (1H, ddd, J = 12.5, 
6.1, 6.1 Hz, CH2-C6), 2.78 (1H, ddd, J = 12.5, 8.4, 4.2 Hz, CH2-C6), 2.60 (1H, dd, J = 17.3, 
5.5 Hz, CH2-C2), 2.04 (1H, dd, J = 17.3, 8.8 Hz, CH2-C2), 0.92–0.77 (2H, m, CH-C3 + CH-
C5), 0.53 (1H, ddd, J = 9.5, 5.3, 5.3 Hz, CH2-C4), 0.45 (1H, ddd, J = 9.5, 5.4, 5.4 Hz, CH2-
C4); 13C NMR (126 MHz; CDCl3): δ  178.6 (CO-C1), 156.6 (CO-Fmoc), 144.2 (2 ´ C-
Arom-Fmoc), 141.4 (2 ´ C-Arom-Fmoc), 127.8 (2 ´ CH-Arom-Fmoc), 127.2 (2 ´ CH-
Arom-Fmoc), 125.3 (2 ´ CH-Arom-Fmoc), 120.1 (2 ´CH-Arom-Fmoc), 66.9 (CH-Fmoc), 
47.4 (CH2-Fmoc), 45.3 (CH2-C6), 37.8 (CH2-C2), 18.4 (CH-C5), 12.9 (CH-C3), 10.3 (CH2-
C4); HRMS (ESI+) for C21H21NNaO4 [M+Na]+ calcd 374.1363, found 374.1356. 
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(S,R)-Fmoc-{GlyΔGly}-OH 162 
 
(S,R)-(Boc)2-{GlyΔGly}-OH 107 (203 mg, 0.61 mmol) was dissolved in CH2Cl2 (6 mL) and 
TFA (0.50 mL, 6.1 mmol) was added. The solution was stirred for 3 h at rt and solvent were 
removed. The resulting TFA salt was dissolved in a dioxane/H2O mixture (3:1, 12 mL) and 
K2CO3 (253 mg, 1.83 mmol) was added. The solution was stirred for 30 min at rt and 
FmocOSu (250 mg, 0.730 mmol) was added. The reaction mixture was stirred overnight at 
rt. The mixture was diluted in 2 м aq. K2CO3 (5 mL) and extracted with EtOAc (3 ´ 5 mL). 
The aq. phase was then acidified carefully using 1 м aq. HCl to pH 1 and extracted with 
EtOAc (3 ´  5 mL). The combined extracts were dried over MgSO4, filtered and concentrated 
under vacuum. The residue was purified by silica gel on column chromatography (PE/EtOAc 
1:1) to give the title compound as a yellow oil (70 mg, 27%). 
Rf (Et2O/PE 1:1): 0.27; [𝛼],6E –18 (c = 0.50, CHCl3); nmax 3325, 3065, 2926, 1707, 1522, 
1451, 1246, 1033 cm−1; 1H NMR (400 MHz; CDCl3): δ 7.76 (2H, d, J = 7.4 Hz, 2 ´ CH-
Arom-Fmoc), 7.62 (2H, d, J = 7.4 Hz, 2 ´ CH-Arom-Fmoc), 7.39 (2H, t, J = 7.4 Hz, 2 ´ 
CH-Arom-Fmoc), 7.31 (2H, dddd, J = 7.4, 7.4, 1.1, 1.1 Hz, 2 ´ CH-Arom-Fmoc), 5.38 (1H, 
bs, NH), 4.37 (2H, d, J = 7.2 Hz, CH2-Fmoc), 4.23 (1H, t, J = 7.2 Hz, CH-Fmoc), 3.44 (1H, 
ddd, J = 12.4, 5.5, 5.5 Hz, CH2-C6), 2.77 (1H, ddd, J = 12.4, 8.2, 4.5 Hz, 1H ´ CH2-C6), 
2.62 (1H, dd, J = 17.6, 5.1 Hz, CH2-C2), 2.11–1.97 (1H, m, CH2-C2), 0.90–0.77 (2H, m, 
CH-C3 + CH-C5), 0.55 (1H, ddd, J = 8.2, 5.2, 5.2 Hz, CH2-C4), 0.46 (1H, ddd, J = 8.2, 4.0, 
4.0 Hz, CH2-C4); 13C NMR (126 MHz; CDCl3): δ  177.0 (CO-C1), 156.6 (CO-Fmoc), 144.2 
(2 ´ C-Arom-Fmoc), 141.5 (2 ´ C-Arom-Fmoc), 127.8 (2 ´ CH-Arom-Fmoc), 127.2 (2 ´ 
CH-Arom-Fmoc), 125.3 (2 ´ CH-Arom-Fmoc), 120.1 (2 ´CH-Arom-Fmoc), 66.9 (CH-
Fmoc), 47.4 (CH2-Fmoc), 45.3 (CH2-C6), 37.5 (CH2-C2), 18.5 (CH-C5), 13.0 (CH-C3), 10.4 
(CH2-C4); HRMS (ESI+) for C21H21NNaO4 [M+Na]+ calcd, 374.1363 found 374.1353. 
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(R,S)-{GlyΔGly}-TrpZip 159 
 
Following the general procedure for SPPS using TentaGel S RAM resin (0.24 mmol/g 
loading), H-K1-W3-T2-W4-K2-resin sequence was synthesised. This was not cleaved from 
the resin for the next coupling.  
(1S,2R)-Fmoc-{GlyΔGly}-OH (39.0 mg, 0.11 mmol, 1.1 equiv.) and HATU (76.0 mg, 0.20 
mmol) were dissolved in 5 mL of DMF. DIPEA (70 μL, 0.40 mmol) was then added. The 
solution was stirred for 5 min for preactivation and then it was added to the resin and spun 
overnight. The reaction was monitored by LCMS ([M+Na] 556.92 g/mol). Unreacted 
peptide was caped using 0.4 mL of acetic acid in 0.6 mL of pyridine and spun for 40 min. 
the resin was then washed with DMF (4 × 10 mL) through a sintered frit.  
The coupling of the rest of the sequence (Fmoc-S-W1-T1-W2-E-OH) to the resin was carried 
out following the procedure for SPPS on a 0.050 mmol scale.  
The crude peptide was purified using semi-preparative HPLC system with a flow rate of 8 
mL/min. A linear gradient of buffer A (H2O and 0.1% TFA) to buffer B (MeCN and 0.1% 
TFA) was used over 50 min from 20 to 70%. UV detection wavelengths were 214 and 280 
nm. (1S,2R)-{GlyΔGly}-TrpZip (15 mg, 19%) was obtained as a colourless solid. Peptide 
content was determined by measuring the absorbance at 280 nm.  
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HRMS (ESI+) for C78H104N18O16 [M+2H]2+ calcd 774.3948, found 774.3944. HPLC: purity 
91.80% (20 min gradient), 85.16% (50 min gradient). 
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 (S,R)-{GlyΔGly}-TrpZip 160 
 
Following the general procedure for SPPS using TentaGel S RAM resin (0.24 mmol/g 
loading), H-K1-W3-T2-W4-K2-resin sequence was synthesised. This was not cleaved from 
the resin for the next coupling.  
(S,R)-Fmoc-{GlyΔGly}-OH (70 mg, 0.20 mmol, 2 equiv.) and HATU (76 mg, 0.20 mmol) 
were dissolved in 5 mL of DMF. DIPEA (70 μL, 0.40 mmol) was then added. The solution 
was stirred for 5 min for preactivation and then it was added to the resin and spun overnight. 
The reaction was monitored by LCMS ([M+Na] 556.92 g/mol). Unreacted peptide was 
caped using 0.4 mL of acetic acid in 0.6 mL of pyridine and spun for 40 min. The resin was 
then washed with DMF (4 × 10 mL) through a sintered frit.  
The coupling of the rest of the sequence (Fmoc-S-W1-T1-W2-E-OH) to the resin was carried 
out following the procedure for SPPS on a 0.050 mmol scale.  
The crude peptide was purified using semi-preparative HPLC system with a flow rate of 8 
mL/min. A linear gradient of buffer A (H2O and 0.1% TFA) to buffer B (MeCN and 0.1% 
TFA) was used over 50 min from 20 to 70%. UV detection wavelengths were 214 and 280 
nm. (S,R)-{GlyΔGly}-TrpZip 155 (15 mg, 19%) was obtained as a colourless solid. Peptide 
content was determined by measuring the absorbance at 280 nm.  
HRMS (ESI+) for C28H38N5O7 [M+H]+ calcd 556.2766, found 556.2752. HPLC: purity 
90.03% (50 min gradient), 95.08% (20 min gradient).  
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